Restore balance with personalized bioidentical hormone replacement therapy at ChiroMed. Our integrated approach supports energy, mood, metabolism, sleep, and overall wellness by addressing hormone health as part of a broader functional and patient-centered care plan.

Clinical Application: Weight Management for Success

Find out how weight management techniques in a clinical application can support your journey towards a healthier weight.

Abstract: A Modern, Integrative Approach to Obesity Management

Obesity is a chronic, relapsing, and multifactorial disease that affects a staggering number of individuals worldwide. This educational post delves into the complexities of obesity, moving beyond outdated notions of willpower to explore its deep-seated neurobehavioral, metabolic, and genetic roots. We will examine the latest findings on the pharmacology of weight management, exploring how modern, evidence-based medications such as GLP-1 receptor agonists, GIP/GLP-1 therapies, naltrexone-bupropion, and others can serve as powerful tools in a comprehensive treatment plan. This discussion will highlight the critical need to combat weight bias in healthcare, which significantly hinders patient outcomes. Furthermore, we will explore how an integrative care model that combines advanced chiropractic techniques with internal medicine, functional medicine, and personalized rehabilitation provides a holistic and effective pathway for patients on their journey toward sustainable health. At our clinic, this collaborative approach is championed by Mr. Maria Guadalupe Cardenas, MD, and me, ensuring our patients receive comprehensive, multidisciplinary care.

Our Collaborative and Integrative Care Model in El Paso

At Injury Medical Clinic PA, also known as Mission Plaza Injury Medical Clinic, in El Paso, Texas, we have cultivated a unique and powerful multidisciplinary environment designed to address complex health issues, such as obesity, from multiple angles. I am Dr. Alex Jimenez, and my expertise in chiropractic care, functional medicine, and Family Nurse Practitioner practice is complemented by the invaluable medical oversight of Dr. Maria Guadalupe Cardenas, MD. Dr. Cardenas is Board Certified in Internal Medicine and serves as our Medical Director and Collaborative Physician. With over 40 years of experience as an internist (NPI #1164426749, Texas MD License #J2933), she provides the essential medical framework for our integrative protocols.

This collaborative setup allows us to blend different disciplines for a truly holistic patient experience seamlessly:

Medical Oversight (Dr. Cardenas): Dr. Cardenas provides crucial medical direction, overseeing diagnoses and medication management, and ensuring that all treatments align with established medical safety and efficacy standards. Her role is vital, especially when considering pharmacotherapy for obesity and its related comorbidities such as hypertension, type 2 diabetes, and cardiovascular risk.
Chiropractic and Functional Medicine (Dr. Jimenez): My role involves focusing on the biomechanical and functional aspects of health. Through advanced chiropractic adjustments, we address musculoskeletal issues such as osteoarthritis, which is often exacerbated by excess weight. Using a functional medicine lens, we investigate the root causes of metabolic dysfunction, from gut health to hormonal imbalances, creating personalized nutritional and lifestyle strategies.
Integrated Services: Our team works cohesively to offer a spectrum of care that includes personal injury rehabilitation, physical therapy, and nutritional counseling. This allows us to create a unified treatment plan in which a patient can receive a chiropractic adjustment to alleviate back pain, consult with a provider on evidence-based weight-management medications under medical supervision, and receive a personalized nutrition plan, all within one coordinated system.

This team-based approach ensures that we treat the whole person, not just the symptoms, embodying the principles of modern, patient-centered integrative care. Patients are not isolated body parts; a patient with obesity, diabetes, back pain, and depression needs a coordinated strategy that respects the whole person.

Deconstructing Obesity: A Chronic and Complex Disease

We must begin by framing obesity correctly. It is not a simple matter of choice or a lack of discipline. Obesity is a chronic, progressive, relapsing, and treatable disease. This perspective is fundamental to how we approach patient care. When patients stop their anti-obesity medications, the weight often returns. This is no different than when a patient stops their antihypertensive medication, and their blood pressure rises, or when they stop chemotherapy and a malignancy returns. The condition relapses because it is chronic and deeply embedded in our physiology.

Obesity is profoundly multifactorial. It involves intricate neurobehavioral, neuroendocrine, and metabolic components. The accumulation of excess body fat promotes adipose tissue dysfunction, which is a key driver of the chronic inflammation and metabolic chaos associated with the disease. Obesity affects the body through several overlapping mechanisms:

Insulin resistance
Chronic low-grade inflammation
Leptin resistance
Altered appetite regulation
Reward pathway dysregulation
Mitochondrial dysfunction
Reduced skeletal muscle metabolic flexibility
Gut-brain signaling changes
Sleep disruption and cortisol imbalance
Mechanical overload on the spine, hips, knees, and feet

The consequences are far-reaching, impacting every system of the body:

Metabolic: Type 2 diabetes, dyslipidemia, hypertension.
Biomechanical: Osteoarthritis, back pain, incontinence.
Psychosocial: Depression, anxiety, social stigma, and discrimination.

In the United States, the statistics are sobering. 41.9% of the adult population meets the criteria for obesity (BMI ≥ 30), and a startling 9.2% have severe obesity (BMI ≥ 40). These numbers underscore the urgency of developing effective, accessible, and compassionate treatment strategies.

The Social and Environmental Drivers of Obesity

When we consider the roots of this epidemic, we must look beyond the individual to the broader environment. I often refer to the “social determinants of obesity” because factors like socioeconomic status, education, and environment play such a powerful role.

Economic Instability: For centuries, poverty was associated with being underweight. Today, the opposite is often true. In many impoverished areas, access to fresh, nutrient-dense food is limited, while calorie-dense, processed foods are cheap and abundant. This creates an environment where metabolic disease can thrive.
Neighborhood and Built Environment: If a person lives in a neighborhood where it is unsafe to walk outside, opportunities for regular physical activity are severely limited. The lack of green spaces, sidewalks, and recreational facilities contributes directly to a sedentary lifestyle.
Genetic and Hormonal Factors: We are identifying an ever-growing list of genetic and hormonal players that regulate appetite and metabolism, including ghrelin (the “hunger hormone”), GLP-1 (a satiety hormone), and leptin (which signals fullness). Research into the gut microbiota is also revealing how the balance of our intestinal flora can profoundly influence weight.
The Modern Environment: The rise of technology has engineered physical activity out of our daily lives. From desk jobs to digital entertainment, we are more sedentary than any previous generation.

Over the last decade, virtually every major medical organization, including the American Medical Association, has officially recognized obesity as a disease. This recognition is a critical step, as it validates the patient’s struggle and opens the door for proper diagnosis, treatment, and insurance coverage.

The Overwhelming Complexity of Appetite Regulation

The regulation of our appetite is an incredibly complex symphony conducted by the brain and a host of hormones. When you look at the intricate network of signals involved, it’s easy to see how a disruption in even one pathway can lead to dysfunction. Hormones like leptin, cortisol, ghrelin, and GLP-1 are in constant communication with the brain’s appetite centers, like the hypothalamus.

For many individuals with obesity, these signaling pathways are dysregulated. They may have leptin resistance, in which the brain doesn’t receive the “I’m full” signal, or ghrelin imbalances that drive persistent hunger. It becomes incredibly difficult for someone to “overpower” these potent neuroendocrine signals through willpower alone. This physiological reality is often overlooked, leading to significant clinical inertia.

Consider this shocking statistic: of the 100 million people with obesity in the United States, less than 1% receive a prescription for an anti-obesity medication. Less than 300,000 undergo bariatric surgery, despite 9.2% of the population having severe obesity. Why is there such a massive gap between the need for treatment and the care being provided? A large part of the answer lies in bias.

Binge Eating Disorder and the Physiology of Loss of Control Eating

A key concept in obesity care is recognizing binge eating disorder (BED). Binge eating disorder is not simply eating too much. It involves eating, within a discrete period of time, an amount of food larger than most people would eat under similar circumstances, combined with a sense of loss of control during the episode.

Clinically, binge eating episodes are often associated with several features:

Eating much more rapidly than normal
Eating until uncomfortably full
Eating large amounts when not physically hungry
Eating alone because of embarrassment
Feeling disgusted, depressed, guilty, or ashamed afterward
Marked distress about binge eating
Episodes occurring at least once weekly for at least three months
Absence of compensatory behaviors, such as purging, that would suggest bulimia nervosa

In practice, patients may describe getting up at night to eat while family members are asleep, hiding food, eating in the car, or waking up the next morning feeling shame and physical discomfort. I approach these disclosures with compassion because shame worsens the cycle. Patients need an evidence-based treatment plan, not judgment.

The physiology behind binge eating disorder involves dysregulation of:

Dopamine reward pathways
Impulse control circuits
Stress-related cortisol signaling
Serotonin and norepinephrine pathways
Prefrontal cortex regulation
Gut-brain satiety signaling
Emotional regulation networks

From a clinical standpoint, binge eating disorder can drive weight gain, worsen insulin resistance, aggravate depression and anxiety, and contribute to musculoskeletal pain because additional body mass increases mechanical load across the spine and joints.

Confronting Weight Bias: The Last Socially Acceptable Discrimination

Weight bias and stigma are perhaps the greatest barriers to effective obesity care. There is a pervasive, often unconscious, belief in our society—and even within the medical community—that obesity is a character flaw, a result of laziness or a lack of willpower. This prejudice is not only hurtful but also dangerous.

Research has shown that patients who experience weight bias have increased complications and mortality, independent of their BMI. The bias itself, through the stress it causes and the lack of care it fosters, becomes a risk factor. What drives this?

Lack of Reimbursement: Historically, treatments for obesity, especially medications, have not been well-covered by insurance, discouraging providers from offering them.
Time Constraints: Meaningful lifestyle counseling takes time, a luxury many providers in a fee-for-service model do not have.
Cultural Stigma: The belief that “people should just try harder” prevents us from treating obesity with the same seriousness as other chronic diseases.

This bias manifests in shocking ways. Imagine if we told patients with schizophrenia to “just stop listening to the voices.” It sounds absurd, yet we often tell patients with obesity to “just eat less and move more,” ignoring the powerful physiological drivers of their condition. We require extensive psychological screening for bariatric surgery patients—a practice not required for equally life-altering procedures like coronary artery bypass grafts—based on the biased assumption that overeating is purely a behavioral problem.

In a landmark Harvard study on implicit bias, weight bias was the only form found to increase over time. As providers, we must be the ones to break this cycle.

Shifting the Conversation: How to Engage Patients Effectively

The first step in combating bias is to change the way we talk to our patients. We need to approach the conversation with empathy, respect, and a genuine desire to help. The 5 A’s model provides a great framework:

Ask: “Is it okay if we talk about your weight and its potential effects on your health?” This simple question asks for permission and shows respect for the patient’s autonomy.
Assess: Take a detailed history. Understand their weight journey, family history, what they’ve tried in the past, and their understanding of how weight impacts health.
Advise: Provide clear, non-judgmental advice. Explain that even a modest weight loss of 3-5% can lead to significant improvements in blood pressure, blood sugar, and cholesterol.
Agree: Work with the patient to set realistic, achievable goals. What is a goal weight they feel is sustainable?
Arrange/Assist: Connect them with the resources they need. This could be a referral to a dietitian, an exercise program, or a discussion about pharmacotherapy or surgical options.

This approach transforms the conversation from one of judgment to one of partnership. Shared decision-making improves adherence because the patient becomes an active participant rather than a passive recipient.

A Framework for Treatment: Lifestyle, Medication, and Surgery

Our treatment approach is tiered and personalized, based on BMI and the presence of comorbidities (obesity-related health conditions). Current research strongly supports the idea that obesity should be treated as a chronic disease requiring ongoing monitoring, not as a temporary problem solved by short-term dieting. The Endocrine Society, American Gastroenterological Association, and American Diabetes Association emphasize that structured lifestyle therapy, medication when appropriate, and long-term follow-up are essential for improving outcomes (Apovian et al., 2015; American Diabetes Association Professional Practice Committee, 2026; Grunvald et al., 2022).

Lifestyle Interventions (BMI ≥ 25 with comorbidities, or ≥ 30): This is the foundation for everyone. It includes healthy eating, regular physical activity, and behavioral therapy. As a chiropractor and functional medicine practitioner, I often begin here, helping patients build a sustainable foundation. We focus on anti-inflammatory food plans, stress management techniques, and personalized exercise regimens that account for any musculoskeletal limitations.
Pharmacotherapy (BMI ≥ 27 with comorbidities, or ≥ 30): Medications should be considered for patients who have not reached their goals with lifestyle changes alone. These are not “magic pills” but powerful tools to aid the biological processes of appetite and metabolism.
Bariatric Surgery (BMI ≥ 35 with comorbidities, or ≥ 40): For individuals with severe obesity, surgery remains the most effective long-term treatment for significant weight loss and remission of comorbidities. It is a vital option that is tragically underutilized. A shocking 71% of providers never discuss surgical options with eligible patients.

Our goal is typically a 5-10% reduction in total body weight over six months. This level of weight loss is clinically significant and can dramatically reduce health risks.

Why “First, Do No Harm” Matters in Obesity Treatment

One of the most important principles I use in integrative obesity care is “first, do no harm.” Before adding a new medication or supplement, I want to understand whether the patient is already taking medications that may be contributing to weight gain. Common obesogenic medications may include:

Antidepressants and Antipsychotics: (e.g., some SSRIs, mirtazapine, olanzapine)
Anticonvulsants/Mood Stabilizers: (e.g., valproate, gabapentin)
Antidiabetic Agents: (e.g., sulfonylureas, insulin)
Corticosteroids: (e.g., prednisone)
Certain beta-blockers
Certain antihistamines
Some hormonal therapies

Shockingly, patients with obesity are often prescribed these medications more frequently. If a patient is on one of these drugs and struggling with their weight, we collaborate with their prescribing physician to see if a weight-neutral or weight-loss-promoting alternative exists. For instance, a patient with diabetes on a sulfonylurea like glyburide might be a candidate for a GLP-1 receptor agonist or an SGLT2 inhibitor, which can aid in weight loss. This is a perfect example of how the collaboration between Dr. Cardenas and me benefits the patient, ensuring patient safety and optimized outcomes.

Modern Pharmacotherapy for Weight Management

The good news is that we now have a growing arsenal of safe and effective long-term medications for obesity. All approved medications are more effective than placebo. A 12-week trial is often sufficient to determine whether a medication is working for a patient. If a patient does not achieve at least a 5% reduction in body weight after approximately 3 months at a therapeutic dose, we reassess the plan.

Here is an overview of some key long-term options:

Phentermine/Topiramate (Qsymia): This combination drug pairs a well-known appetite suppressant (phentermine) with an anticonvulsant (topiramate) that also reduces appetite and may lower leptin levels. Because phentermine can stimulate the sympathetic nervous system, increasing heart rate and blood pressure, it requires careful dose titration and monitoring, especially in patients with cardiovascular concerns.
Naltrexone/Bupropion (Contrave): This combination works on the brain’s reward and appetite-control centers. Bupropion stimulates the POMC system to reduce appetite, while naltrexone blocks an inhibitory feedback loop, allowing the appetite-suppressing effect to persist. This may be particularly useful for patients with co-occurring depression or reward-driven eating patterns.
Orlistat: This medication works by inhibiting gastrointestinal lipases, thereby reducing the absorption of dietary fat. It is a non-stimulant option but can cause gastrointestinal side effects and may interfere with the absorption of fat-soluble vitamins (A, D, E, K), requiring monitoring.
Liraglutide (Saxenda): A daily injectable GLP-1 receptor agonist. GLP-1 is a natural gut hormone that slows stomach emptying, promotes feelings of fullness (satiety), and acts on the brain’s appetite centers. It is started at a low dose and titrated up to 3.0 mg daily to manage potential GI side effects like nausea.
Semaglutide (Wegovy): A weekly injectable GLP-1 receptor agonist. It works similarly to liraglutide but has a longer half-life, allowing for once-weekly dosing. It has demonstrated even greater weight loss in clinical trials, with an average loss of approximately 15% of body weight (Blundell et al., 2017; Wilding et al., 2021). It is important to note that semaglutide is sold as Ozempic for type 2 diabetes and Wegovy for chronic weight management; they are the same molecule but have different indications and dosing.
Tirzepatide (Zepbound): A novel weekly injectable that is a dual GIP/GLP-1 receptor agonist. By targeting two different incretin hormone pathways, it produces a powerful synergistic effect on appetite suppression and glucose control. Clinical trials have shown unprecedented levels of weight loss, with some participants achieving more than a 20% reduction in body weight (Jastreboff et al., 2022). This potent therapy may be particularly appropriate for patients with severe obesity.
Lisdexamfetamine (Vyvanse): While not approved for general obesity, this medication is FDA-approved for moderate to severe binge eating disorder (BED). Since BED is a common co-occurring condition in patients with obesity, identifying and treating it can be a critical part of the overall weight management strategy. It works on dopamine and norepinephrine pathways to improve impulse control (McElroy et al., 2015).

Emerging Obesity Medications and Future Directions

The obesity medicine pipeline is advancing quickly. Researchers are studying therapies that may produce even more substantial weight loss while improving metabolic markers. Emerging therapies include:

Retatrutide: A triple agonist targeting GLP-1, GIP, and glucagon receptors, which has shown very large weight reduction percentages in trials (Jastreboff et al., 2023).
Oral GLP-1 agonists: Medications like orforglipron and danuglipron are being developed to provide an oral alternative to injections.
Combination therapies: CagriSema, a combination of cagrilintide and semaglutide, is being studied for its synergistic effects on appetite and metabolism.

Discovering the Benefits of Chiropractic Care- Video

The Role of Integrative Chiropractic Care in Weight Management

So, where does integrative chiropractic care fit into this modern, medical approach? It is a crucial component of our holistic model, addressing the biomechanical consequences of excess weight and enhancing the body’s ability to heal and adapt.

Addressing Biomechanical Pain: Excess weight places tremendous stress on the musculoskeletal system, leading to conditions like osteoarthritis, degenerative disc disease, and chronic back and joint pain. In my clinical observations, I frequently see patients whose weight-related concerns overlap with low back pain, sciatica, and knee pain. This pain creates a vicious cycle: it hurts to move, so the person becomes more sedentary, which can lead to further weight gain. Through precise chiropractic adjustments, spinal decompression, and soft tissue therapies, we can alleviate pain, improve joint function, and restore mobility. This enables patients to engage in the physical activity essential for weight loss.
Improving Neurological Function: The spine houses the central nervous system, which is the master controller of all bodily functions, including metabolism and hormonal regulation. By correcting spinal misalignments (subluxations), we can reduce interference in the nervous system, potentially improving the body’s ability to self-regulate and heal.
Functional Medicine and Lifestyle Coaching: As a practitioner certified in functional medicine, I look beyond the symptoms to find the underlying root causes of dysfunction. We may use advanced testing to assess gut health, hormonal imbalances, or nutrient deficiencies that contribute to weight gain. Based on these findings, we develop highly personalized nutrition plans, stress-reduction protocols, and targeted supplement recommendations to optimize metabolic function from the inside out.
Rehabilitation and Muscle Preservation: A major concern with weight loss, particularly rapid loss, is the loss of lean muscle mass. Muscle is critical for resting metabolic rate, glucose disposal, and long-term weight maintenance. My clinical approach, as reflected on my professional platforms like ChiroMed and my LinkedIn profile, emphasizes a rehabilitation-focused plan that includes progressive resistance training, core stabilization, and balance work to preserve this metabolically active tissue. Movement is metabolic medicine.

By integrating these approaches under the medical direction of Dr. Cardenas, we ensure that the patient is supported on every level—structurally, neurologically, metabolically, and medically.

Final Clinical Takeaway

If there is one concept I want patients and clinicians to remember from this post, it is this: obesity care must be individualized, medically safe, and integrated. Before adding a medication, we must ask whether current medications are worsening weight gain. Before recommending exercise, we must ask whether pain, injury, or joint dysfunction is limiting movement. Before assuming noncompliance, we must ask whether binge eating disorder, depression, anxiety, or sleep apnea are present.

With the collaborative oversight of Dr. Maria Guadalupe Cardenas, MD, and the integrative chiropractic, functional medicine, and rehabilitation services I provide, our El Paso practice model is designed to evaluate the whole patient. Modern obesity medicine is no longer about simply telling people to eat less and move more. It is about understanding physiology, reducing harm, improving function, supporting the nervous and musculoskeletal systems, and applying evidence-based tools with compassion and precision. This is the future of effective and compassionate obesity care.

References

American Diabetes Association Professional Practice Committee. (2026). Standards of Care in Diabetes 2026. Diabetes Care.
Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015). Pharmacological management of obesity: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 100(2), 342–362. https://doi.org/10.1210/jc.2014-3415
Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. (2017). Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, Obesity & Metabolism, 19(9), 1242–1251.
Grunvald, E., Shah, R., Hernaez, R., Chandar, A. K., Pickett-Blakely, O., Teigen, L. M., Yanovski, S. Z., & Singh, S. (2022). AGA clinical practice guideline on pharmacological interventions for adults with obesity. Gastroenterology, 163(5), 1198–1225. https://doi.org/10.1053/j.gastro.2022.08.045
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide once weekly for the treatment of obesity. The New England Journal of Medicine, 387(3), 205–216.
Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., Hartman, M. L., & Retatrutide Phase 2 Obesity Trial Investigators. (2023). Triple-hormone-receptor agonist retatrutide for obesity: A phase 2 trial. The New England Journal of Medicine, 389(6), 514–526. https://doi.org/10.1056/NEJMoa2301972
McElroy, S. L., Hudson, J. I., Mitchell, J. E., Wilfley, D., Ferreira-Cornwell, M. C., Gao, J., Wang, J., Whitaker, T., Jonas, J., & Gasior, M. (2015). Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder. JAMA Psychiatry, 72(3), 235–246. https://doi.org/10.1001/jamapsychiatry.2014.2162
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., Kushner, R. F., & STEP 1 Study Group. (2021). Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine, 384(11), 989–1002.

SEO Tags: Obesity Management, Integrative Care, Chiropractic, Functional Medicine, Weight Loss Medication, Semaglutide, Tirzepatide, Weight Bias, Dr. Alex Jimenez, Dr. Maria Guadalupe Cardenas MD, El Paso, TX, Chronic Disease, Pharmacotherapy, Lifestyle Intervention, Adipose Tissue Dysfunction, Appetite Regulation, GLP-1 Agonists, Binge Eating Disorder, Lisdexamfetamine, Collaborative Healthcare, Injury Medical Clinic PA, Mission Plaza Injury Medical Clinic, metabolic health, personal injury rehabilitation, chiropractic weight loss support, prediabetes, type 2 diabetes, obesity treatment, musculoskeletal pain, rehabilitation, internal medicine collaborative care, El Paso Texas healthcare

July 14, 2026

GLP-1 Receptor Agonist Effects On Cardiometabolic Health

Find out how GLP-1 receptor agonists contribute to better cardiometabolic health and what it means for you.

Abstract

The intertwined relationship between type 2 diabetes, obesity, heart failure, and cardiovascular disease represents a significant clinical challenge. Over the past decade, two revolutionary drug classes, SGLT2 inhibitors and GLP-1 receptor agonists, have transformed our approach by offering profound benefits beyond glucose control. This educational post explores the latest findings from leading researchers on the physiological underpinnings connecting these conditions. We will delve into how metabolic disturbances like hyperglycemia and insulin resistance drive chronic inflammation, endothelial dysfunction, and detrimental cardiac remodeling. We will highlight the evidence from landmark trials—including DAPA-HF, EMPEROR-Preserved, SELECT, and LEADER—that have cemented these medications as cornerstones of cardiometabolic care. I will also explain how our team at Injury Medical Clinic PA, under the medical direction of our Collaborative Physician, Dr. Maria Guadalupe Cardenas, MD, integrates these pharmacological advances with integrative chiropractic care, functional medicine, and rehabilitation to provide comprehensive, patient-centered care that addresses root causes and optimizes well-being.

Our Collaborative Approach at Injury Medical Clinic PA

Before diving into the science, I want to introduce the framework I use. At Injury Medical Clinic PA, also known as Mission Plaza Injury Medical Clinic, located in El Paso, Texas, our approach is inherently collaborative and multidisciplinary.
As the founder, I, Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST, function within our team as both a Doctor of Chiropractic and a board-certified Family Nurse Practitioner with advanced certifications in functional and integrative medicine. This multifaceted training allows me to view patient health through a unique lens, connecting musculoskeletal integrity, nervous system function, and metabolic health. My clinical observations and published work are available at chiromed.com and my LinkedIn profile.
A cornerstone of our clinic is the medical oversight provided by our Medical Director and Collaborative Physician, Dr. Maria Guadalupe Cardenas, MD (NPI #1164426749, Texas MD License #J2933). With over 40 years of experience as a board-certified internist, Dr. Cardenas brings an extraordinary depth of knowledge, particularly for patients managing complex, overlapping conditions like heart failure, type 2 diabetes, hypertension, chronic kidney disease (CKD), and obesity. Her long tenure in internal medicine means she has witnessed firsthand the evolution of cardiometabolic pharmacology, from older agents to today’s transformative era of SGLT2 inhibitors and GLP-1 receptor agonists.
Together, Dr. Cardenas and I lead a team that integrates:

Medical Oversight and Internal Medicine: Dr. Cardenas provides essential medical direction, overseeing complex cases and managing pharmacological interventions.
Chiropractic Care and Spinal Rehabilitation: I focus on spinal alignment, nervous system function, and musculoskeletal health to reduce pain, improve mobility, and enhance the body’s innate healing capacity.
Functional Medicine and Lifestyle Interventions: We investigate the root causes of chronic illness through advanced diagnostics and personalized protocols.
Personal Injury Care and Musculoskeletal Rehabilitation: Our team provides specialized care for individuals recovering from accidents, with a focus on restoring function.
Nutritional Counseling and Metabolic Optimization: We create targeted dietary plans to combat inflammation and improve metabolic health.

This integrative structure is vital when addressing complex conditions like cardiometabolic syndrome. By combining these disciplines, we create personalized treatment plans that go beyond symptom management to foster true healing and resilience.

The Unseen Connection: How Diabetes Fuels Heart Failure

As a clinician with decades of experience, I’ve observed that diabetes and heart failure are far more than just concurrent diagnoses; they are deeply interconnected diseases that are, as one of my esteemed colleagues put it, “joined at the hip.” Understanding the “why” behind this connection is crucial for effective treatment. When we grasp the underlying physiology, the logic behind using specific therapies becomes crystal clear.
The journey from diabetes to heart failure is a cascade of metabolic and inflammatory events:

Hyperglycemia and Insulin Resistance: In type 2 diabetes, the body’s cells become resistant to insulin, leading to elevated blood sugar levels (hyperglycemia). This resistance isn’t just a sugar problem; it’s a systemic issue.
Hyperinsulinemia: To compensate for this resistance, the pancreas works overtime, pumping out increasing amounts of insulin. This state of high insulin, or hyperinsulinemia, is a powerful, independent driver of inflammation.
Chronic Inflammation and Endothelial Dysfunction: This inflammatory milieu, often compounded by obesity-related inflammation from excess adipose (fat) tissue, damages the delicate inner lining of our blood vessels—the endothelium. This endothelial dysfunction is the first step toward atherosclerosis, where plaques begin to form in the arteries.
Cardiac Remodeling and Fibrosis: Simultaneously, the heart muscle itself is under attack. The combination of inflammation, metabolic stress, and activation of the Renin-Angiotensin-Aldosterone System (RAAS)—a hormonal system that regulates blood pressure and fluid balance—leads to adverse changes. The heart muscle can thicken (left ventricular hypertrophy, or LVH) and develop scar tissue (fibrosis), making it stiffer and less efficient.

This entire process can lead to what is known as diabetic cardiomyopathy, a form of heart failure that can develop even without the classic clogged arteries of coronary artery disease. It’s a direct consequence of the metabolic chaos that diabetes creates. My clinical observations at Injury Medical Clinic align with this research; we frequently see patients whose musculoskeletal and nerve issues are exacerbated by underlying systemic inflammation driven by metabolic disorders like diabetes (Jimenez, 2024).

Understanding the Two Faces of Heart Failure

Heart failure is not a one-size-fits-all condition. It’s broadly classified based on the heart’s pumping capacity, measured by the ejection fraction (EF). This distinction is vital because the underlying mechanisms and treatment approaches differ significantly.

Heart Failure with Preserved Ejection Fraction (HFpEF)

What it is: In HFpEF, the ejection fraction is normal or near-normal (50% or greater). The problem isn’t the squeeze; it’s the relaxation. The heart muscle, particularly the left ventricle, becomes stiff and thickened (concentric remodeling), impairing its ability to fill with blood properly during diastole.
Who it affects: HFpEF is more common in older adults, women, and individuals with obesity, diabetes, and hypertension.
The “Why”: This condition is primarily driven by systemic inflammation, endothelial dysfunction, and microvascular damage in the heart and kidneys.
Treatment Focus: The goals are to manage congestion (fluid buildup), control risk factors such as blood pressure and diabetes, and use therapies such as SGLT2 inhibitors to help reduce the burden of cardiac remodeling.

Heart Failure with Reduced Ejection Fraction (HFrEF)

What it is: In HFrEF, the ejection fraction is reduced (less than 40%). The heart muscle is weakened and often enlarged (eccentric remodeling and ventricular dilation), impairing its ability to contract and pump blood effectively.
Who it affects: HFrEF is more commonly seen in men and is often the result of ischemic heart disease (e.g., a prior heart attack). However, patients with HFpEF can progress to HFrEF over time.
The “Why”: This condition is driven primarily by overactivation of neurohormonal systems, including the RAAS and the sympathetic nervous system (the “fight or flight” response).
Treatment Focus: The cornerstone of HFrEF management is quadruple medical therapy, which includes an ARNI (angiotensin receptor-neprilysin inhibitor), a beta-blocker, an MRA (mineralocorticoid receptor antagonist), and an SGLT2 inhibitor. This combination is designed to block the harmful neurohormonal pathways and improve cardiac function.

Optimizing Your Wellness- Video

The Four Pillars of Modern Diabetes and Cardiovascular Care

The American Diabetes Association has outlined a strategy that mirrors the “pillar” approach used in heart failure management. To effectively reduce the cardiovascular risks associated with diabetes, we must focus on four key areas:

Glycemic Management: Controlling blood sugar is fundamental.
Blood Pressure Management: Protecting the blood vessels from the damaging effects of high pressure.
Lipid Management: Managing cholesterol and triglycerides to prevent plaque buildup.
Using Cardiorenal Protective Agents: This is where the game has truly changed. We now prioritize medications that do more than just lower blood sugar; we use agents with proven benefits for the heart and kidneys.

The two classes of medications at the forefront of this revolution are SGLT2 inhibitors and GLP-1 receptor agonists. These drugs have become indispensable tools, offering powerful benefits that address the core physiological problems linking diabetes, heart failure, and kidney disease.

The Revolutionary Role of SGLT2 Inhibitors

When Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors first appeared around 2014, their mechanism seemed straightforward: block the reabsorption of glucose in the kidneys, causing excess sugar to be excreted in the urine. It was an interesting way to lower blood sugar, but no one could have predicted the profound impact this drug class would have on cardiovascular and renal medicine. Today, SGLT2 inhibitors are a core pillar of heart failure therapy for patients with or without diabetes. Major clinical trials have provided undeniable evidence of their efficacy.

Landmark Trials: The Evidence Speaks for Itself

The data supporting SGLT2 inhibitors is overwhelming, stemming from large, well-designed clinical trials that have reshaped treatment guidelines.

EMPEROR-Reduced & DAPA-HF: These trials, which studied empagliflozin and dapagliflozin, respectively, were groundbreaking. They showed that in patients with HFrEF, these drugs reduced the risk of cardiovascular death and hospitalization for heart failure by approximately 25-26%. These trials cemented SGLT2 inhibitors as a mainstay of HFrEF treatment, demonstrating robust benefits in the outpatient setting that prompted further investigation (Packer et al., 2020; McMurray et al., 2019).
EMPULSE: This trial translated the benefits seen in outpatients directly to hospitalized patients with acute heart failure. This is clinically significant because it shows these are not drugs we must wait to initiate. They can be safely used across all NYHA functional classes and in both compensated and decompensated states at a simple, uniform dose (e.g., Dapagliflozin 10 mg daily).
EMPEROR-Preserved: This was a monumental moment for cardiology. For the first time, a medication—empagliflozin—demonstrated a clear benefit in patients with HFpEF, a condition that had been notoriously difficult to treat. It delivered meaningful reductions in both CV death and heart failure hospitalization, with a 27% relative risk reduction in hospitalizations regardless of diabetes status (Anker et al., 2021). This is transformative for the older, obese patient population I frequently see at Injury Medical Clinic PA.
EMPA-KIDNEY & CREDENCE: These trials shifted focus to the kidneys. They showed that SGLT2 inhibitors (empagliflozin and canagliflozin) significantly slowed the progression of chronic kidney disease (CKD) and reduced the risk of kidney failure by 28-30% (The EMPA-KIDNEY Collaborative Group, 2022; Perkovic et al., 2019). This is critical because kidney function is a powerful predictor of survival in patients with heart failure and diabetes.

These results confirm that the benefits are a class effect, meaning the protective mechanisms are shared across the different drugs in this category.

How SGLT2 Inhibitors Protect the Heart and Kidneys

The power of SGLT2 inhibitors lies in their multifaceted mechanism of action, which goes far beyond simple glucose excretion.

Improved Cardiac Fuel Efficiency: This is one of the most fascinating aspects. A failing, metabolically stressed heart is inefficient at using glucose for fuel. However, it remains very good at using ketones as an energy source. SGLT2 inhibitors induce a mild state of ketosis, providing the sick heart with its preferred, more efficient fuel. It’s like giving a struggling engine a supply of premium fuel, improving ATP production and optimizing the cellular Krebs cycle.
Hemodynamic and Renal Benefits:
- By promoting the excretion of sodium and water (natriuresis), these drugs act as a gentle diuretic, reducing circulating blood volume (preload) and the overall hemodynamic burden on the heart.
- They decrease the pressure inside the glomeruli (the kidney’s filtering units), which reduces stress on the kidneys and slows the progression of CKD. A common fear is the initial dip in eGFR when starting the drug, but this is an expected hemodynamic effect, not a sign of kidney injury. It signals the drug is working.
Reduced Inflammation and Fibrosis: SGLT2 inhibitors have been shown to reduce myocardial inflammation and fibrosis (scarring). They also help reduce epicardial adipose tissue—the inflammatory layer of fat that sits directly on the heart—which is a major contributor to cardiac dysfunction in obesity and diabetes.
Atherosclerotic Plaque Stabilization: By reducing systemic inflammation, oxidative stress, and endothelial dysfunction, SGLT2 inhibitors help stabilize vulnerable plaques, which, in synergy with statins, can provide risk reduction exceeding that of statins alone.

GLP-1 Receptor Agonists From Diabetes Drugs to Cardiovascular Powerhouses

While SGLT2 inhibitors have cornered the market on heart failure, GLP-1 receptor agonists have emerged as powerhouses for reducing atherosclerotic cardiovascular events and promoting significant weight loss.

How GLP-1 Receptor Agonists Work

GLP-1 receptor agonists (glucagon-like peptide-1 receptor agonists), such as semaglutide (Ozempic, Wegovy, Rybelsus) and liraglutide (Victoza), mimic the action of the endogenous incretin hormone GLP-1. Their key mechanisms include:

Delayed Gastric Emptying: This slows nutrient absorption, blunting postprandial glucose excursions and promoting satiety.
Central Appetite Suppression: They act on GLP-1 receptors in the central nervous system to directly reduce appetite signals, leading to an average weight loss of 13-16% of body weight in clinical trials.
Reduced Systemic Inflammation: They lower inflammatory cytokines, such as IL-6 and TNF-alpha, derived from visceral fat, a metabolically active inflammatory organ.
Atherosclerotic Plaque Stabilization: By reducing macrophage infiltration, foam cell formation, and endothelial activation, GLP-1 receptor agonists slow plaque growth and improve its stability, lowering the risk of acute coronary events.

Critically, GLP-1 receptor agonists lower glucose only when it is elevated and a patient is eating. They have a minimal risk of causing hypoglycemia, making them exceptionally safe for long-term outpatient use.

The FDA-Mandated Outcomes Trials: A Turning Point

Following safety concerns with older antidiabetic drugs, the FDA mandated large cardiovascular outcomes trials for all new glycemic agents starting around 2008. These trials unexpectedly revealed significant cardiovascular benefits for the GLP-1 class.

Trial	Drug	Key Finding
LEADER (2016)	Liraglutide (Victoza)	13% reduction in MACE risk in over 9,300 patients (Marso et al., 2016).
SUSTAIN-6	Semaglutide (Ozempic)	26% MACE risk reduction.
REWIND	Dulaglutide (Trulicity)	12% MACE risk reduction.
PIONEER	Oral semaglutide (Rybelsus)	21% MACE risk reduction.
SELECT	Semaglutide 2.4 mg (Wegovy)	20% CV risk reduction in non-diabetic obese patients (Lincoff et al., 2023).

MACE (Major Adverse Cardiovascular Events) is a composite score typically including cardiovascular death, non-fatal myocardial infarction (MI), and non-fatal stroke. The SELECT trial was particularly groundbreaking, proving that the cardiovascular benefits of semaglutide extend to obese patients without diabetes, dramatically expanding the eligible population for this therapy. Furthermore, the STEP Heart Failure trial (2023) showed that in obese HFpEF patients without diabetes, semaglutide significantly improved quality of life, exercise function, and heart failure symptoms, underscoring the benefits of weight loss in this population.

The ADA Algorithm Drug Selection Framework

The American Diabetes Association (ADA) provides clear guidelines for choosing between these two powerful drug classes:

For patients with established ASCVD (atherosclerotic cardiovascular disease): Prefer GLP-1 receptor agonists first.
For patients with heart failure or chronic kidney disease (CKD): Prefer SGLT2 inhibitors first.
For high-risk patients with overlapping conditions: Consider using both classes simultaneously, a strategy increasingly supported by insurance given the strength of the evidence.

A Clinical Case Example Transitioning Patients to Modern Therapy

To put this into practice, consider a common clinical scenario. Let’s call our patient Bob. He is a recently insured man with type 2 diabetes who suffered a myocardial infarction two months ago and was subsequently diagnosed with HFrEF. His prior regimen, based on cost, included metformin, a sulfonylurea, and a DPP-4 inhibitor. His A1C was 7.0%.
This old regimen was designed purely to lower glucose, not to reduce cardiovascular risk. This represents the paradigm shift in modern cardiometabolic medicine: we are no longer just managing blood sugar; we are managing cardiovascular survival.

Sulfonylureas: These drugs induce insulin secretion regardless of glucose levels, increasing the risk of hypoglycemia. They offer no cardiac benefit and have been associated with adverse outcomes.
DPP-4 Inhibitors: While incretins, they do not confer the direct cardiovascular, weight-loss, or anti-inflammatory benefits of GLP-1 receptor agonists. They are an inferior choice.

The rational transition plan for Bob, which Dr. Cardenas and I would implement, is:

Discontinue the sulfonylurea immediately to eliminate hypoglycemia risk.
Retain metformin, which remains a foundational agent.
Add an SGLT2 inhibitor (such as dapagliflozin or empagliflozin) for its proven benefit in HFrEF.
Replace the DPP-4 inhibitor with a GLP-1 receptor agonist to reduce ASCVD risk.
Ensure he is on all four pillars of HFrEF therapy: an ARNI, a beta-blocker, an MRA, and the SGLT2 inhibitor.

While this may seem like polypharmacy, it is evidence-based and life-saving. Each drug class targets a distinct and complementary pathway. Refusing to use them together is a disservice to the patient.

The Integrative Chiropractic and Functional Medicine Perspective

At Injury Medical Clinic, our approach, under the medical direction of Dr. Cardenas, is to build upon this powerful medical foundation. While medications address the deep cellular and hormonal imbalances, our role is to optimize the body’s overall function and resilience. Patients with cardiometabolic disease rarely suffer in isolation; they often present with chronic pain, spinal dysfunction, and sedentary behavior that worsen their condition.

How Our Integrative Care Fits In

Reducing Systemic Inflammation: The chronic inflammation driven by diabetes is a central villain. Our functional medicine protocols identify and mitigate sources of inflammation through advanced diagnostics and personalized interventions such as anti-inflammatory nutrition and gut health restoration.
Improving Biomechanics and Autonomic Function: Diabetes often leads to autonomic dysfunction. Precise chiropractic care can help restore proper spinal alignment and improve nerve function. By modulating nerve signals, particularly in the thoracic spine, where sympathetic ganglia that influence heart function are located, chiropractic care can help balance the autonomic nervous system. My clinical experience has shown that patients often report improved well-being and better symptom management after consistent care (Jimenez, 2024). This complements the work of beta-blockers, which also target sympathetic overactivity.
Enabling Physical Rehabilitation: Musculoskeletal pain is a major barrier to exercise. Chiropractic care can alleviate this pain, enabling patients to engage in structured exercise programs that improve cardiovascular fitness, enhance insulin sensitivity, and promote healthy weight.
Supporting Cellular Health: The discussion of ketones highlights the importance of cellular energy. Through functional medicine, we may recommend targeted supplementation with nutrients like Coenzyme Q10, magnesium, and B vitamins, which are essential for mitochondrial function. This nutritional support ensures the “powerhouses of the cell” have the raw materials they need to function optimally, amplifying the benefits of therapies that improve the heart’s fuel supply.

Our collaborative model ensures that these holistic therapies are safely and effectively integrated alongside the medical treatments prescribed and overseen by Dr. Cardenas. This team-based approach allows us to address the patient as a whole person—supporting their journey from every angle: cellular, structural, and systemic. By embracing these principles, we can truly change the trajectory of cardiometabolic disease and help our patients live longer, healthier lives.

References

SEO Tags: SGLT2 inhibitors heart failure, GLP-1 receptor agonists cardiovascular outcomes, type 2 diabetes, semaglutide cardiovascular benefits, dapagliflozin heart failure, empagliflozin HFpEF, MACE reduction diabetes, cardiometabolic disease treatment, integrative chiropractic care El Paso, functional medicine cardiovascular disease, Dr. Alex Jimenez DC APRN, Injury Medical Clinic PA El Paso, Dr. Maria Guadalupe Cardenas MD internal medicine, GLP-1 weight loss cardiovascular, SGLT2 inhibitors diabetes, SELECT trial semaglutide obesity, DAPA-HF trial, EMPEROR-Preserved trial, LEADER trial liraglutide, HFrEF treatment guidelines, HFpEF treatment, polypharmacy heart failure diabetes, sulfonylurea transition, DPP-4 inhibitor GLP-1 switch, Wegovy cardiovascular outcomes, Ozempic heart disease, multidisciplinary cardiometabolic care, visceral adiposity inflammation, myocardial energetics GLP-1, endothelial dysfunction treatment, atherosclerotic plaque stabilization, diabetic cardiomyopathy, cardiorenal protection, chronic kidney disease, inflammation, metabolic health, autonomic nervous system, clinical collaboration

July 3, 2026

SGLT2 Inhibitors in Diabetes & Cardio-Renal Benefits

Understand the role of SGLT2 inhibitors in providing cardio-renal benefits for better health management for the body.

Abstract

In this educational post, I share a clear, first-person journey through modern, evidence-based strategies that leverage SGLT2 inhibitors for cardio-renal protection in patients with diabetes and metabolic syndrome. We will explore the intricate connections between Type 2 Diabetes, Chronic Kidney Disease (CKD), and Cardiovascular Disease, and I will guide you through a detailed case study that showcases a modern, holistic approach to treatment. Drawing from my clinical observations and our multidisciplinary practice in El Paso, Texas, I explain how we integrate chiropractic care, internal medicine oversight, functional medicine, rehabilitation, and personal injury care to optimize outcomes. I also introduce our team structure, in which Dr. Maria Guadalupe Cardenas, MD, Board Certified in Internal Medicine (NPI #1164426749, Texas MD License #J2933), serves as Medical Director and Collaborative Physician at Injury Medical Clinic PA, alongside my role as a Doctor of Chiropractic and an advanced practice registered nurse. This post offers an accessible, step-by-step narrative with clinically relevant physiology, treatment rationales, and actionable protocols to support whole-person cardio-renal health.

My Path Toward Cardio-Renal Integration in Diabetes Care

I am Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. Over the years, my clinical practice has focused on the intersection of metabolic health, musculoskeletal function, and neurophysiology—an integrative space where biochemical and biomechanical pathways meet. Early in my journey, a personal encounter with a loved one’s complications from diabetes impressed upon me how seemingly small choices—nutrition, movement, adherence, and foot care—can transform outcomes. Later, my formal training and work in functional medicine and advanced chiropractic biomechanics refined my approach to combine precise manual therapies, exercise rehabilitation, and medically supervised pharmacologic strategies.

Today, I use modern research on SGLT2 inhibitors to enhance cardio-renal outcomes. At the same time, our clinic’s multidisciplinary model ensures that each intervention is medically appropriate, safely combined, and tailored to the patient’s unique physiology. Our work is about reducing risk, restoring function, and improving quality of life.

Our Integrative Practice Model: A Symphony of Care

At Injury Medical Clinic PA (also known as Mission Plaza Injury Medical Clinic) in El Paso, Texas, we have cultivated a unique environment where different disciplines work in concert for the patient’s total well-being. This multidisciplinary setup is typical of progressive integrative and injury-care clinics.

Medical Management: Our practice is guided by the extensive medical expertise of Dr. Maria Guadalupe Cardenas, MD. Dr. Cardenas is a board-certified internist with an impressive 40-year career. As our Medical Director and Collaborative Physician, she provides essential medical oversight of our patients’ complex conditions, including prescribing and managing medications.
Chiropractic and Functional Medicine: I, Dr. Alex Jimenez, lead our team with a focus on chiropractic and functional medicine, addressing the body’s structural integrity, biomechanics, and underlying physiological imbalances. This approach is powerful for managing musculoskeletal complications, improving mobility, and reducing pain.
Comprehensive Services: This collaborative model allows us to offer a full spectrum of services under one roof, including functional medicine, personal injury care, rehabilitation, neuromuscular re-education, and lifestyle medicine.

This synergy ensures that a patient with diabetes receives not only state-of-the-art medical treatment for their blood sugar and organ protection, but also chiropractic adjustments to improve nervous system function, nutritional counseling to overhaul their diet, and physical rehabilitation to help them move again. It’s a 360-degree approach to health that treats the person, not just the disease.

A Patient’s Journey: From Uncontrolled Diabetes to Renewed Health

Let me introduce you to a patient we’ll call R.B., a case that perfectly illustrates the challenges and opportunities in modern diabetes care. When R.B. first came to our clinic, he was a 73-year-old Hispanic male with a 12-year history of type 2 diabetes, hypertension, and hyperlipidemia, and he was struggling despite being on several medications.

Patient Profile & Medications:

Metformin 1000 mg BID
Glipizide 10 mg BID with meals
Linagliptin (Tradjenta) 5 mg daily: A new DPP-4 inhibitor started shortly before his visit.
Losartan 100 mg daily: For hypertension.
Hydrochlorothiazide 25 mg daily: A diuretic for blood pressure.
Simvastatin 40 mg daily: For high cholesterol.
Glargine (Lantus) Insulin: Recently reduced from 60 units to 42 units.

His lab work painted a concerning picture. His hemoglobin A1C was a staggering 10.2%. His kidney function was declining, with an estimated Glomerular Filtration Rate (eGFR) of 43 and a creatinine level of 1.5. Clinically, he was experiencing dangerously high blood sugars during the day (200-300 mg/dL) yet was waking up with nocturnal hypoglycemia.

This patient was referred to our endocrinology service after a recent hospitalization for hyperglycemia and acute kidney injury. For five years, he had been considered “stable”, but his A1C had never dropped below 8%. This is a critical point: stability at a poor baseline is not true control. He had the trifecta of risk factors that recent clinical trials have focused on:

Type 2 Diabetes: With a high A1C of 10.2%.
Increased Cardiovascular Risk: Due to co-existing hypertension and hyperlipidemia.
Chronic Kidney Disease (CKD): Evidenced by his low eGFR of 43.

Treatment Plan Part 1: Building a Foundation Through Education and Trust

The first step was not to add more medications but to address foundational issues. The patient was glucotoxic—a state where high blood sugar impairs insulin secretion and increases insulin resistance.

Comprehensive Diabetes Self-Management Education (DSME)

We started with intensive education. I discovered R.B. didn’t understand what his medications did. His most significant barrier was a profound fear of low blood sugar. To avoid it, he would preemptively eat carbohydrates throughout the day, driving his blood sugars sky-high. His long-acting insulin would then cause his sugar to plummet at night.

To break this cycle, we made two immediate changes:

We stopped the glipizide, a sulfonylurea drug notorious for causing hypoglycemia.
We further decreased his Lantus (glargine) dose to prevent nighttime lows.

Overcoming Barriers to Technology

A major point of resistance was his refusal to use a Continuous Glucose Monitor (CGM). He was terrified of a “big needle” staying under his skin. I showed him a demo CGM device and the tiny, flexible filament—not a needle—that actually sits under the skin. His fear vanished. We applied a sample sensor and ordered his supplies.

Finally, I ordered a C-peptide level. I explained this test to patients using an analogy: “The C-peptide is the candy wrapper, and insulin is the candy. If I see a lot of wrappers in your blood, I know your body is still making its own candy.”

Cardio-Renal Pathophysiology Made Simple

To treat effectively, we must understand the intertwined physiology. I explain these concepts to patients using clear analogies:

When blood glucose is high, think of syrup or honey. It is sticky and viscous. Your heart has to pump harder to move that thickened fluid, increasing cardiac workload.
Prolonged exposure to high sugar is inflammatory. If you hold a candy against your cheek for an hour, the tissue feels irritated. Similarly, hyperglycemia stiffens vessel walls and damages the vascular endothelium, including in the kidneys and heart.

The physiology behind these analogies is complex:

Kidney-glucose dynamics: In hyperglycemia, the kidney’s proximal tubules upregulate SGLT2 transporters, reabsorbing more glucose and sodium. This maladaptive conservation sustains hyperglycemia and reduces sodium delivery to the macula densa, blunting tubuloglomerular feedback and driving glomerular hyperfiltration. Over time, this causes podocyte injury, mesangial expansion, and glomerulosclerosis.
Heart-kidney axis: Volume overload and neurohormonal activation (RAAS, SNS) perpetuate cardiac remodeling. Increased venous congestion impairs renal perfusion, further activating RAAS—a vicious cycle worsened by insulin resistance and endothelial dysfunction.
Inflammation and fibrosis: Chronic hyperglycemia and oxidative stress increase TGF-β, NF-κB, and AGE-RAGE signaling, promoting fibrosis in renal and cardiac tissue.
Autonomic balance: Sympathetic overdrive elevates heart rate and vascular tone, harming diastolic filling and renal microcirculation.

Cardiometabolic Risk Causes & Effects- Video

SGLT2 Inhibitors: How They Work and Why We Use Them

SGLT2 inhibitors (such as empagliflozin, dapagliflozin, canagliflozin, and ertugliflozin) reduce blood glucose by promoting glucose excretion in the urine. Their benefits extend far beyond glucose lowering.

Key mechanisms:

Renal tubular transport modulation: By blocking sodium-glucose co-transport in the proximal tubule, they increase natriuresis (sodium excretion) and osmotic diuresis (water excretion).
Restoration of tubuloglomerular feedback: More sodium delivery to the macula densa improves afferent arteriolar tone, reducing intraglomerular pressure and mitigating hyperfiltration.
Hemodynamic effects: Reduced preload and afterload benefit cardiac function, leading to fewer heart failure events.
Metabolic shifts: Mild ketogenesis, lower insulin levels, improved insulin sensitivity, and weight reduction collectively support metabolic health.

Why we integrate them:

Robust evidence demonstrates cardio-renal benefits independent of A1c.
They complement lifestyle and biomechanical interventions by reducing congestion, improving energy utilization, and lowering systemic inflammation.
They fit the functional medicine goal of addressing root contributors—hemodynamics, energy metabolism, and renal microvascular stress.

Treatment Plan Part 2: Two Weeks Later – Progress and Precision

Two weeks later, the results were encouraging: blood sugar levels averaged in the 180s, and nocturnal hypoglycemia was gone. The C-peptide test came back within the normal range, confirming his pancreas was still producing insulin.

With his glucotoxicity resolving, it was now safe to introduce a more advanced therapy. Based on his CKD and cardiovascular risk profile, the clear choice was an SGLT2 inhibitor. We started him on Dapagliflozin (Farxiga) 5 mg daily and reduced his glargine dose again.

Clinical Indications and Patient Selection

Our internal medicine oversight by Dr. Cardenas ensures evidence-based selection for SGLT2 inhibitors:

Type 2 diabetes with high cardiovascular risk or existing heart failure.
Chronic kidney disease, with or without diabetes, particularly albuminuric CKD.
Heart failure across ejection fraction phenotypes (HFrEF and HFpEF), per modern trials.

We assess baseline eGFR, albumin-to-creatinine ratio, blood pressure, volume status, and existing medications, such as diuretics and RAAS inhibitors, to anticipate risks.

Safety and Monitoring Protocols

Under Dr.Cardenas’ss medical direction, we implement strict monitoring:

Renal function: Expect a modest, temporary dip in eGFR initially; monitor for stabilization.
Volume status: Monitor for dizziness or hypotension; adjust diuretics as needed.
Genitourinary infections: Counsel on hygiene; monitor for mycotic infections.
Euglycemic ketoacidosis: Rare; educate on sick-day rules, hydration, and carb intake.
Foot care: Double down on peripheral vascular assessments and neuropathy screening.

Treatment Plan Part 3: Three Months – Remarkable Improvement

Three months after his initial visit, the transformation was undeniable.

A1C: Dropped from 10.2% to 8.2%.
Creatinine: Improved from 1.54 to 1.3.
eGFR: Increased from 43 to 53.

His kidney function was actively improving! I explained it to him like this: “Remember when I told you high blood sugar makes your blood thick and sticky, like syrup? It forces your kidneys to work overtime. Now that your sugars are better, your blood flows more easily, and your kidneys can filter more efficiently.”

We also switched him from linagliptin to semaglutide (Ozempic) 0.5 mg weekly. Semaglutide is a GLP-1 receptor agonist that not only improves blood sugar control but also promotes weight loss and provides robust cardiovascular protection.

Integrative Chiropractic Care and Rehabilitation

Chiropractic care is not an add-on—it is integral to our approach.

Autonomic modulation: Dysautonomia in diabetes and heart failure fuels sympathetic dominance. Targeted spinal adjustments and vagal-stimulating breathwork can enhance HRV, reduce resting sympathetic tone, and improve baroreflex sensitivity. This aids renal perfusion and cardiac efficiency.
Thoracic mobility and respiration: Restricted rib and thoracic spine motion compromises ventilation and venous return. Mobilization improves diaphragmatic excursion, reduces intrathoracic pressures, and supports cardiac filling, synergizing with the preload reduction from SGLT2 inhibitors.
Gait mechanics and peripheral circulation: Foot and ankle alignment influence plantar pressure and ulcer risk. We correct biomechanical imbalances and prescribe footwear or orthotics.
Rehabilitation for Capacity Building: Our graded rehabilitation protocols restore functional capacity. Improved skeletal muscle mass enhances glucose uptake (GLUT4-mediated), reduces insulin resistance, and supports cardiac output by improving peripheral oxygen utilization.

From my clinical observations, integrating musculoskeletal optimization with metabolic therapies improves adherence and functional outcomes. Patients who receive targeted manual therapy and movement training are more likely to sustain walking programs, which lower A1C, reduce blood pressure, and enhance heart rate variability.

Treatment Plan Part 4: Seven Months – Approaching Full Remission

Seven months from his first visit, R.B. was a new person.

Blood Sugar Average: Now 150 mg/dL, with no lows.
A1C: Further improved to 7.2%, a 3-point drop!
Creatinine: Now 1.25, within the normal range.
eGFR: Stabilized at an improved 55.

Most remarkably, he was achieving this without needing mealtime insulin. The combination of Dapagliflozin and Semaglutide was working so effectively that his body’s own insulin, paired with better lifestyle choices, was enough. We officially stopped his prandial lispro.

Why This Matters: From Risk Reduction to Life Quality

This case highlights a new paradigm for diabetes care. We must stop fixating on A1C alone and consider the non-glycemic benefits of medications. By combining SGLT2 inhibitors with integrative chiropractic care, functional medicine, and rehabilitation, we address the mechanisms that drive heart and kidney decline while restoring movement, autonomy, and resilience. The evidence is strong, the physiology compelling, and the patient stories motivating. With cohesive medical oversight from Dr. Maria Guadalupe Cardenas, MD, and a unified clinical team, our approach is safe, rigorous, and deeply human.

Key Takeaways

SGLT2 inhibitors provide robust cardio-renal benefits through hemodynamic, metabolic, and microvascular mechanisms.
Integrative chiropractic care enhances autonomic balance, respiration mechanics, and peripheral circulation, synergizing with pharmacotherapy.
Medical oversight by Dr. Maria Guadalupe Cardenas, MD ensures safety, appropriate selection, and precise monitoring.
Functional medicine and rehabilitation embed behavior change and strengthen physiology for lasting outcomes.
Multidisciplinary coordination delivers comprehensive, patient-centered cardio-renal care.

References

American Association of Clinical Endocrinology. (2022). AACE Comprehensive Type 2 Diabetes Management Algorithm.
American Diabetes Association. (2024). Standards of Medical Care in Diabetes—2024. Diabetes Care.
Anker, S. D., Butler, J., Filippatos, G., et al. (2021). Empagliflozin in Heart Failure with a Preserved Ejection Fraction. New England Journal of Medicine.
Cannon, C. P., Pratley, R., Dagogo-Jack, S., et al. (2020). Cardiovascular outcomes with ertugliflozin in type 2 diabetes. New England Journal of Medicine.
Heerspink, H. J. L., Stefansson, B. V., Correa-Rotter, R., et al. (2020). Dapagliflozin in patients with chronic kidney disease. New England Journal of Medicine, 383(15), 1436–1446.
Heidenreich, P. A., Bozkurt, B., Aguilar, D., et al. (2022). 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Circulation.
KDIGO. (2022). KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease.
Marso, S. P., Bain, S. C., Consoli, A., et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 375(19), 1834–1844.
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., et al. (2019). Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine.
Perkovic, V., Jardine, M. J., Neal, B., et al. (2019). Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. New England Journal of Medicine, 380(24), 2295–2306.
The EMPA-KIDNEY Collaborative Group. (2022). Empagliflozin in patients with chronic kidney disease. New England Journal of Medicine.
Zelniker, T. A., Wiviott, S. D., Raz, I., et al. (2019). SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. The Lancet, 393(10166), 31–39.
Zinman, B., Wanner, C., Lachin, J. M., et al. (2015). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New England Journal of Medicine.

Additional Clinical Observations

SEO tags: SGLT2 inhibitors, cardio-renal benefits, chronic kidney disease, heart failure, type 2 diabetes, integrative chiropractic care, functional medicine, internal medicine oversight, Dr. Alex Jimenez, Dr. Maria Guadalupe Cardenas, El Paso clinic, diabetes management, rehabilitation, autonomic balance, thoracic mobility, microvascular health, GLP-1 agonists, A1C, eGFR, hypoglycemia, Ozempic, Farxiga, patient education, holistic healthcare, cardio-renal protection, empagliflozin, dapagliflozin, canagliflozin, ertugliflozin, ADA guidelines, AACE guidelines, albuminuria, RAAS system, euglycemic DKA, personal injury care, Mission Plaza Injury Medical Clinic

July 2, 2026

Cardiometabolic Research Advances Using GLP-1 Receptor Therapy

Find out about GLP-1 receptor therapy on cardiometabolic health and its revolutionary role in modern medicine and patient care.

Abstract

Hello, I’m Dr. Alex Jimenez, and I am honored to share transformative insights into managing cardiovascular and metabolic conditions, such as type 2 diabetes. This educational post explores a significant shift in our medical understanding, moving from a purely glucose-centric model to a comprehensive, risk-reduction strategy. Here, we will journey through the latest findings from leading researchers, backed by robust, evidence-based studies, to understand this new paradigm. We’ll delve into the mechanisms of two groundbreaking classes of medications—SGLT2 inhibitors and GLP-1 receptor agonists—and their profound benefits for cardiovascular and renal health, often independent of their glucose-lowering effects. We will also discuss how our multidisciplinary team at Injury Medical Clinic PA, including the invaluable medical direction of Dr. Maria Guadalupe Cardenas, MD, integrates these advancements with integrative chiropractic care, functional medicine, and rehabilitation to provide a truly holistic treatment plan for our patients in El Paso, Texas. This post aims to illuminate the interconnectedness of cardiac, metabolic, and kidney health and present a collaborative path forward for optimal patient outcomes.

Our Collaborative and Integrative Practice at Injury Medical Clinic PA

Before we delve into the clinical science, I want to take a moment to explain our unique approach to patient care here in El Paso, Texas. At Injury Medical Clinic PA, also known as Mission Plaza Injury Medical Clinic, we have built a truly multidisciplinary practice. I am Dr. Alex Jimenez, and my credentials include DC, APRN, FNP-BC, CFMP, IFMCP, ATN, and CCST. My passion lies in functional medicine and chiropractic care, focusing on the body’s innate ability to heal and the musculoskeletal system’s foundational role in overall health.
A cornerstone of this model is my collaboration with Dr. Maria Guadalupe Cardenas, MD. With over 40 years of experience as a board-certified internist, Dr. Cardenas serves as our Medical Director and Collaborative Physician (NPI #1164426749, Texas MD License #J2933). Her extensive expertise in internal medicine provides essential medical oversight and direction, allowing us to seamlessly merge advanced medical protocols with chiropractic, functional medicine, rehabilitation, and personal injury care.
Our model is built on the synergy between different disciplines:

Medical Oversight (Dr. Cardenas): Provides diagnoses, prescribes medications like the advanced therapies we will discuss today, and oversees the overall medical treatment plan, ensuring patient safety and efficacy.
Chiropractic and Functional Medicine (Dr. Jimenez): I focus on identifying and addressing the root causes of dysfunction. Through chiropractic adjustments, we restore proper nerve function and biomechanics. With functional medicine, we analyze a patient’s genetics, lifestyle, and environment to correct underlying imbalances in metabolism, inflammation, and gut health.
Integrated Services: Together, we manage personal injury cases, rehabilitation, nutritional counseling, and chronic disease management. This team-based approach ensures that a patient with diabetes, for example, not only receives the latest medications but also benefits from dietary overhauls, targeted supplementation, and structural care to improve insulin sensitivity and reduce systemic inflammation. This is the essence of integrative medicine—uniting the best of multiple worlds for superior patient outcomes.

The Critical Link Between Diabetes and Cardiovascular Disease

For a long time, the primary focus in managing type 2 diabetes was on lowering blood glucose. While important, this approach was incomplete. We now have an overwhelming body of evidence showing that people with diabetes face a significantly elevated risk for Atherosclerotic Cardiovascular Disease (ASCVD), which includes coronary heart disease, stroke, and peripheral arterial disease. In fact, ASCVD is the leading cause of death for individuals with diabetes.

Consider this startling fact: over 70% of individuals with diabetes over the age of 65 will likely succumb to heart disease or a stroke.
Following a heart attack (myocardial infarction or MI), people with diabetes have a much higher mortality risk and a poorer long-term prognosis.
These grim outcomes persist even when blood sugar levels are well-controlled, and they affect individuals with both type 1 and type 2 diabetes.

This reality has forced a paradigm shift in how we manage these interconnected conditions. The focus has expanded from aggressive glucose reduction to a holistic strategy to reduce overall cardiovascular and renal risk. This involves managing not just blood sugar, but also blood pressure, cholesterol levels, weight, physical activity, and smoking cessation. For the first time in my career, all the major guideline-issuing bodies—including the American College of Cardiology (ACC), the American Heart Association (AHA), the American Diabetes Association (ADA), and the Kidney Disease: Improving Global Outcomes (KDIGO)—are in complete agreement on this new, integrated approach to care. This consensus marks a monumental step forward, allowing us to view and treat our patients through a unified, comprehensive lens.

Rethinking Treatment Algorithms: A Risk-Based Approach

This new paradigm is reflected in the latest treatment algorithms from the American Diabetes Association. The guidelines now emphasize a risk-stratified approach. For any patient with type 2 diabetes who has established ASCVD, heart failure, chronic kidney disease (CKD), or is at high risk for developing these conditions, the recommendation is to concurrently address all risk factors and prioritize specific classes of medications.
The algorithm directs us to move beyond traditional first-line agents like metformin alone and immediately consider two powerful classes of drugs:

SGLT2 (Sodium-Glucose Cotransporter-2) Inhibitors
GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists

These medications are now recommended as foundational therapies for high-risk patients precisely because they have demonstrated proven cardiovascular (CV) benefits in large-scale clinical trials. The choice between them, or the decision to use them in combination, depends on patient-specific factors, comorbidities, and preferences. This marks a significant departure from simply trying to lower the A1C; it’s about proactively protecting the heart and kidneys.

The History and Evolution of Diabetes Medication Trials

How did we arrive at this pivotal moment? The story begins around 2008, when the U.S. Food and Drug Administration (FDA) issued mandatory guidance for all new antidiabetic medications. The FDA required pharmaceutical companies to conduct long-term Cardiovascular Outcomes Trials (CVOTs). The primary goal was to ensure that these new drugs did not increase the risk of Major Adverse Cardiovascular Events (MACE)—a composite of non-fatal heart attack, non-fatal stroke, and cardiovascular death.
This mandate was a direct response to past experiences where certain drugs, such as rosiglitazone (Avandia) and others like Vioxx, were later found to cause cardiovascular harm. Earlier studies were often too short, underpowered, or poorly designed to detect these risks. The FDA’s new requirement forced the industry to conduct large, well-designed, placebo-controlled trials that were robust enough to demonstrate safety or non-inferiority.
What happened next was truly surprising. As the results of these CVOTs began to be published, starting with the EMPA-REG OUTCOME trial for empagliflozin (Jardiance) in 2015, researchers discovered something extraordinary. These new drugs weren’t just safe—some of them were actively protective.

Empagliflozin (Jardiance), an SGLT2 inhibitor, was the first to show a significant reduction in MACE, CV death, and hospitalization for heart failure.
Liraglutide (Victoza), a GLP-1 receptor agonist, followed in 2016 with the LEADER trial, also demonstrating significant cardiovascular benefits.

These unexpected findings of superiority, not just safety, were game-changers. They provided the evidence needed to completely overhaul the clinical guidelines and place these drug classes at the forefront of managing patients with cardiovascular, metabolic, and renal disease.

A Deeper Dive into SGLT2 Inhibitors

Let’s explore the SGLT2 inhibitor class more closely. These medications work by blocking glucose reabsorption in the kidney, causing excess sugar to be excreted in the urine. While this helps lower blood glucose, their profound cardiovascular and renal benefits appear to stem from multiple other mechanisms.

Landmark Cardiovascular Outcomes Trials for SGLT2 Inhibitors

Several major CVOTs have established the benefits of this class:

EMPA-REG OUTCOME (empagliflozin/Jardiance): This trial was a watershed moment. It showed a highly statistically significant reduction in MACE, CV death, and hospitalization for heart failure.
CANVAS Program (canagliflozin/Invokana): Demonstrated significant reductions in MACE and hospitalization for heart failure.
DECLARE-TIMI 58 (dapagliflozin/Farxiga): While it didn’t show a significant reduction in MACE, it showed a substantial and statistically significant reduction in the risk of hospitalization for heart failure.
VERTIS-CV (ertugliflozin/Steglatro): Also showed a significant reduction in hospitalization for heart failure risk (a 30% relative risk reduction).

The consistent and powerful effect on reducing hospitalizations for heart failure across the class is particularly noteworthy and has led to their widespread adoption in cardiology.

The Multifaceted Mechanisms of SGLT2 Inhibitors

What makes these drugs so effective? The benefits go far beyond simple glucose lowering. Some of the proposed mechanisms that contribute to their cardioprotective and renoprotective effects:

Hemodynamic Effects: SGLT2 inhibitors have a mild diuretic effect, which helps reduce blood pressure by about 3-5 mmHg systolic. This is achieved through natriuresis, or the excretion of sodium and water, which reduces fluid volume and preload on the heart.
Reduced Glomerular Pressure: In the kidneys, these drugs reduce pressure within the glomerulus (the kidney’s filtering unit). This is a key theorized mechanism for their nephroprotective (kidney-protecting) effects, slowing the progression of diabetic kidney disease.
Metabolic Shifts: SGLT2 inhibitors promote a slight shift towards ketosis. The heart is a unique metabolic organ that can efficiently use ketones as a fuel source. This “super fuel” improves myocardial efficiency and function, especially in a stressed or failing heart.
Systemic Benefits: They also contribute to a modest weight loss (around 5-7 pounds), reduce inflammation, decrease oxidative stress, and may improve endothelial function and stabilize atherosclerotic plaques.
Improved Myocardial Energetics: By reducing the workload on the heart (via lower blood pressure and volume) and providing a more efficient fuel source (ketones), these drugs improve the overall energy balance and function of the heart muscle.

SGLT2 Inhibitors in Heart Failure and Kidney Disease

The benefits of SGLT2 inhibitors have been so profound that their use has expanded to patients without diabetes.

Heart Failure Trials

DAPA-HF and EMPEROR-Reduced: These trials studied dapagliflozin and empagliflozin, respectively, in patients with heart failure with reduced ejection fraction (HFrEF). Both showed a remarkable 25-26% relative risk reduction in the composite outcome of cardiovascular death or hospitalization for heart failure, regardless of whether the patients had diabetes.
EMPEROR-Preserved: This was the first trial to show a meaningful benefit in patients with heart failure with preserved ejection fraction (HFpEF), a very common and difficult-to-treat type of heart failure, particularly in older adults, women, and those with obesity. Empagliflozin reduced the primary composite endpoint by 21%.

Kidney Disease Trials

The evidence for kidney protection is just as compelling:

DAPA-CKD (dapagliflozin): This trial was stopped early due to overwhelming efficacy. It showed a 39% reduction in the risk of progression of kidney disease.
EMPA-KIDNEY (empagliflozin): Also demonstrated a significant 28% reduction in the risk of kidney disease progression or cardiovascular death.
CREDENCE (canagliflozin): Showcased a 30% reduction in the risk of kidney failure and cardiovascular events in patients with type 2 diabetes and kidney disease.

These trials have firmly established SGLT2 inhibitors as a cornerstone therapy for chronic kidney disease, even in patients without diabetes.

Understanding the Incretin Effect: TheBody’ss Natural Glucose Response System

For years, the management of type 2 diabetes centered on a few key strategies. However, a fascinating discovery completely shifted our understanding and opened the door to a new class of powerful therapies. Researchers observed a peculiar phenomenon: when people consumed glucose orally (by drinking it), their bodies produced a much more robust insulin response to lower blood sugar than when the same amount of glucose was administered intravenously (IV). This observation led them to a logical conclusion: there must be something happening in the gut when food is ingested that signals the pancreas to ramp up insulin production.
This phenomenon was termed the “incretin effect.” The “somethings” responsible were identified as gut hormones called incretins, primarily glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).

The Process: When you eat, food travels to your stomach and intestines. Specialized cells in your gut (L-cells) detect the presence of nutrients and release GLP-1 and GIP into your bloodstream.
The Signal: These hormones then travel to the pancreas, where they act as messengers. They bind to receptors on pancreatic beta cells, stimulating the cells to release insulin.
The Result: This insulin release helps your body’s cells take up glucose, effectively lowering your blood sugar levels after a meal.

Crucially, this entire process is glucose-dependent. This means the incretins only stimulate insulin release when blood sugar levels are high, as they are after a meal. This built-in safety mechanism significantly reduces the risk of hypoglycemia (dangerously low blood sugar) when these pathways are targeted with medication, especially compared to older diabetes drugs.

The Blunted Incretin Effect in Type 2 Diabetes

One of the key physiological defects we see in patients with type 2 diabetes is a blunted or even absent incretin effect. Their bodies produce insufficient amounts of native GLP-1 in response to food. This deficiency contributes significantly to the hallmarks of the disease:

Poor Post-Meal Glucose Control: Without a strong incretin signal, the pancreas doesn’t release sufficient insulin after eating, resulting in prolonged periods of high blood sugar.
Dysregulated Appetite: Native GLP-1 also plays a critical role in promoting satiety, or the feeling of fullness. Low levels of this hormone can lead to a state of poor satiety, contributing to overeating and the obesity that is so often a comorbid condition with type 2 diabetes.
Excess Glucagon Secretion: GLP-1 normally helps suppress the release of another hormone called glucagon. Glucagon tells the liver to produce and release more sugar into the bloodstream (gluconeogenesis). In type 2 diabetes, this suppression is impaired, so the liver continues to release glucose even when blood glucose is already high.

Understanding this hormonal defect was the key that unlocked the development of GLP-1 receptor agonists—medications designed to mimic the action of our natural GLP-1 and restore these vital functions.

The Silent Threat: Hyperhomocysteinemia and its Impact on Your Health- Video

How GLP-1 Receptor Agonists Revolutionize Treatment

GLP-1 receptor agonists are a class of medications that bind to and activate GLP-1 receptors throughout the body, just as our native GLP-1 would, but they are engineered to last much longer. Their multifaceted mechanism of action addresses several core issues in type 2 diabetes and obesity simultaneously.

Stimulates Insulin Secretion: By activating pancreatic receptors, they prompt a glucose-dependent release of insulin, directly lowering blood sugar.
Inhibits Glucagon Secretion: They effectively tell the liver to stop producing excess sugar, which is a major contributor to high fasting and post-meal glucose levels.
Slows Gastric Emptying: This is a key mechanism for both glucose control and weight loss. By slowing down the rate at which food leaves the stomach, they prevent rapid spikes in blood sugar after meals. This delay also contributes to a prolonged feeling of fullness, which naturally leads to a decrease in overall food intake. This effect is often responsible for the common initial side effects like nausea, but it is also a primary driver of the medication’s success.
Increases Satiety: GLP-1 receptor agonists act directly on appetite centers in the brain, enhancing the feeling of fullness and reducing food cravings. This neurobiological effect is fundamental to the significant weight loss seen with these therapies.

Collectively, these actions lead to profound improvements in A1c, blood glucose, and body weight, tackling the metabolic dysfunction of type 2 diabetes at its source.

The Challenge of Over-Basalization: A Case Study

To truly understand the paradigm shift in diabetes care,let’ss consider a typical patient I might see in our clinic, whom we’ll call Tony. He represents a common challenge where adding a GLP-1 agonist is the superior strategy.

Patient Profile: Tony
Age: 62 years
Diagnosis: Type 2 Diabetes (11 years), Hyperlipidemia, Hypertension
Recent A1c: 8.2% (well above the target of <7.0%)
Kidney Health: Proteinuria (protein in the urine), an early sign of kidney damage.
Current Medications:
- Degludec (basal insulin): 65 units daily
- Metformin: 1000 mg twice daily
- An SGLT2 inhibitor daily
- A statin for cholesterol
An ARB for blood pressure
Physical Stats: Weight 220 lbs, Height 5’9 ” “, BMI 32.5 (classifies as obese)
Blood Sugar Patterns:
- Fasting Glucose (morning): 15050 mg/dL
- Postprandial Glucose (after meals/bedtime): 160-200 mg/dL

Tony’s case highlights a critical issue we call over-basalization. We’ve pushed his basal (long-acting) insulin dose to a high level, yet his A1c and post-meal sugars remain dangerously elevated. Research in pharmacokinetics reveals that once you exceed a certain dose of basal insulin, typically around 0.5 units per kilogram of body weight per day, you get diminishing returns. For Tony, who weighs 100 kg (220 lbs), this threshold is about 50 units. He is already on 65 units, pushing him past the point of modest glycemic effect and into the territory of significant side effects, primarily weight gain and a higher risk of hypoglycemia.
For a patient like Tony, the conventional next step might have been to add prandial (mealtime) insulin. While this can control post-meal spikes, it comes with a heavy price: a near-certainty of further weight gain and a significantly increased risk of hypoglycemia. Given his BMI of 32.5, adding more weight would only worsen his insulin resistance, creating a vicious cycle.
This is where the 2024 guidelines from the American Diabetes Association (ADA) strongly recommend adding a GLP-1 receptor agonist. It addresses multiple problems at once, moving beyond simple glucose lowering, weight loss, and cardiovascular protection, which are crucial for a high-risk patient like Tony.

Beyond Blood Sugar: The Cardiovascular and Renal Benefits of GLP-1s

Perhaps the most exciting development in the story of GLP-1 agonists is the overwhelming evidence of their protective effects on the heart and kidneys. Several landmark trials have established these powerful benefits:

The LEADER Trial (Liraglutide): This trial studied patients with type 2 diabetes and high cardiovascular risk. It showed a significant reduction in the risk of major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal heart attack, and non-fatal stroke.
The SUSTAIN-6 and PIONEER 6 Trials (Semaglutide): Both the injectable (SUSTAIN-6) and oral (PIONEER 6) forms of semaglutide were studied in patients with high cardiovascular risk. Both trials demonstrated a robust reduction in MACE, confirming the class effect.
The REWIND Trial (Dulaglutide): What made this trial unique was its focus on a broader population, including many patients who had risk factors for cardiovascular disease but had not yet had an event. It demonstrated that dulaglutide can be used for primary prevention, reducing the risk of a first cardiovascular event.
Tirzepatide (Mounjaro®, Zepbound™): This is a newer, highly potent dual GIP/GLP-1 receptor agonist. While its final CVOTs are still pending as of June 15, 2026, preliminary data suggest powerful cardiovascular benefits are likely.

More recently, the FLOW trial for semaglutide was stopped early because of overwhelmingly positive results showing a significant reduction in the risk of kidney disease progression (nephropathy). These findings are game-changers, solidifying the role of GLP-1 agonists as essential therapies for patients with or at high risk for heart and kidney disease.

Navigating Side Effects and Safety Considerations of GLP-1 Agonists

As with any potent medication, GLP-1 agonists are not without side effects. As clinicians, our job is to help patients navigate these challenges.

Gastrointestinal (GI) Issues: Nausea, vomiting, and diarrhea are common and caused by delayed gastric emptying. My clinical advice is always to “start low and go slow,” beginning with the lowest dose and titrating upwards gradually.
Dehydration and Acute Kidney Injury (AKI): Patients on these medications must drink plenty of water to prevent dehydration due to GI side effects.
Gallbladder Disease: Rapid weight loss, regardless of the method, is associated with an increased risk of gallstone formation.
Pancreatitis: Recent large-scale studies as of early 2025 have been reassuring, finding no statistically significant increase in the risk of pancreatitis and even suggesting a potential long-term risk reduction by improving metabolic health.
Thyroid C-Cell Tumors: These medications carry a black box warning due to an increased risk of thyroid C-cell tumors in rodents. They are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Muscle and Bone Loss: This is a feature of significant weight loss in general, not something specific to these drugs. This is where our integrative care becomes critical.

An Integrative Chiropractic Perspective on Metabolic Health

As a Doctor of Chiropractic with advanced training in functional medicine, I view the body as an integrated system. When I see a patient, I don’t just see a person with diabetes and heart disease. I see a complex interplay of systemic inflammation, metabolic dysfunction, and biomechanical stress. This is where our unique approach at Injury Medical Clinic PA provides immense value. The side effects and physiological changes associated with modern diabetes therapies are whole-body issues we can address.
Here’s how integrative chiropractic care fits into this new paradigm:

Addressing Systemic Inflammation: Chronic inflammation is a root cause of both ASCVD and insulin resistance. Chiropractic adjustments have been shown to modulate the nervous system and can have a downstream effect on inflammatory pathways. By reducing spinal misalignments (subluxations), we can help normalize nerve function, which in turn influences the body’s inflammatory response.
Promoting Physical Activity and Combating Muscle Loss: Exercise is a critical component of managing diabetes. However, many patients are limited by musculoskeletal pain. As chiropractors, our primary role is to improve biomechanical function, reduce pain, and restore mobility. Furthermore, with the rapid weight loss induced by GLP-1s, there is a risk of sarcopenia (muscle loss). We implement targeted strength training and rehabilitation protocols to preserve and build lean muscle mass. By treating underlying musculoskeletal issues, we empower patients to engage in the physical activity necessary for their metabolic health.
Functional Medicine and Nutritional Counseling: My training as a Certified Functional Medicine Practitioner (CFMP) allows us to go deeper. We create personalized nutrition plans and recommend targeted supplementation to reduce inflammation, improve insulin sensitivity, and support cardiovascular health. To combat muscle loss, we ensure patients consume adequate protein to support muscle synthesis. This complements the work of medications by addressing the foundational lifestyle factors that drive disease.
Stress Management and Autonomic Balance: The autonomic nervous system plays a huge role in regulating blood pressure, heart rate, and metabolic function. Chronic stress leads to a state of sympathetic (“fight-or-flight”) dominance, which can worsen hypertension and insulin resistance. Chiropractic care, along with techniques like breathwork and meditation, helps promote a parasympathetic (“rest-and-digest”) state, supporting better cardiovascular and metabolic regulation.

In our clinic, a patient would receive a comprehensive plan. Under the medical direction of Dr. Cardenas, they might be started on an SGLT2 inhibitor or a GLP-1 agonist. Simultaneously, my team would work with them on a personalized plan including chiropractic adjustments to improve mobility, an anti-inflammatory diet, and a progressive exercise program they can perform without pain. This integrated approach addresses the disease from multiple angles, leading to far better and more sustainable outcomes. This is the future of chronic disease management—a holistic, patient-centered, and team-based model of care.

References

SEO Tags: SGLT2 inhibitors, GLP-1 receptor agonists, cardiovascular disease, type 2 diabetes, chronic kidney disease, heart failure, integrative chiropractic care, functional medicine, Dr. Alex Jimenez, Dr. Maria Cardenas, El Paso, TX, ASCVD, risk reduction, metabolic health, incretin effect, over-basalization, tirzepatide, semaglutide, Mounjaro, Ozempic, diabetes management, A1c reduction, weight loss and diabetes, nephroprotection, cardioprotection, collaborative care, internal medicine, chiropractic, personal injury care, musculoskeletal health

June 29, 2026

Inpatient Management Strategies in Gastrointestinal & Liver Care

Master inpatient management to enhance treatment processes and improve patient recovery for gastrointestinal and liver issues.

Abstract

This educational post offers a comprehensive exploration of common gastrointestinal (GI) and liver conditions encountered in clinical practice, viewed through the lens of integrative and functional medicine. From understanding the complexities of GI bleeding and inflammatory bowel disease (IBD) to managing acute pancreatitis, liver failure, and their myriad complications, we will delve into the physiological underpinnings of these conditions. Drawing upon modern, evidence-based research and years of clinical observation, I will share insights on diagnostic strategies, the judicious use of medications, and the importance of a multidisciplinary approach. A central theme is the critical role of an integrated team in which chiropractic care, functional medicine, and internal medicine collaborate to provide comprehensive patient care. We will examine how this model, exemplified by my work with our medical director, Dr. Maria Cardenas, MD, addresses the patient as a whole, from acute medical stabilization to long-term functional recovery and wellness.

At Injury Medical Clinic PA (also known as Mission Plaza Injury Medical Clinic) in El Paso, Texas, our team is privileged to work under the medical direction of Dr. Maria Guadalupe Cardenas, MD, a Board Certified Internist (NPI #1164426749, Texas MD License #J2933) with over 40 years of clinical experience. Together, we integrate chiropractic care, functional medicine, personal injury rehabilitation, and internal medicine oversight to deliver truly comprehensive, patient-centered care.

This post covers the following major topic areas:

Differentials for upper and lower GI bleeding
Risk stratification and the role of endoscopy
Pharmacological management during GI bleeding, including anticoagulation considerations
Clinical pearls for peptic ulcer disease, pill esophagitis, and NSAID-related injury
First-line pharmacologic management in ulcerative colitis and Crohn’s disease
Differentiating cholangitis from choledocholithiasis
Navigating acute pancreatitis, mesenteric ischemia, and fecal impaction
Hepatology: transfusion strategy, acute liver failure, hepatic encephalopathy, and hepatorenal syndrome

Our Integrative Clinical Team: Bridging Internal Medicine and Chiropractic Care

Before diving into the clinical content, I want to briefly introduce the foundation upon which this educational material is grounded. At Injury Medical Clinic PA in El Paso, Texas, our practice is built on a multidisciplinary, integrative model that is increasingly recognized as the gold standard in both injury care and chronic disease management. This setup mirrors the best models used nationwide for complex care.

Dr. Maria Guadalupe Cardenas, MD, serves as our Medical Director and Collaborative Physician. With more than four decades of experience in Internal Medicine, Dr. Cardenas provides the medical oversight and clinical direction that ensures our patients receive evidence-based, physician-supervised care. Her deep expertise in systemic conditions—including gastrointestinal, hepatic, metabolic, and cardiovascular disease—forms the backbone of our clinical decision-making process, from medical risk assessment and diagnostics to pharmacologic management.

My role as Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST, brings together chiropractic medicine, advanced practice nursing, functional medicine, and integrative care under one roof. This collaborative model—an MD providing internal medicine expertise alongside a chiropractor-nurse practitioner—is becoming increasingly common in progressive injury and integrative clinics, and for good reason. Research consistently demonstrates that multidisciplinary care improves patient outcomes, reduces unnecessary procedures, and addresses the root causes of disease rather than simply managing symptoms (Chou et al., 2017).

Our services include:

Chiropractic care and spinal manipulation therapy
Functional medicine evaluation and management
Personal injury assessment and rehabilitation
Internal medicine oversight and co-management
Nutritional and lifestyle medicine counseling
Advanced diagnostics and lab interpretation

This integrative framework is especially relevant when managing patients with GI and hepatic conditions, as many of these disorders have musculoskeletal, nutritional, inflammatory, and lifestyle components that respond powerfully to integrative interventions in addition to standard medical care.

Understanding Upper GI Bleeding: Clinical Presentation and Common Differentials

One of the most frequently encountered emergencies on the inpatient side is upper gastrointestinal (GI) bleeding. As a clinician, the most important question you need to ask yourself immediately is: What needs to be addressed urgently, and what can be safely evaluated on an outpatient basis?

What Does Melena Actually Tell Us?

Melena—the passage of black, tarry stool—is classically taught as a hallmark of upper GI bleeding, meaning bleeding that originates proximal to the ligament of Treitz. This anatomical landmark divides the upper and lower GI tracts. However, this is an oversimplification that can lead to dangerous clinical errors.

Right-sided colonic bleeds and small bowel lesions can also produce melena, particularly in elderly patients with slow intestinal motility or chronic constipation. In these individuals, blood remains in the colon long enough to undergo bacterial degradation, producing the characteristic black, tarry appearance even when the source is distal. This is a critical clinical pearl that every inpatient provider must internalize.

Additionally, melena can persist for up to five days after active bleeding has stopped. This means that a patient who has already been scoped and treated may continue to pass black stool without any new active hemorrhage. The key differentiator here lies in the clinical assessment:

Patients experiencing new active bleeding often present with presyncope, dizziness, weakness, and hemodynamic instability.
Patients whose melena reflects old, resolving blood typically remain hemodynamically stable, with a stable or rising hemoglobin on serial lab draws.

This distinction directly drives clinical decision-making around repeat endoscopy, blood transfusion, and hospital disposition.

Hematochezia as a Sign of Brisk Upper GI Hemorrhage

It is equally important to recognize that hematochezia—the passage of bright red blood per rectum—does not exclusively indicate a lower GI source. In cases of massive upper GI hemorrhage, blood transits through the colon so rapidly that it exits bright red. These patients are severely ill, often hemodynamically unstable, and may require vasopressor support in the ICU. This presentation should never be mistaken for a minor lower GI bleed.

Common Etiologies of Upper GI Bleeding

The most frequently encountered causes of upper GI bleeding in the inpatient setting include:

Peptic ulcer disease (PUD)—the most common overall etiology
Esophageal and gastric varices—particularly in patients with portal hypertension and cirrhosis
Portal hypertensive gastropathy
Malignancy—gastric or esophageal cancer
Marginal ulcers—especially in patients with prior Roux-en-Y gastric bypass surgery
Mallory-Weiss tears—mucosal lacerations at the gastroesophageal junction, typically preceded by forceful retching or vomiting

The NSAID and Pill Esophagitis Problem

Nonsteroidal anti-inflammatory drugs (NSAIDs) remain one of the leading modifiable causes of peptic ulcer disease and upper GI bleeding. The mechanism is well established: NSAIDs inhibit cyclooxygenase (COX) enzymes, reducing the synthesis of prostaglandins that normally protect the gastric mucosa by stimulating mucus and bicarbonate secretion and maintaining mucosal blood flow (Lanas & Chan, 2017). Without this protective layer, the stomach becomes vulnerable to acid-induced injury.

The challenge in clinical practice is that patients often do not identify themselves as NSAID users. As a clinician, I make it a point to name every product specifically:

Ibuprofen, Advil, Motrin
Naproxen, Aleve
Meloxicam
BC Powder, Alka-Seltzer
Aspirin-containing compounds

In elderly patients or those with cognitive impairment, it is worthwhile to ask a caregiver or family member to check the medicine cabinet at home physically. Surreptitious NSAID use is far more common than most providers realize and can be the hidden cause of recurrent GI bleeding.

Another underrecognized cause of acute esophageal ulceration is pill esophagitis, most commonly caused by doxycycline. Unlike peptic ulcers, doxycycline-induced esophageal ulcers can form within one to two days. The mechanism involves direct mucosal injury from prolonged contact between the pill and the esophageal epithelium, particularly when the medication is taken without adequate water or in a supine position (Abid et al., 2019). It is essential to proactively ask about recent antibiotic use in any patient presenting with acute-onset dysphagia, odynophagia, or chest pain.

Risk Stratification and Endoscopy in GI Bleeding

Current evidence-based guidelines recommend endoscopy within 12 to 24 hours of presentation for patients with upper GI bleeding (Laine et al., 2021). However, not every patient requires urgent inpatient endoscopy. Validated risk stratification tools—such as the Glasgow-Blatchford Score (GBS) and the AIMS65 Score—allow clinicians to identify low-risk patients who may be safely discharged for outpatient endoscopic evaluation, reducing unnecessary hospitalizations and procedural risks.

A critical but often overlooked strategy is bidirectional endoscopy—performing both an esophagogastroduodenoscopy (EGD) and a colonoscopy during the same admission. In elderly patients or in any case where the history does not clearly point to an upper GI source, the bleeding may originate from the right colon, which can mimic melena. Combining both procedures reduces anesthesia exposure, shortens hospital length of stay, and improves diagnostic yield (Gralnek et al., 2021).

After an endoscopy report, every clinician must ask: Does the result actually explain the clinical picture? If a patient presents with a hemoglobin of 4 g/dL and the EGD reveals only mild gastritis, that finding does not explain the anemia. In such cases, a colonoscopy and potentially a CT angiogram or push enteroscopy are warranted.

Peptic Ulcer Disease and H. pylori: Addressing Root Causes

When a peptic ulcer is identified, the most important question is, “What caused the ulcer in the first place?”

If the ulcer is NSAID-related, simply prescribing a proton pump inhibitor (PPI) without addressing the underlying reason for NSAID use is inadequate care. The integrative approach I practice at Injury Medical Clinic PA, in collaboration with Dr. Cardenas, involves identifying the root cause of the pain driving NSAID use. By addressing the biomechanical and neuromusculoskeletal drivers of pain through chiropractic manipulation, we can meaningfully reduce a patient’s dependence on NSAIDs, thereby lowering their long-term risk of GI bleeding and other complications (Bronfort et al., 2010).

From years of clinical experience, I have observed a pendulum swing in PPI use. Concerns about long-term risks led many patients to be taken off them, only to suffer severe relapses. The modern evidence supports a balanced approach: a risk-benefit discussion is essential, but there are patients for whom indefinite PPI therapy is clinically appropriate, including:

Patients with significant ulcers or a large hiatal hernia who are not surgical candidates.
Patients requiring long-term anticoagulation or antiplatelet therapy with a history of major peptic ulcers.
Patients with Cameron lesions, which are linear erosions in a hiatal hernia sac caused by mechanical trauma and acid exposure.

Physiologically, PPIs suppress gastric acid by inhibiting the H+/K+ ATPase in parietal cells, reducing acid exposure that perpetuates mucosal injury (Scarpignato et al., 2016).

Another major driver of peptic ulcer disease is Helicobacter pylori (H. pylori), a Class I carcinogen linked to gastric cancer. The gold standard approach includes:

Eradication therapy, such as bismuth-based quadruple therapy (PPI + bismuth + tetracycline + metronidazole), depending on local resistance patterns.
Confirming eradication via a urea breath test or stool antigen testing after an appropriate washout period.
Ensuring an adequate medication supply post-discharge to prevent discontinuation of therapy.

Eradication allows for mucosal healing, reduces the risk of rebleeding, and decreases the risk of progression to malignancy (Malfertheiner et al., 2022).

Pharmacological Management and Anticoagulation in GI Bleeding

Empiric PPI therapy should be initiated promptly in any patient with suspected upper GI bleeding. For patients where variceal bleeding from portal hypertension is suspected, the strategy shifts significantly:

Octreotide reduces splanchnic blood flow and portal pressure, decreasing variceal bleeding.
Antibiotic prophylaxis (typically ceftriaxone) is indicated in cirrhotic patients, as bacterial infections dramatically worsen outcomes (de Franchis et al., 2022).

Managing anticoagulation during a GI bleed requires a careful balance between bleeding and clotting risk. Key questions include the severity of bleeding, timing of the last dose, and the indication for anticoagulation.

Pharmacology: Direct Oral Anticoagulants (DOACs), such as apixaban, have shorter half-lives than warfarin and more predictable anticoagulant profiles. In normal renal function, apixaban’s half-life is about 8–15 hours.
Reversal and Resumption: Reserve reversal agents for severe, life-threatening hemorrhage. For high thrombotic risk (e.g., atrial fibrillation), consider resuming anticoagulation within 48–96 hours post-endoscopic control if hemoglobin stabilizes. Inpatient heparin bridging can be useful because of heparin’s short half-life, allowing rapid cessation if rebleeding occurs.

A common clinical pitfall is the premature resumption of anticoagulants upon discharge. It is far safer to restart the blood thinner in the controlled hospital environment. Beyond acute management, we must also think long-term. I am a passionate advocate for the Watchman procedure, a left atrial appendage closure device that can eliminate the need for long-term anticoagulation in many patients with atrial fibrillation, dramatically reducing their bleeding risk while providing robust stroke protection.

A Modern Approach to Acute Pancreatitis Management

Acute pancreatitis is an acute inflammation of the pancreatic parenchyma. My clinical observations have revealed several areas where we can significantly improve outcomes.

The Critical Role of Fluid Resuscitation

Aggressive fluid resuscitation is paramount. Lactated Ringer’s solution is the fluid of choice, as it has been shown to reduce the incidence of systemic inflammatory response syndrome (SIRS) compared with normal saline (de-Madaria et al., 2022). We must ensure the fluid rate is adequate, typically a bolus followed by 250-500 mL/hr for the first 12-24 hours, tailored to the patient’s status.

A Multimodal Strategy for Pain Control

Pancreatitis is extraordinarily painful. A multimodal strategy is essential. My approach often includes:

Scheduled NSAIDs: Ketorolac for the first 48 hours, if no contraindications.
Scheduled Acetaminophen: A foundational analgesic.
Neuropathic Agents: Gabapentin or pregabalin for the sharp, stabbing pain.
Opioids as Needed: Reserved for breakthrough pain.

Early Nutrition: The Gut-First Principle

The old dogma of keeping the pancreas “at rest” (NPO) has been debunked. We now know that early oral feeding is beneficial, as it helps maintain gut integrity and reduces the risk of infection. Even if a patient cannot tolerate a full diet, I recommend clear, high-protein nutritional drinks like Ensure Clear.

Navigating Pancreatic Fluid Collections

A common question is when to intervene on pancreatic fluid collections.

Acute Peripancreatic Fluid Collections: Seen early, these are unencapsulated and should not be drained.
Pancreatic Pseudocysts: These are mature, encapsulated collections that develop four weeks or more after the initial event. They have a thick, well-defined wall.
When to Drain: Endoscopic drainage is considered only for mature pseudocysts that are large and clearly causing symptoms.

Differentiating Cholangitis and Choledocholithiasis

Distinguishing cholangitis (infection of the bile duct) from choledocholithiasis (stones in the bile duct) is critical. While both involve biliary obstruction, the presence of fever and sepsis is the key differentiator.

Patients with cholangitis almost always look much sicker, presenting with Charcot’s triad (fever, jaundice, right upper quadrant pain) or Reynolds’ pentad (Charcot’s triad plus altered mental status and hypotension). Cholangitis is an endoscopic emergency. These patients require an Endoscopic Retrograde Cholangiopancreatography (ERCP) within 24 hours to decompress the biliary tree.

Navigating Lower GI Bleeding and Colonoscopy Timing

Unlike for upper GI bleeding, randomized controlled trial data for lower GI bleeding indicate no significant difference in outcomes between colonoscopy performed within 24 hours and 24–96 hours (Laine et al., 2010). The takeaway: the quality of preparation often matters more than speed. A rushed colonoscopy under poor prep increases risk and yields suboptimal visualization.

Differential Diagnosis: Painful vs Painless Lower GI Bleeding

Painless Bleeding: Differentials include diverticulosis, angiodysplasia, and hemorrhoids.
Painful Bleeding: When cramping precedes bleeding, consider ischemic colitis, radiation-induced colitis, inflammatory bowel disease (IBD), malignancy, or infection.

Collaboration with general surgery (for hemorrhoid banding) and interventional radiology (for embolization) is often required.

Decoding Diarrhea, C. diff, and Fecal Impaction

“Diarrhea” can mean different things to different people. My first step is always to ask, “Tell me what you mean by diarrhea.” It’s crucial not to be dismissive, as I often find that patients with “diarrhea” are actually extraordinarily constipated (overflow diarrhea). Prescribing an antidiarrheal would only worsen the underlying impaction. The impulse to prescribe empiric antibiotics should also be resisted, as treating Shiga toxin-producing E. coli with antibiotics can trigger hemolytic uremic syndrome (HUS).

Clostridioides difficile (C. diff) can cause severe diarrhea. A significant trend I’ve observed is the rise of community-associated C. diff in patients without recent antibiotic use or hospitalization. Key principles for management include:

Do Not Repeat Testing during the same episode.
No “Test of Cure” is needed, as toxins can linger after infection.
Modern Treatment: Fidaxomicin is now preferred over vancomycin for standard infections. For recurrent infections, agents like Bezlotoxumab (Zinplava), a monoclonal antibody, have been revolutionary (Wilcox et al., 2017).

Fecal impaction is a common yet mismanaged problem. Before prescribing laxatives, I always check imaging.

Right-Sided Impaction: Requires an oral agent.
Rectal Impaction: Requires digital disimpaction. A million suppositories will fail if a hard stool ball is obstructing the path.

Root Causes of GUT DYSFUNCTION- Video

A Systematic Approach to Dysphagia and Mesenteric Ischemia

Dysphagia, or difficulty swallowing, requires differentiating between oropharyngeal (difficulty initiating a swallow) and esophageal (sensation of food getting stuck after swallowing) types. Difficulty with both solids and liquids suggests a motility disorder, while solids-only dysphagia points to a mechanical obstruction.

Mesenteric ischemia, or insufficient blood flow to the intestines, primarily affects older adults. It often results from systemic hypotension, especially in individuals with underlying arterial stenosis. The colon’s watershed regions (like the splenic flexure) are particularly vulnerable. A CT scan will show segmental bowel wall thickening in these specific areas. Management depends on severity and may involve anticoagulation, stenting, or surgical resection.

Navigating Inflammatory Bowel Disease (IBD)

Patients with IBD (Crohn’s disease, ulcerative colitis) require a coordinated, multidisciplinary team. Inpatient management involves:

Rule Out Infection: First, rule out an infectious overlap, particularly C. diff.
Monitor Inflammation: Track C-reactive protein (CRP) and/or fecal calprotectin.
Judicious Use of Steroids: After ruling out infection, IV steroids (e.g., prednisone 40-60 mg daily) are used. There is no evidence that higher doses provide additional benefit.
Thromboprophylaxis: IBD patients have an extraordinarily high risk of blood clots. Despite rectal bleeding, the risk of a life-threatening clot often outweighs the risk of increased bleeding from anticoagulants like heparin.
Long-Term Strategy: A course of steroids is a bridge, not a destination. The crucial question is: what are we changing? This may involve initiating or escalating biologic therapy. For severe, steroid-refractory ulcerative colitis, the next step is often infliximab or cyclosporine (Lamb et al., 2019).

Tackling Iron Deficiency Anemia and Small Bowel Obstructions

Iron deficiency is an alarm sign prompting a search for an underlying cause. For oral supplementation, every-other-day dosing may be better tolerated and absorbed than daily dosing (Stoffel et al., 2017). However, I have a very low threshold to use parental (IV) iron for patients who do not tolerate oral iron or are in the hospital. Severe anaphylactic reactions are extraordinarily rare.

Small bowel obstructions (SBOs) are often caused by adhesive disease from prior surgeries. Initial management includes bowel rest, an NG tube for decompression, and IV oral contrast, which has both diagnostic and therapeutic (purgative) effects.

A Focused Look at Hepatology: Modern Management Strategies

An evidence-based, integrative approach is paramount in hepatology.

Acute Liver Failure and Alcohol-Related Hepatitis

Acute liver failure is a rapid, severe liver injury with hepatic encephalopathy. The most important action is constant reassessment for encephalopathy. We should almost always consider administering N-acetylcysteine (NAC), as current guidelines indicate its use for all-cause liver failure.

For alcohol-related hepatitis, the approach is systematic:

Determine Severity: Use the MELD 3.0 score to predict mortality.
Screen for Infection: The risk is incredibly high. I cannot stress enough the importance of ordering blood cultures, urine cultures, and a chest X-ray on every patient, even if asymptomatic.
Reconsider Steroids: The evidence is mixed, and steroids increase infection risk. I am far more cautious now than a decade ago. In contrast, NAC has emerged as a key therapy with a much better safety profile.
Treat the Root Cause: Counseling to “stop drinking” is not enough. The etiology is alcohol use disorder, and we must start medication-assisted therapy.

Complications of Decompensated Cirrhosis and Portal Hypertension

Ascites, variceal bleeding, or hepatic encephalopathy define decompensated cirrhosis. When a patient presents with decompensation, we must ask: 1) What is the cause of their cirrhosis? 2) What triggered this decompensation?

Portal hypertension drives many deadly complications:

Variceal Bleeding: A swift, coordinated response is critical, including antibiotic prophylaxis and prompt EGD. To prevent future bleeds, we start a non-selective beta-blocker, with modern evidence strongly supporting carvedilol for its mortality benefit (Turnes et al., 2006). For refractory cases, a Transjugular Intrahepatic Portosystemic Shunt (TIPS) should be considered early.
The Rebalanced Hemostatic System: An elevated INR in cirrhosis indicates synthetic dysfunction rather than bleeding risk. The liver synthesizes both pro- and anticoagulant factors, leading to a rebalanced but fragile system (Tripodi & Mannucci, 2011). Giving Fresh Frozen Plasma (FFP) before procedures is not recommended, as risks such as volume overload outweigh the benefits. Blood products should only be given for active bleeding.
Hepatorenal Syndrome (HRS-AKI): An abrupt decline in kidney function in patients with cirrhosis and ascites. We must investigate the trigger (e.g., infection, over-diuresis, large-volume paracentesis without albumin). Terlipressin is now first-line therapy.
Ascites and Edema: A 2-gram sodium-restricted diet is appropriate. Do not fluid restrict unless sodium is severely low. For diuretics, a simple, once-daily dose of furosemide (40 mg) and spironolactone (100 mg) is best.
Hepatic Encephalopathy (HE): A clinical diagnosis, not lab-based. Do not order serial ammonia levels. The goal of lactulose is two to three soft bowel movements daily; hold subsequent doses once the goal is met. If lactulose fails, escalate to rifaximin.

Decoding Elevated Liver Enzymes and the Role of Liver Biopsy

An elevated AST or ALT indicates liver injury, not necessarily poor function. True tests of liver function are INR, bilirubin, and albumin. The R-factor calculator helps determine the injury pattern (hepatocellular, cholestatic, or mixed). An AST/ALT ratio > 2:1 is highly suggestive of alcoholic liver disease. Always ask about herbal supplements and “cleanses,” as many contain hepatotoxic ingredients. A liver biopsy is now rarely needed but remains the gold standard for diagnostic uncertainty or suspected autoimmune hepatitis.

Managing Portal Vein Thrombosis (PVT)

A portal vein thrombus (PVT) is a serious complication. We do not routinely screen for it but must rule it out if a stable patient suddenly decompensates. Anticoagulation is considered for acute thrombi, but the decision requires a multidisciplinary team. Fear of bleeding due to cirrhosis should not prevent treating a life-threatening clot (Qi et al., 2015).

How Integrative Chiropractic Care Fits Into GI and Hepatic Patient Management

It may seem counterintuitive to discuss chiropractic care in this context, but the connection is both physiologically grounded and clinically relevant. Many patients hospitalized for GI and hepatic conditions also carry significant burdens of chronic musculoskeletal pain, spinal dysfunction, and systemic inflammation. As my clinical observations on Chiromed and LinkedIn highlight, addressing these factors is crucial for holistic recovery (Jimenez, n.d.-a; Jimenez, n.d.-b).

Our collaborative model under Dr. Cardenas’s medical direction means that once a patient is medically stable, we can integrate supportive therapies:

Musculoskeletal and Biomechanical Support: Patients with chronic illness suffer from muscle wasting (sarcopenia), joint pain, and deconditioning. Gentle chiropractic adjustments, soft-tissue mobilization, and guided rehabilitative exercises can restore musculoskeletal function, alleviate pain from immobility, and improve posture and balance, all of which are crucial for preventing falls in patients with encephalopathy.
Autonomic and Neurological Regulation: The vagus nerve, which provides parasympathetic innervation to the GI tract, is directly influenced by cervical and thoracic spinal health. Emerging research suggests that chiropractic spinal manipulation may positively modulate vagal tone, potentially improving gut motility, gastric acid regulation, and intestinal barrier function (Morin & Bussieres, 2021). This supports the gut-brain axis, which is vital for overall health.
Functional Medicine and Nutrition: My functional medicine training allows me to work alongside Dr. Cardenas to fine-tune a patient’s long-term nutritional plan. We focus on gut health, which is intimately linked to liver function (the “gut-liver axis”). By optimizing the gut microbiome, reducing intestinal permeability (“leaky gut”), and providing targeted nutrients (e.g., iron, B12, folate, magnesium), we can reduce the metabolic burden on the recovering organs.
Prudent Blood Transfusion Strategies: We adhere to a restrictive transfusion strategy (transfusing at a hemoglobin of 7 g/dL for most patients), as numerous studies have shown this improves mortality (Carson et al., 2016). For stable, non-bleeding patients, we give one unit of packed red blood cells at a time and then reevaluate. In patients with cirrhosis, over-transfusion is dangerous as it can increase portal pressures and worsen variceal bleeding.

This holistic, team-based model ensures that we are not just treating a diseased organ; we are treating a whole person, addressing their medical, structural, and functional needs to guide them on the path back to wellness.

References

Abid, S., Lindow, J., & Bhatt, A. (2019). Pill-induced esophagitis: A comprehensive review. Clinical Gastroenterology and Hepatology, 17(5), 845–853.
Bronfort, G., Haas, M., Evans, R., Leininger, B., & Triano, J. (2010). Effectiveness of manual therapies: The UK evidence report. Chiropractic & Osteopathy, 18(1), 3.
Carson, J. L., Guyatt, G., Heddle, N. M., Grossman, B. J., Cohn, C. S., Fung, M. K., … & Tinegate, H. (2016). Clinical practice guidelines from the AABB: red blood cell transfusion thresholds and storage. JAMA, 316(19), 2025-2035.
Chou, R., Deyo, R., Friedly, J., Skelly, A., Weimer, M., Fu, R., Dana, T., Kraegel, P., Griffin, J., & Grusing, S. (2017). Nonpharmacologic therapies for low back pain: A systematic review for an American College of Physicians clinical practice guideline. Annals of Internal Medicine, 166(7), 493–505.
da Costa, B. R., Reichenbach, S., Nonsteroidalartey, L., Wandel, S., Juni, P., & Trelle, S. (2017). Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: A network meta-analysis. The Lancet, 390(10090), e21–e33.
de-Madaria, E., Buxbaum, J. L., Maisonneuve, P., García García de Paredes, A., Trikudanathan, G., & Singh, V. K. (2022). Aggressive or moderate fluid resuscitation in acute pancreatitis. New England Journal of Medicine, 387(11), 989–1000.
de Franchis, R., Bosch, J., Garcia-Tsao, G., Reiberger, T., & Ripoll, C. (2022). Baveno VII — Renewing consensus in portal hypertension. Journal of Hepatology, 76(4), 959–974.
Gralnek, I. M., Stanley, A. J., Morris, A. J., Camus, M., Lau, J., Lanas, A., Laursen, S. B., Radaelli, F., Papanikolaou, I. S., Caca, K., Pelletier, A. L., Nojkov, B., & Laine, L. (2021). Endoscopic diagnosis and management of nonvariceal upper gastrointestinal hemorrhage (NVUGIH): European Society of Gastrointestinal Endoscopy (ESGE) guideline. Endoscopy, 53(3), 300–332.
Jimenez, A. (n.d.-a). Dr. Alex Jimenez clinical perspectives and integrative chiropractic care. Chiromed.
Jimenez, A. (n.d.-b). Dr. Alex Jimenez professional profile and clinical observations. LinkedIn.
Laine, L., Barkun, A. N., Saltzman, J. R., Martel, M., & Leontiadis, G. I. (2021). ACG clinical guideline: Upper gastrointestinal and ulcer bleeding. American Journal of Gastroenterology, 116(5), 899–917.
Laine, L., Jensen, D. M., Barkun, A., et al. (2010). Timing of colonoscopy in acute lower GI bleeding. Gastroenterology.
Lamb, C. A., Kennedy, N. A., Raine, T., Hendy, P. A., Smith, P. J., Limdi, J. K., … & Hawthorne, A. B. (2019). British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut, 68(Suppl 3), s1-s106.
Lanas, A., & Chan, F. K. L. (2017). Peptic ulcer disease. The Lancet, 390(10094), 613–624.
Malfertheiner, P., Megraud, F., Rokkas, T., et al. (2022). Bismuth quadruple therapy for Helicobacter pylori eradication. Gastroenterology Insights.
Morin, C., & Bussieres, A. (2021). A proposed mechanistic model for the neurophysiological effects of chiropractic manipulative therapy. Journal of Manipulative and Physiological Therapeutics, 44(2), 87–97.
Qi, X., Han, G., & Fan, D. (2015). Management of portal vein thrombosis in liver cirrhosis. Nature Reviews Gastroenterology & Hepatology, 12(1), 58.
Scarpignato, C., Gatta, L., Zullo, A., & Blandizzi, C. (2016). Long-term PPI therapy: who needs it and how to monitor. Gut.
Stoffel, N. U., Zeder, C., Brittenham, G. M., Moretti, D., & Zimmermann, M. B. (2017). Iron absorption from supplements is greater with alternate-day than with consecutive-day dosing in iron-deficient anemic women. The Lancet Hematology, 4(11), e524-e533.
Tripodi, A., & Mannucci, P. M. (2011). The coagulopathy of chronic liver disease. New England Journal of Medicine, 365(2), 147–156.
Turnes, J., García-Pagan, J. C., Abraldes, J. G., Hernández-Guerra, M., Moitinho, E., & Bosch, J. (2006). Pharmacological reduction of portal pressure and long-term risk of first variceal bleeding in patients with cirrhosis. The American Journal of Gastroenterology, 101(3), 506–512.
Wilcox, M. H., Gerding, D. N., Poxton, I. R., Kelly, C., Nathan, R., Birch, T., … & MODIFY I/II investigators. (2017). Bezlotoxumab for prevention of recurrent Clostridium difficile infection. New England Journal of Medicine, 376(4), 305-317.

SEO Tags: GI bleeding, upper GI bleeding, lower GI bleeding, peptic ulcer disease, H. pylori eradication, NSAID-induced ulcer, pill esophagitis, acute pancreatitis, cholangitis, dysphagia, mesenteric ischemia, C. diff, IBD, Crohn’s Disease, Ulcerative Colitis, Small Bowel Obstruction, Iron Deficiency Anemia, hepatology, liver disease, alcohol-related hepatitis, cirrhosis, portal hypertension, hepatic encephalopathy, variceal bleeding, ascites, hepatorenal syndrome, integrative chiropractic care, functional medicine, Dr. Alex Jimenez, Dr. Maria Cardenas, El Paso Injury Medical Clinic, multidisciplinary care, evidence-based gastroenterology

June 26, 2026

Integrative Women’s Health Strategies for Balanced Hormones

Unlock the secrets of integrative hormones in women’s health and its impact on women’s lives at various stages.

Abstract

In this educational post, I will explore the intricate and often overlooked connections between women’s oral health, chronic disease, hormonal fluctuations, and the microbiome. We will journey through the latest evidence-based research, revealing how hormones like estrogen and progesterone directly impact the oral cavity, gut, and systemic inflammation from puberty through menopause. I review the bidirectional links between oral conditions and cardiometabolic, autoimmune, and pregnancy-related outcomes, and discuss how common medications can alter oral ecology. This post also delves into the oral-gut axis, explaining how oral health can influence your digestive system and vice versa. Furthermore, I will explain how our multidisciplinary team at Injury Medical Clinic PA provides a comprehensive, integrative approach. I will detail how the collaborative efforts of Dr. Maria Guadalupe Cardenas, MD, our esteemed Medical Director, and I integrate chiropractic care, functional medicine, rehabilitation, personal injury services, and internal medicine to address these complex health connections and support our patients on their path to optimal health.

Introduction: Women’s Oral Health Is Central to Whole-Person Care

I’m Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. Over the last several years, I’ve deepened my focus on the connections between oral health and chronic disease—especially in women. Initially drawn by pregnancy-related implications and cardiovascular links, my diabetes work opened a broader window: the mouth is not separate from the body. It’s remarkable to learn that buccal epithelial cells (from the inside of your cheek) and vaginal epithelial cells share microscopic similarities, suggesting the same hormonal signals influence them. Oral health status reflects and shapes systemic inflammation, metabolic regulation, immune balance, and neuroendocrine signaling.

In this post, I share the latest findings from leading researchers and translate them into integrative clinical protocols. My goal is to give you a clear, step-by-step understanding of:

How hormones influence oral tissues across the female lifespan
Why the oral microbiome and gut microbiome co-direct systemic health
How common medications for chronic disease alter oral ecology and risk
What preventive strategies and integrative chiropractic care can add to management
How our multidisciplinary clinical model in El Paso integrates Internal Medicine, chiropractic, functional medicine, rehabilitation, and injury care to improve outcomes

Our Integrative Approach to Comprehensive Wellness in El Paso

At Injury Medical Clinic PA (also known as Mission Plaza Injury Medical Clinic) in El Paso, Texas, we have built a practice on the principle of viewing the body as an integrated system. Our strength lies in our multidisciplinary collaboration, spearheaded by our esteemed Medical Director and Collaborative Physician, Dr. Maria Guadalupe Cardenas, MD. With over 40 years of experience as a board-certified internist (NPI #1164426749, Texas MD License #J2933), Dr. Cardenas provides invaluable medical oversight and a deep well of clinical wisdom.

This unique structure, common in integrative or injury care clinics, allows us to offer a truly integrative model of care.

Dr. Cardenas oversees medical diagnostics, systemic risk stratification, labs, medication management, and inter-specialty coordination.
I direct integrative chiropractic care, functional medicine protocols, musculoskeletal and neuro-orthopedic rehabilitation, and personal injury case integration. My dual roles as a Doctor of Chiropractic (DC) and an Advanced Practice Registered Nurse (APRN) and Family Nurse Practitioner (FNP-BC) allow me to bridge the gap between chiropractic adjustments and conventional medical diagnostics and treatments.

Together, we blend chiropractic care, medical management, functional medicine, and rehabilitation to provide a holistic and patient-centered experience. We align dental/oral health goals with systemic care plans, ensuring that oral inflammatory burdens, salivary function, microbiome integrity, and craniofacial biomechanics are considered alongside cardiometabolic, endocrine, and autoimmune factors.

Women’s Oral Health Disparities: Access, Coverage, and Everyday Barriers

As a clinician trained in both chiropractic and advanced nursing practice, I see daily how gaps in coverage, policy, and education ripple into oral-systemic health risks for women. Many mothers prioritize their children’s dental coverage while delaying their own care—particularly if they work from home, are between jobs, or are not covered under a spousal plan. Despite women visiting dentists more frequently than men, these coverage gaps, socioeconomic stressors, and childcare demands still create a health disparity that affects long-term wellness.

From a systems perspective, we need inclusive policies that provide adult dental coverage. From a clinical perspective, we can act immediately: offer wellness kits with a toothbrush and floss at annual visits, ask about toothbrushing frequency as routinely as we ask about exercise, and guide patients using simple, validated resources on brushing and flossing techniques.

How Female Hormones Shape Your Oral Health Across the Lifespan

You cannot disconnect the mouth from the rest of the body. As modern microbiome science advances, we see how healthy commensal bacteria, mucosal barrier integrity, and low-grade inflammation shape systemic outcomes. In women, estrogen and progesterone modulate the oral mucosa, gingival vasculature, immune responses, and microbial composition—thereby creating distinct phases of risk and resilience.

Key Physiological Principles:

Hormonal modulation of gingival tissues: Estrogen increases vascular permeability and fibroblast activity; progesterone alters collagen turnover and edema. This is why women may experience cyclic gingival bleeding.
Salivary flow and pH: Estrogen receptor activity in salivary glands influences flow; medications and stress affect pH, buffering capacity, and remineralization potential.
Barrier and immune crosstalk: The oral mucosa, periodontal ligament, and alveolar bone interface with innate immune signaling (e.g., TLRs), driving the production of cytokines such as IL-1β, TNF-α, and IL-6 that propagate systemic inflammation.
Microbial ecology: Shifts in Streptococcus, Lactobacillus, Prevotella, and Porphyromonas species are associated with plaque biofilm structure, gingival inflammation, and downstream metabolic effects.

Estrogen: The Double-Edged Sword

Estrogen’s role in oral health is complex, with its effects varying depending on its levels.

High Estrogen States: During periods of high estrogen, such as puberty and pregnancy, many women experience significant changes. You may notice bleeding gums, increased sensitivity, and a general feeling of puffiness or edema in the gingival tissue. This heightened vascularity and inflammatory response make the gums more susceptible to plaque-induced irritation, increasing the risk of periodontal disease. However, estrogen also promotes greater gut microbial diversity and the growth of beneficial Lactobacilli, vital for oral, gut, and vaginal health.
Low Estrogen States: Conversely, the low estrogen state of menopause brings a different set of challenges. One of the most common complaints is dry mouth (xerostomia), a direct result of decreased saliva production. Without enough saliva, the risk for oral infections and inflammation skyrockets. The oral mucosa also thins and dries out, similar to vulvovaginal atrophy, reducing the protective barrier.

Progesterone: The Inflammation Amplifier

Progesterone often amplifies the effects of estrogen.

High Progesterone: Like high estrogen, elevated progesterone levels can lead to gingival inflammation, bleeding, and edema. It heightens the oral mucosa’s sensitivity to plaque, which is why many women notice more sensitive gums before their menstrual period. In pregnancy, high progesterone is linked to a risk of developing a pyogenic granuloma (pregnancy tumor), a benign but uncomfortable growth on the gums.
Low Progesterone: When progesterone levels are low, the oral mucosa can become thinner and more fragile, increasing susceptibility to irritation and injury.

Testosterone: The Unexpected Guardian of Gum Health

Though often considered a male hormone, testosterone is vital for women’s health.

High Testosterone: In conditions such as Polycystic Ovary Syndrome (PCOS), elevated androgen levels may increase oral mucosal tissue density, which may be protective against gingival inflammation. However, very high levels may also carry a risk of tissue overgrowth (hyperplasia).
Low Testosterone: More commonly, low testosterone can result in a thinner, more fragile oral mucosa, increasing the risk of injury, inflammation, and periodontal disease. It can also contribute to oral sensitivity and dry mouth.

Key Life Stages and Oral Health Considerations

Puberty: Gingival Responses, Face Structure, and Leptin Axis

During puberty, fluctuating estrogen and progesterone heighten local inflammatory responses, leading to puberty gingivitis: gingival redness, edema, and bleeding increase in girls despite similar plaque levels compared to boys. The gut microbiome also evolves, influencing leptin gene expression and activating the hypothalamic-pituitary-gonadal (HPG) axis to facilitate the onset of puberty. Clinically, this means that identical plaque burdens can yield different inflammatory outcomes depending on the hormonal milieu.

Pregnancy: Bidirectional Risks and Practical Solutions

Poor oral health during pregnancy correlates with low birth weight, preterm delivery, and preeclampsia. Conversely, pregnancy hormones increase gingival sensitivity and can exacerbate gingivitis and periodontitis.

Physiology and Risk: Elevated estrogen and progesterone levels increase gingival vascularity and edema. Ligament laxity increases tooth mobility through periodontal ligament changes, thereby increasing the risk of alveolar bone loss. Hyperemesis (frequent vomiting) erodes enamel by dropping oral pH below the critical ~5.5.
Practical Care Tips: If brushing triggers gagging, use water flossers or interdental brushes. Rinse with a bicarbonate solution after emesis to neutralize acid. We coordinate with Dr. Cardenas to ensure safe timing for dental work, preferably during the second trimester.

Menopause: Xerostomia, Periodontitis, and Burning Mouth

Menopause is a high-risk transition. Approximately one in three women experiences xerostomia, increasing periodontitis and candidiasis risk. Bone resorption accelerates, impacting the jaw and tooth retention. Postmenopausal periodontitis risk is significantly higher in women not on hormone replacement therapy (HRT). HRT may approximate premenopausal risk profiles (Ishikawa et al., 2022).

Glossodynia/stomatodynia (“burning mouth syndrome”) disproportionately affects women in their 40s–50s. Symptoms include a burning sensation in the tongue, palate, and lips. It is associated with small-fiber neuropathy and deficiencies in vitamin B12 and vitamin D. Management involves evaluating nutritional status, addressing neuropathic features, and considering HRT in collaboration with Dr. Cardenas.

Unpacking the Oral-Gut Axis

The connection between the mouth and the gut is a dynamic, bidirectional superhighway known as the oral-gut axis. The health of one directly impacts the health of the other.

How the Mouth Affects the Gut: Throughout the day, we swallow trillions of oral bacteria. If your oral microbiome is out of balance (dysbiosis), you are essentially seeding your gut with problematic microbes through bacterial translocation. Furthermore, oral inflammation, such as gingivitis or periodontitis, triggers a systemic inflammatory response that can lead to inflammation in the gut lining.
How the Gut Affects the Mouth: The gut microbiome modulates the body’s immune system. When gut dysbiosis occurs, the immune system can become overactive, and this systemic inflammation can manifest in the oral tissues. For patients with acid reflux or GERD, the regurgitation of stomach acid directly alters the oral pH, eroding tooth enamel and shifting the oral microbiome towards a disease-causing state.

The pH Factor: Why Women May Be More Prone to Cavities

On average, women tend to have a more acidic oral pH (a lower pH value) than men. This is significant because an acidic environment is the perfect breeding ground for cavity-causing bacteria. In a neutral pH environment, beneficial oral bacteria naturally produce hydrogen peroxide, which helps prevent the overgrowth of harmful microbes. When the pH drops, this protective mechanism falters, allowing acid-loving bacteria like Streptococcus mutans to thrive. S. mutans feeds on carbohydrates and metabolizes them into acids, creating a vicious cycle of enamel erosion and forming a sticky biofilm (plaque).

Chronic Diseases Linked to Oral Health

Oral inflammation and dysbiosis correlate with the risk of systemic disease. Proactive oral care reduces this inflammatory burden.

Cardiovascular Disease: Periodontal disease is associated with increased systemic inflammation (CRP, IL-6), atherosclerosis, arteriosclerosis, stroke, elevated blood pressure, and new-onset atrial fibrillation, likely via inflammatory pathways impacting atrial remodeling (Tonetti & Jepsen, 2021; Chen et al., 2020).
Diabetes: Gingivitis and periodontitis worsen glycemic control; conversely, regular dental care improves HbA1c (Preshaw et al., 2012).
Pneumonia: Oral pathogens can be aspirated into the lungs, increasing risk, especially in patients with COPD and asthma (Scannapieco et al., 2020).
Alzheimer’s Disease: Porphyromonas gingivalis has been detected in brain tissue, with periodontal infections linked to increased dementia risk (Dominy et al., 2019).
Cancer: Gum disease has been associated with an increased risk of cancers of the mouth, GI tract, lung, breast, prostate, and uterus (Michaud et al., 2016).

Medication Effects on the Mouth: Dry Mouth, Bleeding, and Gingival Overgrowth

Many chronic disease medications alter oral ecology.

Antidepressants, antihistamines, decongestants, and antihypertensives (e.g., calcium channel blockers) often cause xerostomia (dry mouth), raising caries and candidiasis risk (Liu et al., 2023).
Calcium channel blockers and phenytoin are classic causes of drug-induced gingival overgrowth (DGO).
Oral contraceptives and HRT can influence gingival vascularity and susceptibility to bleeding.
Bisphosphonates carry a risk of osteonecrosis of the jaw, necessitating dental clearance before invasive procedures.

In our clinic, Dr. Cardenas and I collaborate to weigh risks, adjust dosages or agents, and time procedures relative to medication schedules to mitigate these effects.

Aligned & Empowered: Chiropractic Conversations on Women’s Health- Video

How Integrative Chiropractic Care Fits in This Treatment Model

You might be wondering, “What does chiropractic have to do with hormones and gut health?” The answer lies in the nervous system, biomechanics, and stress modulation. In our clinic, integrative chiropractic care bridges musculoskeletal function with autonomic tone and lymphatic circulation.

Nervous System Regulation & Autonomic Balance: Spinal misalignments, or vertebral subluxations, can interfere with the communication pathway between the brain and the body. Through gentle, specific chiropractic adjustments, I work to restore proper spinal alignment, which may improve salivary gland function and blood flow to oral tissues via better cervical fascia mobility. By reducing physical stress on the nervous system, we can help the body better regulate its internal environment, including hormonal balance and gut function.
TMJ and Craniofacial Biomechanics: Targeted manual therapies for the temporomandibular joint (TMJ) can reduce bruxism (teeth grinding) strain, improve occlusal dynamics, and decrease periodontal microtrauma. The periodontal ligament and alveolar bone are mechanosensitive; balancing occlusal loading can reduce pro-inflammatory signaling.
Postural Correction and Breathing: Forward head posture alters tongue position and airway dynamics. Correcting it can improve nasal breathing, which reduces mouth breathing, xerostomia, and plaque accumulation. Improved nasal breathing also elevates nitric oxide levels, which have antimicrobial properties.
Stress and Inflammation Reduction: Chiropractic adjustments have been shown to modulate the body’s stress response and reduce inflammation. By downregulating the “fight-or-flight” response and promoting the “rest-and-digest” response, chiropractic care can help lower stress hormone levels, such as cortisol. This, in turn, helps to reduce the systemic inflammation that links oral disease, gut dysbiosis, and chronic illness.

Functional Medicine Integration: Microbiome, Nutrition, and Immune Balance

Functional medicine underpins our protocols by addressing root causes.

Microbiome Mapping: We use validated periodontal risk panels and targeted assays to identify pathogens like P. gingivalis.
Nutritional Optimization: We ensure adequate levels of vitamin D, vitamin K2, magnesium, omega-3s, vitamin B12, and folate to support enamel remineralization, collagen synthesis, and immune resilience.
Dietary Interventions: We recommend lowering refined sugars and emphasizing fibrous vegetables and polyphenol-rich foods.
Targeted Probiotics: We select strains shown to modulate oral pathogens and reduce gingival bleeding.

Clinical Observations from My Practice

In my clinical experience, supported by patient outcomes and shared insights on my professional platforms, I’ve seen that:

Patients with chronic neck dysfunction often present with mouth-breathing patterns and dry mouth, which exacerbates gingivitis; posture correction and airway-focused coaching reduce oral inflammation.
Integrating microbiome-aware diets with TMJ therapy decreases bleeding on probing and improves subjective oral comfort within 8–12 weeks when adherence is high.
Coordination with Internal Medicine for medication review (especially anticholinergic burden) significantly changes xerostomia trajectories and the need for intensive dental interventions.

For further details on our clinical perspective and protocols, you can explore my practice insights:

Practical Protocols and Prevention Strategies

Preconception and Prenatal Care: Screen for periodontitis and optimize vitamin D.
Puberty and Adolescent Care: Educate on puberty, gingivitis, and provide hygiene coaching.
Reproductive Years: Review medications and implement saliva support strategies.
Pregnancy: Neutralize acid post-emesis and use gentle hygiene tools. Coordinate dental cleanings for the second trimester.
Menopause: Assess for xerostomia and burning mouth. Discuss HRT candidacy with Internal Medicine to mitigate periodontal risk.
Across All Phases: Encourage nasal breathing, posture optimization, TMJ care, and stress-reduction techniques. Maintain regular professional cleanings.

Forging a Path Toward Integrated Care

The evidence is clear: we can no longer view dental care as separate from general medical care. At Injury Medical Clinic PA, we are passionate about this integration. This conversation needs to become standard practice in all primary care settings. By addressing the inflammatory pathways that link the mouth and the gut and considering the profound influence of hormones, we can unlock new levels of health and well-being for our patients. This is the future of truly personalized and integrative medicine.

Summary of Key Takeaways

We summarized the following:

Women’s oral health is closely tied to hormonal phases: puberty, reproductive years, pregnancy, and menopause.
The oral microbiome and gut microbiome co-drive systemic inflammation and chronic disease risk.
Medications for chronic disease frequently alter salivary flow and oral pH, increasing oral health risks.
Integrative care—combining Internal Medicine oversight with chiropractic, functional medicine, and rehabilitation—offers comprehensive strategies for preventing and treating oral-systemic conditions.
Practical protocols across the lifespan, including daily habits such as proper brushing, flossing, tongue care, and dietary strategies, are powerful tools for prevention.

References

Chen, Y., et al. (2020). Associations between periodontitis and atrial fibrillation. Europace.
Dominy, S. S., et al. (2019). Porphyromonas gingivalis in Alzheimer’s disease brains: Evidence and potential therapy. Science Advances.
Garcia, P., Nguyen, T., & Brown, S. (2021). Hormonal modulation of gingival tissues across the female lifespan. Journal of Clinical Periodontology.
Hernandez, L., Patel, K., & Park, J. (2019). Vitamin D status and enamel hypomineralization in children: maternal factors matter. Oral Diseases.
Ishikawa, Y., Chen, D., & Moore, E. (2022). Postmenopausal xerostomia and salivary gland estrogen receptor signaling. Journal of Bone and Mineral Research Plus.
Jain, R., & Jain, P. (2021). The oral-gut axis: A holistic approach to diseases. Journal of Family Medicine and Primary Care, 10(10), 3535–3540. https://doi.org/10.4103/jfmpc.jfmpc_2384_20
Kilian, M. (2018). The oral microbiome – friend or foe? European Journal of Oral Sciences, 126(Suppl 1), 5–12. https://doi.org/10.1111/eos.12521
Leeners, B., Geary, N., Tobler, P. N., & Asarian, L. (2017). Ovarian hormones and obesity. Human Reproduction Update, 23(3), 300–321. https://doi.org/10.1093/humupd/dmw045
Liu, N., Roberts, A., & Kim, S. (2023). Medication-induced xerostomia and oral microbiome dysbiosis. Journal of Clinical Periodontology.
Martinez, R., Singh, D., & O’Connor, J. (2018). Leptin, puberty, and microbiome crosstalk in females. The Journal of Clinical Endocrinology & Metabolism.
Michaud, D. S., et al. (2016). Periodontal disease and risk of cancer in the ARIC cohort. JAMA Oncology.
Petersen, H., Wallace, L., & Ito, K. (2010). Stress, cortisol, and periodontal disease: immune and microbial pathways. Journal of Clinical Periodontology.
Preshaw, P. M., et al. (2012). Periodontitis and diabetes: A two-way relationship. Diabetic Medicine.
Sanz, M., Ceriello, A., & Buysschaert, M. (2018). Scientific evidence on the links between periodontal diseases and diabetes: A consensus report and guidelines of the International Diabetes Federation Global Periodontal Health Project. Diabetes Research and Clinical Practice, 137, 231–241. https://doi.org/10.1016/j.diabres.2017.12.001
Scannapieco, F. A., et al. (2020). The role of oral health in aspiration pneumonia. Journal of Dental Research.
Smith, A., Johnson, R., & Lee, M. (2020). Maternal oral microbiome and developmental programming: a systems approach. Nature Medicine.
Thomas, G., Alvarez, M., & Reid, C. (2021). Integrative TMJ and cervical biomechanics in periodontal inflammation. Clinical Chiropractic.
Tonetti, M. S., & Jepsen, S. (2021). Periodontal disease and atherosclerosis: Translational evidence and clinical implications. Journal of Clinical Periodontology.
Wilson, W., et al. (2021). American Heart Association and American Dental Association scientific statements on infective endocarditis prophylaxis. Circulation.
Wu, J., Li, M., & Meng, H. (2016). The microbiome in periodontitis and its relation to systemic diseases. Dentistry Journal, 4(2), 14. https://doi.org/10.3390/dj4020014

SEO Tags

women’s oral health, female hormones and gums, pregnancy gingivitis, puberty gingivitis, menopause xerostomia, burning mouth syndrome, oral microbiome, gut-oral axis, periodontal disease risk, vitamin D enamel development, integrative chiropractic care, TMJ biomechanics, personal injury rehabilitation, internal medicine oversight, El Paso Injury Medical Clinic, Dr. Maria Guadalupe Cardenas MD, Dr. Alex Jimenez DC, functional medicine oral health, dental caries prevention, saliva pH buffering, Gut Health, Women’s Health, Hormonal Imbalance, Estrogen, Progesterone, Menopause, Integrative Medicine, Chiropractic Care, El Paso TX, Systemic Inflammation, Periodontal Disease, Gut Microbiome, Leaky Gut, Internal Medicine, dental coverage policy, dry mouth medications, gingival overgrowth, estrogen bleeding gums, fluoride brushing no rinse, atrial fibrillation oral health, diabetes periodontal link, aspiration pneumonia dental hygiene, Porphyromonas gingivalis Alzheimer’s, risk gum disease

June 19, 2026

Integrative Care: A New Approach in Women’s Health

Discover the importance of integrative care for women’s health for a holistic approach to women’s well-being.

Abstract

This educational post explores the deeply interconnected relationship between oral health and chronic disease in women across their entire lifespan, from fetal development through menopause and beyond. As a clinician with dual licensure in chiropractic and family nursing practice, I have dedicated my career to understanding these intricate connections. Drawing on the latest evidence-based research, I walk you through how hormonal fluctuations—from puberty and pregnancy to perimenopause and postmenopause—fundamentally alter the oral microbiome, gingival tissue integrity, salivary gland function, and bone density in ways that differ uniquely from those in men. We will delve into the bidirectional relationship between oral disease and systemic conditions such as cardiovascular disease, diabetes, and autoimmune disorders, as well as how medications commonly prescribed for these chronic diseases can contribute to oral deterioration. Finally, this post outlines how integrative and chiropractic care, functional medicine, and collaborative physician oversight—as practiced at Injury Medical Clinic PA in El Paso, Texas—can offer women a comprehensive, whole-body approach to oral health and chronic disease management that standard care alone may miss.

You Cannot Separate the Mouth from the Rest of the Body

As a clinician holding dual licensure as both a Doctor of Chiropractic (DC) and an Advanced Practice Registered Nurse—Family Nurse Practitioner Board-Certified (APRN, FNP-BC), and certified in functional and integrative medicine (CFMP, IFMCP, ATN, CCST), I have spent decades emphasizing one foundational truth in my practice: the mouth is not an isolated organ. It is a gateway—an ecosystem that both reflects and influences the health of every system in the human body. My interest in oral health deepened significantly during my research into diabetes management and the gut microbiome. What I discovered was that the connections between oral health and systemic disease in women are not only real—they are profound, underappreciated, and clinically actionable. That is why I am presenting this material today.

At Injury Medical Clinic PA (also known as Mission Plaza Injury Medical Clinic) in El Paso, Texas, our philosophy is rooted in a holistic, patient-centered model. We believe that effective healthcare requires a collaborative effort that addresses the body as an interconnected system rather than a collection of isolated symptoms. This is why our practice is built on a multidisciplinary foundation. Working alongside me is our Medical Director and Collaborative Physician, Dr. Maria Guadalupe Cardenas, MD. Dr. Cardenas is a highly respected, Board Certified Internist (NPI #1164426749, Texas MD License #J2933) with over 40 years of experience. Her extensive background in internal medicine provides the critical medical oversight and diagnostic acumen necessary for our integrative model. This collaborative setup, common in modern injury and integrative clinics where an MD provides medical direction alongside a chiropractor, allows us to assess and address the full spectrum of a patient’s health needs.

Our team integrates:

Chiropractic Care: To address spinal alignment, nerve function, and biomechanical stress that contribute to systemic inflammation.
Internal Medicine Oversight: Led by Dr. Cardenas for comprehensive diagnostics and management of systemic diseases.
Functional Medicine: To identify and treat the root causes of illness through advanced testing and personalized lifestyle interventions.
Personal Injury Rehabilitation: To restore function and promote healing after an injury, with targeted strategies for TMJ, cervical strain, and stress-mediated oral inflammation.
Evidence-Based Nutritional Interventions: To empower patients with the tools for long-term health.

Oral health fits squarely within this integrative model because—as the research clearly shows—inflammation in the mouth is inflammation in the body.

For more on my clinical approach and observations, you can review my professional work here:

ChiroMed clinical observations: https://chiromed.com/
Professional profile: https://www.linkedin.com/in/dralexjimenez/

The Bidirectional Nature of Oral Health and Systemic Disease

One of the most important concepts I want to establish early is the bidirectional relationship between oral disease and chronic systemic disease. This is genuinely a “chicken or the egg” situation, and the honest clinical answer is: it is both.

Poor oral health—specifically periodontal disease and gingivitis—generates a chronic, low-grade systemic inflammatory state. This occurs through the translocation of pathogenic oral bacteria from bleeding gums into the bloodstream and the release of pro-inflammatory cytokines, including interleukin-1 (IL-1), tumor necrosis factor-alpha (TNF-α), and prostaglandin E2. These molecules do not stay in the gum tissue. They circulate. They reach the endothelium of blood vessels, pancreatic beta cells, placental tissue, cardiac valves, and joints—including the spinal joints and the temporomandibular joint—that we regularly assess and treat in our chiropractic and integrative care setting (Monsarrat et al., 2016).

Conversely, chronic diseases such as type 2 diabetes, cardiovascular disease, autoimmune disorders, and osteoporosis—and the medications used to manage them—can directly impair salivary gland function, disrupt the oral microbiome, accelerate alveolar bone loss, and increase susceptibility to gingival infection. The disease creates the oral problem; the oral problem worsens the disease. Understanding this loop is the foundation of everything that follows.

The Oral Microbiome and the Oral-Gut Axis in Women

We are now two decades into a revolution in microbiome science, and the clinical implications are enormous. The oral microbiome consists of more than 700 microbial species living in a dynamic equilibrium. When that equilibrium is disrupted—through hormonal changes, dietary shifts, antibiotic exposure, or disease—the resulting dysbiosis sets the stage for pathology both locally (cavities, gingivitis, periodontal disease) and systemically.

Women’s oral physiology presents unique challenges. They tend to have a lower oral pH (more acidic), which increases risk for cavities and enamel erosion. Their salivary glands are often smaller, reducing the volume of saliva available for its natural antibacterial and buffering functions. Crucially, the presence of estrogen receptors in the oral mucosa makes oral tissues more responsive to plaque, increasing the risk of bleeding during high-estrogen phases.

The gut and oral microbiomes are in constant bidirectional communication via the oral-gut axis. Oral bacteria are swallowed, influencing gut dysbiosis, while systemic inflammation originating in the gut can increase oral tissue reactivity. The clinical implication is clear: when we prescribe antibiotics, hormonal contraceptives, or medications for chronic diseases, we must ask—what is this doing to the microbiome? At our clinic, this question is central to every treatment plan Dr. Cardenas and I develop together.

A Woman’s Lifespan: Hormonal Shifts and Oral Health

Hormones are the primary drivers of the unique oral health challenges women face. Let’s walk through the key stages of a woman’s life.

Oral Health Begins Before Birth: Fetal Development

Most clinicians focus their prenatal counseling on weight, blood pressure, and folic acid. We need to add oral health assessment to that list. The maternal oral microbiome is transferred to the newborn, establishing the infant’s early microbial colonization patterns. If a mother harbors cariogenic flora such as Streptococcus mutans, her infant is at higher risk of early childhood caries (Kolenbrander et al., 2010).

Furthermore, there are direct epigenetic effects. Vitamin D deficiency in the mother significantly increases the risk of enamel hypomineralization in the fetus, leading to compromised teeth from birth (Schroth et al., 2016). One finding that deserves more clinical attention is the sex-differentiated developmental timing of palate closure. In female fetuses, the palate closes approximately one week later than in males. This extends their window of vulnerability to environmental factors that can interfere with palate closure, explaining why cleft palate is more common in female infants.

Puberty and the Oral Cavity: Hormones Rewrite the Rules

When a girl enters puberty, the surge of estrogen and progesterone binds to receptors in her gingival tissue, altering vascular permeability and immune responses. This can lead to puberty gingivitis, a condition in which the gums become red, swollen, and bleed easily, even without increased plaque. The local tissue response in girls is dramatically different from boys due to these hormonal influences. Untreated, this can progress to periodontitis, the irreversible loss of supporting bone around the teeth.

The Reproductive Years: Pregnancy and Oral Contraceptives

Pregnancy is perhaps the most clinically significant period for oral health. Periodontal disease during pregnancy is associated with preterm birth, low birth weight, and preeclampsia. The mechanism is inflammatory: oral pathogens such as Fusobacterium nucleatum can travel to the placenta, triggering uterine contractions (Offenbacher et al., 2006).

Simultaneously, pregnancy makes the mouth more vulnerable. Pregnancy gingivitis is common, ligamentous laxity affects the ligaments holding teeth in place, and nausea can lead to acid erosion of enamel. Oral contraceptives can also exert similar, though less intense, hormonal effects on the gums. Chronic psychological stress, common in these years, further elevates cortisol and promotes a pro-inflammatory state that worsens periodontal health.

Menopause and Oral Health: An Underrecognized Consequence of Estrogen Decline

The decline of estrogen at menopause has profound oral consequences. One in three postmenopausal women report xerostomia (dry mouth), dramatically increasing their risk of cavities and oral infections (Tarkkila et al., 2001). Saliva is our natural antimicrobial, buffering, and remineralizing agent; its loss is devastating. This decline in estrogen also accelerates alveolar bone loss, mirroring systemic osteoporosis and increasing tooth loss.

Glossodynia (burning mouth syndrome) affects women at a 7:1 ratio compared to men, typically beginning in the 40s and 50s. It presents as a burning sensation on the tongue, palate, and lips. The pathophysiology is complex, involving small-fiber neuropathy, potentially modulated by declining sex hormones, and linked to Vitamin B12 and Vitamin D deficiencies. In my practice, I assess these levels in any perimenopausal or postmenopausal woman with these symptoms, as they are correctable deficiencies. The evidence supporting Hormone Replacement Therapy (HRT) for preserving oral health—by reducing xerostomia and bone loss—is compelling enough to warrant inclusion in the risk-benefit discussion.

The Mouth-Body Connection: Oral Health and Chronic Disease

The inflammation and bacteria originating in the mouth do not stay there. They enter the bloodstream through bleeding gums, contributing to a host of chronic diseases.

Endocarditis: Oral bacteria can circulate in the blood and attach to damaged areas of the heart, causing a rare but potentially fatal infection of the heart’s inner lining (Kinane et al., 2017).
Cardiovascular Disease: The link between periodontal disease and atherosclerosis (hardening of the arteries) is well-established. The chronic inflammation from gum disease contributes to systemic inflammation, a key driver of heart disease (Lockhart et al., 2012).
Hypertension and Atrial Fibrillation (AFib): Research shows a direct association between periodontal disease and both high blood pressure and new-onset AFib. Inflammatory mediators like interleukin-6 can trigger atrial remodeling and arrhythmic events (Rydén et al., 2016).
Pneumonia: Oral bacteria can be aspirated into the lungs, leading to respiratory infections, especially in vulnerable individuals.
Diabetes: The relationship is bidirectional. Uncontrolled diabetes impairs the body’s ability to fight infection, worsening gum disease. Conversely, gum inflammation makes it harder to control blood glucose levels.
Cancer: Emerging research has linked gum disease to an increased risk for several cancers, including mouth, GI, lung, breast, prostate, and uterine cancers.
Alzheimer’s Disease and Dementia: A specific bacterium, Porphyromonas gingivalis, found in periodontal disease has been identified as a significant risk factor. Its toxins have been found in the brains of Alzheimer’s patients, suggesting it may contribute to neuroinflammation (Ryder, 2020).

The mechanism connecting these conditions is inflammation. Periodontal disease elevates inflammatory markers that damage the endothelium (the lining of blood vessels), leading to chronic, low-grade systemic inflammation, a common pathway for many diseases.

Aligned & Empowered: Chiropractic Conversations on Women’s Health- Video

When Medication Becomes the Problem

As a Family Nurse Practitioner, I am acutely aware that the medications we prescribe can have unintended oral side effects.

Antidepressants, Antihypertensives, and Decongestants: Many cause xerostomia (dry mouth) by reducing saliva flow, dramatically increasing the risk for cavities.
Calcium Channel Blockers (e.g., Amlodipine), Phenytoin, and Cyclosporine: These can cause Drug-Induced Gingival Overgrowth (DIGO). The gums become enlarged and inflamed, creating deep pockets that trap bacteria and accelerate periodontal disease.
Corticosteroids: These impair immune surveillance and increase susceptibility to oral candidiasis (thrush).
Bisphosphonates: Used for osteoporosis, these carry a risk of medication-related osteonecrosis of the jaw (MRONJ), a serious complication.

Every medication review should include a question about oral symptoms: “Have you noticed any changes in your mouth, your gums, or your saliva since starting this medication?”

Microbiome-Focused Strategies for Prevention and Management

The key to unlocking better oral and systemic health lies in the microbiome. An imbalance, or dysbiosis, leads to inflammation. Here are some evidence-based strategies we recommend in our clinic.

Proper Oral Hygiene: It’s More Than Just Brushing

Brush Twice a Day for Two Minutes: Use a soft-bristled toothbrush at a 45-degree angle toward the gum line, making small, circular motions.
Clean All Surfaces: Remember the front, back, and chewing surfaces of every tooth. Don’t forget your tongue.
Floss Daily: This is non-negotiable for removing biofilm from between teeth. A water flosser is a great alternative, especially for those with dexterity issues or during pregnancy-related nausea.
Let the Toothpaste Work: After brushing, spit out the excess but avoid rinsing with water for 15-20 minutes. This allows ingredients like fluoride or hydroxyapatite to remain on the teeth.
Replace Your Toothbrush: Change it every 3-4 months or after an illness.

Dietary and Probiotic Interventions

Promote a Healthy Gut: We guide patients toward a plant-rich diet rich in fiber and polyphenols that feed beneficial bacteria.
Utilize Prebiotics and Probiotics: Specific strains, such as Lactobacilli, are protective in the oral cavity. They help crowd out pathogenic bacteria like Streptococcus mutans.
Reduce Sugar and Refined Carbohydrates: High-sucrose diets feed the very bacteria that produce acid and cause tooth decay.
Incorporate pH-Balancing Tools: We recommend xylitol gum to lower S. mutans load and arginine-containing toothpaste for pH buffering.

Integrative Chiropractic Care and Its Role in Oral-Systemic Health

You might wonder how chiropractic care connects to oral health. The connection is direct and physiologically sound.

Neurological Connections

The trigeminal nerve—the primary sensory nerve of the face and oral cavity—is intricately connected to upper cervical spine function. Cervicogenic headaches, temporomandibular joint (TMJ) dysfunction, and chronic orofacial pain frequently have a cervical spine component that responds to chiropractic manipulation and soft tissue therapy (Alcántara et al., 2018). Addressing the cervical component often provides measurable relief of orofacial symptoms. Malalignment can also increase parafunctional habits such as clenching, causing microtrauma to the teeth and gums.

Systemic Inflammation Reduction

Chiropractic spinal manipulation has been documented to influence systemic inflammatory markers, including reductions in IL-6 and TNF-α (Roy et al., 2010). Because the oral-systemic inflammation connection is bidirectional, reducing the body’s overall inflammatory burden through chiropractic care may lower the inflammatory load on periodontal tissues.

Functional Medicine and Autonomic Tone

In our practice, the collaboration between chiropractic and internal medicine extends into functional medicine. We assess nutritional deficiencies (vitamin D, B12), gut microbiome health, hormonal balance, and medication side effects. Furthermore, chiropractic care, coupled with breathwork and mind-body strategies, can reduce sympathetic overdrive and improve vagal tone. Improved vagal tone supports saliva production and mucosal immune resilience, directly benefiting oral health.

Conclusion: Oral Health Is Women’s Health

The evidence is unambiguous: oral health is inseparable from systemic health, and in women, that connection is uniquely shaped by hormones at every phase of life.

As clinicians, we owe it to our female patients to:

Ask about oral health at every visit.
Assess oral health implications before prescribing medications.
Counsel on oral hygiene during pregnancy and hormonal transitions.
Consider HRT’s oral health benefits in menopause management.
Correct nutritional deficiencies (vitamin D, B12) that affect oral tissue.
Integrate chiropractic and functional medicine care to address the full inflammatory and neurological burden.

At Injury Medical Clinic PA, this integrated approach is not aspirational—it is the standard of care we deliver every day. Dr. Cardenas and I are committed to ensuring that no system is treated in isolation and that the mouth receives the same clinical attention we give to the heart, spine, and gut.

References

Alcántara, J., Alcántara, J. D., & Alcántara, J. (2018). The chiropractic care of patients with temporomandibular disorders: A systematic review of the literature. Journal of Evidence-Based Complementary & Alternative Medicine, 23(1), 100–108.
Bowen, W. H., & Koo, H. (2011). Biology of Streptococcus mutans-derived glucosyltransferases: Role in extracellular matrix formation of cariogenic biofilms. Caries Research, 45(1), 69- 86.
Hernández, C., Molenaar, T., & Valdés, A. M. (2023). Hormones, microbiome, and mucosal immunity across the female lifespan. Trends in Endocrinology & Metabolism.
Jimenez, A. (n.d.). Clinical observations and integrative care resources. ChiroMed.
Jimenez, A. (n.d.). Professional profile and clinical insights. LinkedIn.
Johannsen, A., Rylander, G., Soder, B., & Asberg, M. (2010). Dental plaque, gingival inflammation, and elevated levels of interleukin-6 and cortisol in gingival crevicular fluid from women with stress-related depression and exhaustion. Journal of Periodontology, 77(8), 1403–1409. https://doi.org/10.1902/jop.2006.050411
Kinane, D. F., Stathopoulou, P. G., & Papapanou, P. N. (2017). Periodontal diseases. Nature Reviews Disease Primers, 3, 17038.
Kitamoto, S., Nagao-Kitamoto, H., Jiao, Y., et al. (2020). The microbiota–oral–gut axis and its role in health and disease. Nature Reviews Gastroenterology & Hepatology.
Kolenbrander, P. E., Palmer, R. J., Periasamy, S., & Jakubovics, N. S. (2010). Oral multispecies biofilm development and the key role of cell-cell distance. Nature Reviews Microbiology, 8(7), 471–480. https://doi.org/10.1038/nrmicro2381
Lockhart, P. B., Bolger, A. F., Papapanou, P. N., Osinbowale, O., Trevisan, M., Levison, M. E., Taubert, K. A., Newburger, J. W., Gornik, H. L., Gewitz, M. H., Wilson, W. R., Smith, S. C., Jr, & Baddour, L. M. (2012). Periodontal disease and atherosclerotic vascular disease: does the evidence support an independent association?: a scientific statement from the American Heart Association. Circulation, 125(20), 2520–2544.
Mojon, P., Nabet, C., & Samson, J. (2021). Pregnancy gingival granuloma: A narrative review. Clinical Oral Investigations.
Monsarrat, P., Blaizot, A., Kemoun, P., Ravaud, P., Nabet, C., Sixou, M., & Vergnes, J. N. (2016). Clinical research activity in periodontal medicine: A systematic mapping of trial registers. Journal of Clinical Periodontology, 43(5), 390–400. https://doi.org/10.1111/jcpe.12534
Offenbacher, S., Boggess, K. A., Murtha, A. P., Jared, H. L., Lieff, S., McKaig, R. G., Mauriello, S. M., Moss, K. L., & Beck, J. D. (2006). Progressive periodontal disease and risk of very preterm delivery. Obstetrics & Gynecology, 107(1), 29–36. https://doi.org/10.1097/01.AOG.0000190212.87012.96
Roy, R. A., Boucher, J. P., & Comtois, A. S. (2010). Inflammatory response following a short-term course of chiropractic treatment in subjects with and without chronic low back pain. Journal of Chiropractic Medicine, 9(3), 107–114. https://doi.org/10.1016/j.jcm.2010.06.002
Rydén, L., Buhlin, K., Ekstrand, E., de Faire, U., Gustafsson, A., & Kjellström, B. (2016). Periodontitis Increases the Risk of a First Myocardial Infarction: A Report From the PAROKRANK Study. Circulation, 133(6), 576–583.
Ryder, M. I. (2020). Porphyromonas gingivalis and Alzheimer disease: A tragic coincidence or a causal relationship? Journal of Periodontology, 91(Suppl 1), S45–S49.
Sánchez-Alcoholado, L., Bueno, M. J., Castellano-Castillo, D., Claros, M. G., González-Jiménez, A., Alcaide-Torres, J., & Queipo-Ortuño, M. I. (2020). Gut microbiome-mediated metabolism effects on immunity in rural and urban African populations. Nature Communications, 11(1), 2624. https://doi.org/10.1038/s41467-020-16017-7
Schroth, R. J., Lavelle, C., Tate, R., Bruce, S., Billings, R. J., & Moffatt, M. E. (2016). Prenatal vitamin D and dental caries in infants. Pediatrics, 133(5), e1277–e1284. https://doi.org/10.1542/peds.2013-2215
Shirazi, M., Long, T., & Gill, S. R. (2022). Estrogen, microbiome, and mucosal barrier: Mechanistic insights in women’s health. Frontiers in Microbiology.
Tarkkila, L., Linna, M., Tiitinen, A., Lindqvist, C., & Meurman, J. H. (2001). Oral symptoms at menopause — the role of hormone replacement therapy. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology, 92(3), 276–280. https://doi.org/10.1067/moe.2001.115778
Teeuw, W. J., Gerdes, V. E., & Loos, B. G. (2010). Effect of periodontal treatment on glycemic control of diabetic patients: A systematic review and meta-analysis. Diabetes Care, 33(2), 421–427. https://doi.org/10.2337/dc09-1378
Zhang, Y., Wang, X., Li, H., et al. (2020). Gender differences in the human oral microbiome. Journal of Oral Microbiology.

SEO Tags: Oral Health, Systemic Health, Functional Medicine, Integrative Chiropractic Care, Chronic Disease, Gut Microbiome, Periodontal Disease, Cardiovascular Health, Diabetes, Alzheimer’s Disease, Dr. Alex Jimenez, Dr. Maria Guadalupe Cardenas, El Paso TX, Inflammation, Women’s Health, Medication Side Effects, Gingival Hyperplasia, Dry Mouth, Health and Wellness, oral health and chronic disease in women, women’s oral health across the lifespan, hormones and periodontal disease, pregnancy gingivitis, menopause and dry mouth, oral microbiome and systemic disease, burning mouth syndrome women, puberty gingivitis, integrative chiropractic oral health, functional medicine oral health, Dr. Alex Jimenez DC El Paso, Injury Medical Clinic PA, vitamin D enamel development, oral contraceptives gum health, xerostomia menopause, hormone replacement therapy periodontal disease, periodontal disease diabetes connection, chiropractic care inflammation, molar incisor hypomineralization, estrogen and oral microbiome, progesterone gums inflammation, testosterone effects in women’s oral health, oral–gut axis, Streptococcus mutans cavities, internal medicine medical director, biofilm dental hygiene, GERD enamel erosion, PCOS oral health, autoimmune periodontal disease, hydrogen peroxide oral commensals, lactobacilli oral benefits

June 18, 2026

Non-Pharmaceutical Strategies to Consider in Chronic Care

Implement non-pharmaceutical chronic care strategies to better manage chronic conditions and improve health.

Abstract: A New Paradigm in Patient Care

This educational post explores the critical role of an integrative, non-pharmaceutical approach in modern healthcare for managing both acute and chronic health conditions. We will begin by defining key strategies, such as lifestyle modifications, mind-body practices, and nutritional therapies, drawing upon insights from leading experts. I will then share insights from my clinical practice, showcasing how these evidence-based strategies can significantly improve patient outcomes by treating the whole person, not just their symptoms. We will delve into the physiological mechanisms behind these strategies, explain why they work, and explore the latest research in areas such as hormone therapy, functional foods, microbiome health, and technology-enabled supplementation. Furthermore, I will detail how our unique multidisciplinary clinic in El Paso, Texas—Injury Medical Clinic PA—integrates the expertise of chiropractic care, functional medicine, and internal medicine under the medical direction of Dr. Maria Guadalupe Cardenas, MD, to provide a comprehensive, patient-centered path to wellness that goes beyond medication alone.

Our Collaborative Care Model: A Fusion of Medical and Chiropractic Expertise

Hello, I’m Dr. Alex Jimenez. My practice is built on a foundation of diverse and extensive training, holding credentials as a Doctor of Chiropractic (DC), Advanced Practice Registered Nurse (APRN), a Board-Certified Family Nurse Practitioner (FNP-BC), and certifications in Functional Medicine (CFMP, IFMCP), Advanced Technology Neurology (ATN), and Cranial Cervical Spinal Techniques (CCST). This unique combination of expertise allows me to view health and wellness through multiple lenses, integrating the best of conventional and complementary medicine.
At our practice, Injury Medical Clinic PA (also known as Mission Plaza Injury Medical Clinic), we have pioneered a clinical model that brings together diverse specialties under one roof to provide comprehensive care. I serve as the clinical lead for integrative chiropractic and functional medicine services, focusing on the structural, biomechanical, and metabolic root causes of disease. My work is complemented and medically directed by Dr. Maria Guadalupe Cardenas, MD, a highly respected internist with over 40 years of invaluable experience.
Dr. Cardenas is board-certified in Internal Medicine and holds Texas Medical License #J2933 (NPI #1164426749). As our Medical Director and Collaborative Physician, she provides essential medical oversight, ensuring our treatment plans are safe, effective, and grounded in the highest standards of evidence-based medicine. This multidisciplinary structure allows us to integrate seamlessly:

Medical Oversight (Dr. Cardenas): Diagnosis, management of complex medical conditions, prescription medication management, and ensuring all therapies are appropriate for the patient’s overall health profile.
Chiropractic and Functional Medicine (Dr. Jimenez): Spinal adjustments, soft tissue therapies, and rehabilitation to address musculoskeletal pain, alongside functional medicine protocols to investigate and treat the root causes of systemic inflammation and metabolic dysfunction.
Integrative Services: Together, our team offers personal injury care, rehabilitation, nutritional counseling, and lifestyle education, creating a truly holistic patient journey from diagnosis to recovery and long-term wellness.

This collaborative environment is particularly beneficial for patients with complex conditions where musculoskeletal pain and chronic disease intersect, allowing us to address the whole person, not just a set of isolated symptoms.

The Rise of Integrative and Functional Medicine

To fully appreciate the power of non-pharmaceutical strategies, it’s essential to understand the philosophical frameworks that guide their application: integrative medicine and functional medicine. While related, they offer distinct perspectives on health and healing.

Integrative Medicine: This approach blends the best of conventional medicine with evidence-based complementary therapies. The core focus is on treating the whole person—mind, body, and spirit—rather than just the disease. It champions patient-centered care and highlights the profound impact of lifestyle factors such as stress management, nutrition, and physical activity. The goal is to use all appropriate therapeutic approaches to achieve optimal health and healing.
Functional Medicine: This model takes a systems-biology approach, seeking to identify and address the root causes of disease. Instead of merely managing symptoms, functional medicine asks why a person is ill. It is highly personalized, often utilizing advanced diagnostic testing, genetic insights, and comprehensive health histories to understand the intricate web of interactions within the body’s physiological systems. Nutrition and lifestyle interventions are the cornerstones of functional medicine treatment plans.

Together, these frameworks remind us that health is a multidimensional state. Effective, sustainable healing often requires a broader strategy than a prescription pad can offer, one that empowers patients and promotes long-term wellness.

A Journey Toward Mainstream Acceptance

The shift toward embracing complementary and alternative medicine (CAM) has been decades in the making. Patient demand has been a powerful catalyst, compelling the medical establishment to take notice.

1993: The National Institutes of Health (NIH) established the Office of Alternative Medicine, which later became the National Center for Complementary and Integrative Health (NCCIH). This was the government’s first formal acknowledgment that these therapies warranted serious scientific research and oversight.
1997: A landmark study published in JAMA revealed a startling trend: visits to CAM providers had surpassed the total number of visits to all primary care physicians in the United States (Eisenberg et al., 1998). This highlighted the immense public interest in holistic, non-drug therapies.
2004: The Institute of Medicine (now the National Academy of Medicine) formally addressed the role of integrative medicine, marking a significant shift toward viewing these therapies as part of a comprehensive healthcare model rather than “fringe” practices.
2020: Fast forward to recent years, and Americans were spending approximately $30 billion out-of-pocket annually on CAM services and products. This staggering figure underscores both the persistent demand and the ongoing challenges with insurance coverage.

The “when” and “why” are clear: patients are actively seeking holistic, non-pharmaceutical therapies not just for symptom management, but for prevention, wellness, and a greater sense of control over their health journey.

Categorizing Non-Pharmaceutical Interventions

When we talk about non-pharmaceutical strategies, we are referring to a wide spectrum of practices that fall outside traditional drug-based treatments. As a practitioner, I find it helpful to group these into several key categories to better understand their application and guide my patients.

Mind-Body Practices: These interventions focus on the powerful connection between our mental and emotional state and our physical health. Examples include meditation, mindfulness, cognitive behavioral therapy (CBT), and stress-reduction techniques.
Physical and Manual Therapies: This category involves hands-on approaches to improve structure and function. It includes chiropractic care, physiotherapy, massage therapy, and structured rehabilitation programs.
Lifestyle Interventions: These are the foundational changes we can make in our daily lives. This encompasses exercise, sleep hygiene, and environmental modifications.
Nutritional Therapies: This is a cornerstone of functional medicine, involving dietary modifications, structured meal planning, elimination diets, and targeted supplementation to influence health outcomes.
Herbal and Botanical Medicine: This involves using plants and plant-derived substances for therapeutic purposes.

Our role as clinicians is to understand these categories, evaluate their safety and effectiveness, and thoughtfully consider when they can complement evidence-based medical care.

The “Why”: The Clinical Impact of Non-Drug Strategies

Incorporating these approaches is not just a philosophical preference; it delivers tangible, evidence-based benefits that can transform patient outcomes.

Improved Patient Outcomes: Lifestyle modifications can have a profound impact. For instance, meditation has been shown to reduce anxiety levels by as much as 25% (Goyal et al., 2014). In my practice, I frequently observe how targeted dietary changes dramatically improve symptoms in patients with chronic inflammatory conditions.
Reduced Medication Burden and Side Effects: This is especially critical for older adults or those with multiple chronic conditions. By integrating non-drug pain management strategies, such as chiropractic adjustments and targeted exercises, we can help reduce reliance on medications like opioids. Research has shown such integrative approaches can reduce opioid use by up to 60%.
Addressing Root Causes: Unlike medications that often provide only symptomatic relief, these strategies target the underlying drivers of disease—inflammation, nutritional deficiencies, gut dysbiosis, stress, and environmental exposures.
Patient Empowerment: When patients are actively involved in their care through diet, exercise, and mindfulness, they feel a greater sense of agency. This improves adherence, reduces hospital readmissions, and fosters a collaborative partnership between patient and provider.
Cost-Effectiveness and Prevention: Exercise, mindfulness, and dietary interventions not only slow disease progression but also lower long-term healthcare costs. An investment in lifestyle change today can prevent costly medical interventions tomorrow.

These strategies are not mere “add-ons”; they are essential tools for modern, patient-centered care. Today, over 60 academic medical centers, including renowned institutions like the Cleveland Clinic and Mayo Clinic, have established integrative medicine programs, signaling a clear shift toward the mainstream.

Applying Integrative Strategies for Acute Conditions

While often associated with chronic disease, these interventions are also incredibly valuable for managing acute illnesses. Let’s begin by examining a common scenario we often see in primary care.
A 29-year-old female patient presented to our clinic with a three-day history of sore throat, nasal congestion, dry cough, mild headache, and low-grade fever. She reported no shortness of breath, ear pain, or rash. Her medical history was unremarkable. Upon examination, her throat showed mild redness (erythema), but no pus-like discharge (exudate), and her lungs were clear. A rapid strep test came back negative.
This clinical picture is a classic presentation of an acute viral upper respiratory infection (URI), commonly known as the cold. This is a critical diagnostic moment. Recognizing this as a viral, not bacterial, infection immediately guides our treatment strategy away from unnecessary antibiotics and toward supportive, non-pharmaceutical interventions.
Based on this case, we can distinguish it from other possibilities:

Acute Bacterial Sinusitis: This diagnosis is less likely, as it typically involves symptoms lasting more than ten days or a “double-worsening” course (getting better, then worse again).
Streptococcal Pharyngitis (Strep Throat): This usually presents with more severe symptoms, such as tonsillar exudates, tender neck lymph nodes, higher fever, and the absence of a cough. Her negative strep test further rules this out.
Influenza (The Flu): While it shares some symptoms, influenza typically has an abrupt onset with a high fever and prominent systemic symptoms, such as severe body aches (myalgias) and fatigue.

This correct diagnosis allows us to have a crucial conversation with the patient about effective, evidence-based supportive care. It’s equally important to educate patients on what is not indicated. In this case, an antibiotic like azithromycin would be ineffective against a virus and could contribute to the growing problem of antibiotic resistance. This moment of patient education is a cornerstone of responsible integrative care.

Evidence-Based Non-Pharmaceutical Strategies for Acute URIs

When a patient has a viral infection, our goal is to support their body’s natural immune response and alleviate symptoms to improve comfort and speed up recovery. Instead of reaching for a prescription pad, we can recommend several strategies backed by solid research.

Acute Respiratory Infections (The Common Cold)

Evidence-Based Options: Zinc lozenges, elderberry, vitamin C, echinacea.
Evidence:
- Zinc: If started within 24 hours of symptom onset, zinc lozenges may reduce the duration of a cold by about one day (Science et al., 2012). Zinc is believed to interfere with viral replication in the nasopharynx.
- Elderberry Syrup (Sambucus nigra): Some clinical trials suggest that elderberry may shorten the duration of flu and cold symptoms. It is thought to work by inhibiting viral replication and stimulating the immune response through its rich concentration of flavonoids and anthocyanins (Hawkins et al., 2019).
- Vitamin C: While regular use may have a mild preventative effect, there is little evidence that it is effective once an illness has begun.
- Echinacea: Study results are inconsistent, with some showing a small benefit and others showing none.

Sore Throat (Pharyngitis)

Evidence-Based Options: Honey, marshmallow root, slippery elm, and licorice root tea.
Evidence:
- Honey: There is strong evidence, particularly for children over one year of age, that honey can soothe the throat and reduce cough frequency (Oduwole et al., 2018; Ashkin & Mounsey, 2013). It acts as a demulcent, coating the irritated tissues, while its natural antimicrobial and anti-inflammatory components may offer additional benefits.
- Herbal Teas: Teas like marshmallow root and slippery elm can provide temporary symptomatic relief by coating the throat, but they do not shorten the illness.

Acute Sinusitis

Evidence-Based Options: Saline irrigation, bromelain, and eucalyptus oil steam inhalation.
Evidence:
- Saline Irrigation: There is robust evidence that nasal saline rinses improve mucus drainage, reduce congestion, and can shorten recovery time (Rabago & Zgierska, 2009). Using a neti pot or saline spray helps to flush out mucus, allergens, and viral particles from the nasal passages.
- Bromelain: This enzyme, derived from pineapple, has anti-inflammatory properties. While some smaller studies show promise, the evidence is still emerging.
- Eucalyptus Oil: Inhalation can provide temporary relief from congestion, but its effect on the overall course of the illness is modest.

Gastroenteritis (“Stomach Flu”)

Evidence-Based Options: Probiotics, ginger, and peppermint oil.
Evidence:
- Probiotics: Specific strains, such as Lactobacillus rhamnosus GG, have strong evidence supporting reductions in the duration and severity of diarrhea, especially in children (Guarino et al., 2014).
- Ginger: It is well-supported by research for reducing nausea and vomiting. It can be taken as a capsule, tea, or even chewed raw.
- Peppermint Oil: May help with abdominal cramping and nausea, though the evidence is not as strong as it is for ginger.

The Role of Integrative Chiropractic and Physical Medicine in Acute Illness

Beyond herbal and supplement therapies, physical medicine plays a crucial role. This is where our integrative model at Injury Medical Clinic PA truly shines.

Chiropractic Care: For musculoskeletal issues that can accompany acute illnesses, such as the body aches from influenza or the neck stiffness from coughing, gentle chiropractic adjustments can be very beneficial. By restoring proper joint motion and reducing nerve irritation, we can alleviate pain and improve overall comfort. While chiropractic care does not treat the infection itself, it effectively manages the associated neuromusculoskeletal symptoms. For adults, it is a safe and effective adjunctive therapy.
Acupuncture: This ancient practice can be surprisingly effective for acute symptoms. Research has demonstrated its utility in relieving the pain associated with respiratory illnesses and sinusitis. For gastroenteritis, stimulation of the P6 (Neiguan) acupressure point on the inner forearm is a well-documented method for relieving nausea and vomiting. This point is so effective that it is also used to manage motion sickness, pregnancy-related, postoperative, and chemotherapy-induced nausea (Lee & Done, 2015). Learning to apply pressure to this point can be an empowering self-care tool for patients.
Lifestyle Support: We also emphasize foundational support, which is often overlooked during an acute illness: Hydration and Rest, Good Handwashing, Humidified Air, Avoiding Smoke Exposure, and Balanced Nutrition. These provide the body with the resources it needs to fight infection.

By integrating these strategies through the collaborative care of Dr. Cardenas and me, we provide a holistic treatment plan. A patient might receive medical advice from Dr. Cardenas, a chiropractic adjustment from me to relieve associated body aches, nutritional guidance to support their immune system, and instruction on using the P6 point for nausea. This is the essence of true integrative care.

Shifting Focus to Chronic Disease Management

While acute illnesses are common, the bulk of our work involves managing chronic diseases. These conditions—like hypertension, type 2 diabetes, and high cholesterol—are the leading drivers of healthcare costs. This is where non-pharmaceutical interventions truly shine, not as replacements for necessary medication, but as powerful adjuncts that can reduce medication dependency, improve quality of life, and address the root causes of the disease.

Hypertension (High Blood Pressure)

Hypertension is often called the “silent killer” because it has no symptoms but significantly increases the risk of heart attack and stroke. Lifestyle is the cornerstone of management.

Nutritional Strategies:
- The DASH (Dietary Approaches to Stop Hypertension) and Mediterranean Diets are among the most powerful dietary interventions.
- Garlic: Contains allicin, a compound that may promote vasodilation (widening of blood vessels).
- Hibiscus Tea: Studies have shown it can lower blood pressure, possibly due to diuretic effects and inhibition of angiotensin-converting enzyme (ACE) (McKay et al., 2010).
- Coenzyme Q10 (CoQ10): Functions as an antioxidant and improves endothelial function, helping blood vessels relax.
- Omega-3 Fatty Acids: Help reduce inflammation and improve vessel elasticity.
Mind-Body Practices: Practices like deep breathing, meditation, and yoga activate the parasympathetic nervous system (“rest and digest”), which counteracts the “fight or flight” stress response that drives up blood pressure.

Type 2 Diabetes

This metabolic disorder is characterized by insulin resistance and elevated blood sugar levels.

Herbal and Nutritional Support:
- Berberine: This plant alkaloid has shown remarkable effects, in some studies rivaling the efficacy of metformin in lowering hemoglobin A1c and fasting glucose. It works by activating an enzyme called AMPK, a master regulator of metabolism (Lan et al., 2015).
- Cinnamon: May improve insulin sensitivity and has been shown to reduce fasting glucose levels modestly.
Lifestyle: Regular physical activity is crucial for improving insulin sensitivity, as it helps muscle cells take up glucose from the blood. A low-glycemic diet rich in fiber is also essential.

Hyperlipidemia (High Cholesterol)

Elevated LDL (“bad”) cholesterol is a major risk factor for atherosclerosis.

Nutritional Strategies:
- Red Yeast Rice: Contains monacolin K, a compound chemically identical to the active ingredient in the statin drug lovastatin. It requires the same liver function monitoring as prescription statins.
- Plant Sterols and Stanols: Found in nuts and seeds, these compounds block cholesterol absorption in the gut.

Depression

Lifestyle and nutrition can play a significant supportive role.

Herbal and Nutritional Support:
- St. John’s Wort (Hypericum perforatum): Effective for mild to moderate depression but has significant drug interactions and must be used with extreme caution under professional guidance.
- Omega-3 Fatty Acids (EPA/DHA): Critical components of brain cell membranes with anti-inflammatory effects.
- Saffron: Emerging research shows promise in improving mood, with effects comparable to some antidepressants in certain studies (Lopresti & Drummond, 2014).

Osteoarthritis and Chronic Pain

Inflammation is a key driver of pain in conditions like osteoarthritis.

Anti-Inflammatory Botanicals:
- Turmeric (Curcumin): A potent anti-inflammatory agent that works by inhibiting multiple inflammatory pathways, including NF-kB and COX-2.
- Ginger: Contains gingerols, which also have powerful anti-inflammatory and analgesic properties.
Structural Support:
- Glucosamine and Chondroitin: These are building blocks of cartilage. While evidence is mixed, some patients report long-term benefits in pain reduction.

Advanced Integrative Strategies: Hormones, Microbiome, and Functional Foods

This section spotlights leading research trends you may encounter. The key is understanding what is supported by evidence, what is emerging, and where caution is warranted.

Hormone Therapy in Integrative Medicine: Menopause and Testosterone

Menopause Hormone Therapy (MHT): Timing is Crucial

MHT remains the most effective therapy for vasomotor symptoms (hot flashes, night sweats) and genitourinary syndrome of menopause (GSM) (vaginal dryness, recurrent UTIs). Evidence consistently supports initiating MHT before age 60 or within 10 years of menopause to improve the risk-benefit profile, including lower all-cause mortality (Ravn-Haren & colleagues, 2022).

Physiological Rationale: Early MHT supports vascular health when atherosclerosis is low, maintains bone mineral density (BMD) by regulating osteoclast activity, and stabilizes neuroendocrine pathways.
Safety: For GSM symptoms, local, low-dose vaginal estrogen offers high efficacy with minimal systemic absorption, providing a favorable safety profile (NAMS, 2023). MHT is not an anti-aging therapy; it is for symptom relief and risk modulation when clinically appropriate.

Testosterone Replacement Therapy (TRT) in Men

TRT is considered for symptomatic men with biochemically confirmed hypogonadism.

Benefits: Restores sexual function, improves body composition by supporting myogenesis (muscle growth), enhances BMD, and can improve depressive symptoms in truly deficient individuals (Corona et al., 2014).
Cautions: It is crucial to distinguish persistent hypogonadism from reversible factors like obesity, stress, or sleep apnea. Monitoring of prostate health, hematocrit (polycythemia risk), and cardiometabolic status is essential.

Functional Foods: Evidence-Based Nutrition That Acts Like Medicine

Functional foods deliver bioactive compounds with health benefits beyond basic nutrition.

Key Examples:
Fortified foods: Calcium and vitamin D-enriched milks for bone health; plant sterols in spreads lower LDL by inhibiting cholesterol absorption (Gylling & Miettinen, 1999).
Probiotics and prebiotics: Yogurt and kefir improve gut composition and short-chain fatty acid (SCFA) production.
Polyphenol-rich foods: Berries and green tea possess antioxidant properties that support vascular function.
Advanced delivery systems: Liposomal curcumin and nano-curcumin increase bioavailability, enhancing anti-inflammatory effects for arthritis (Hewlings & Kalman, 2017).

Beyond Adjustments: Chiropractic and Integrative Healthcare- Video

The Gut Microbiome: Probiotics, Prebiotics, and Precision Nutrition

The microbiome influences systemic health through immune regulation and gut-brain communication.

Probiotics: Live microorganisms that confer health benefits. Specific strains have shown benefit for Irritable Bowel Syndrome (Ford et al., 2014), antibiotic-associated diarrhea (Saccharomyces boulardii) (McFarland, 2010), and even anxiety (Lactobacillus rhamnosus JB-1) (Bravo et al., 2011).
Prebiotics: Non-digestible fibers (inulin, FOS) that selectively feed beneficial bacteria.
Physiological Mechanisms: Probiotics can improve gut barrier function, reduce endotoxemia (leaky gut), and modulate immune responses and neurovisceral pathways affecting mood.

Technology-Enabled Supplementation and Precision Care

We leverage wearables, continuous glucose monitoring (CGM), and digital health apps to individualize supplementation.

Metabolic Syndrome: CGM helps identify glycemic excursions. Targeted supplements like berberine (for AMPK activation) and magnesium are aligned with real-time data.
Autoimmune Conditions: Symptom trackers guide adjustments to curcumin and vitamin D to modulate inflammatory markers such as CRP.
Regulatory Oversight: Supplements lack pharmaceutical-level rigor. We rely on reputable resources like the NIH Office of Dietary Supplements and the Natural Medicines Database for safety and efficacy data. Large trials such as AREDS2 for macular degeneration show that supplements can be effective but require well-defined formulations and dosing (NEI, 2013).

The Role of Integrative Chiropractic Care in Chronic Disease

At first glance, chiropractic care might seem limited to back pain. However, in our integrative model, its role is far more expansive. Pain is a profound physiological stressor, keeping the body in a constant state of “fight or flight” driven by the sympathetic nervous system. This chronic stress response:

Elevates stress hormones like cortisol, which can worsen insulin resistance and make blood sugar control more difficult.
Contributes to hypertension by constricting blood vessels.
Can lead to or worsen depression and anxiety.
Causes systemic inflammation, a root cause of nearly every chronic disease.

By using chiropractic adjustments, soft tissue mobilization, and rehabilitative exercises, we address musculoskeletal pain. Alleviating this pain helps to down-regulate the sympathetic stress response. The result is a cascade of positive physiological changes:

Spinal and Extremity Adjustments: Optimize joint kinematics and neuromuscular firing, decreasing pain signals and improving functional capacity.
Breathing and Postural Mechanics: Thoracic mobility work improves oxygenation and autonomic balance, supporting vasomotor stability.
Neurofunctional Rehabilitation: Sensorimotor exercises recalibrate balance and coordination, lowering fall risk—critical for individuals with changing bone density.

Reduced pain improves sleep, mood, and exercise adherence—which magnify the benefits of MHT, TRT, functional foods, and microbiome-targeted nutrition. This is the essence of our integrative approach: using chiropractic care to break the pain-stress-inflammation cycle, thereby supporting the entire body’s return to balance.

Applying Knowledge: A Case Study in Chronic Care

Let’s consider a 61-year-old male with hypertension and type 2 diabetes. His blood pressure is 146/92 mmHg, and his hemoglobin A1c is 7.4%. He is motivated to explore natural strategies.

Integrative Plan:
- Diet: We would counsel him on a Mediterranean-style or DASH diet, which has been shown to lower blood pressure and improve A1c.
- Supplements: For his diabetes, we could discuss adding cinnamon or berberine as an adjunct to his medication (Lan et al., 2015). For hypertension, garlic could be added for its modest benefit.
- Mind-Body: Daily deep breathing or meditation can reduce chronic stress, which contributes to both conditions.
- Chiropractic Care: If musculoskeletal pain limits his ability to exercise, chiropractic care would be crucial to get him moving again, which is vital for managing both conditions.

By layering these strategies, we empower the patient, address root causes, and work toward his health goals in a holistic, sustainable way.

Closing Reflections

The most powerful outcomes arise from combining conventional medicine, lifestyle strategies, evidence-based supplements, mind-body tools, and integrative chiropractic care. This model does not replace modern medicine; it expands and refines it for safer, smarter, more compassionate care.
My clinical observations, case insights, and ongoing commentary on integrative musculoskeletal and functional care are available at:

ChiroMED: https://chiromed.com/
LinkedIn: https://www.linkedin.com/in/dralexjimenez/

References

Ashkin, E., & Mounsey, A. (2013). A spoonful of honey helps a coughing child. The Journal of Family Practice, 62(3), 145–147.
Bravo, J. A., Forsythe, P., Chew, M. V., Escaravage, E., Savignac, H. M., Dinan, T. G., Bienenstock, J., & Cryan, J. F. (2011). Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Neuropharmacology, 61(5-6), 1097-1110.
Corona, G., Sforza, A., & Maggi, M. (2014). Testosterone and sleep: A tale of two hormones. Journal of Neuroendocrinology, 26(2), 65-71.
Eisenberg, D. M., Davis, R. B., Ettner, S. L., Appel, S., Wilkey, S., Van Rompay, M., & Kessler, R. C. (1998). Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA, 280(18), 1569–1575.
Ford, A. C., Quigley, E. M. M., Lacy, B. E., et al. (2014). Efficacy of probiotics in irritable bowel syndrome: A systematic review and meta-analysis. American Journal of Gastroenterology, 109(6), 768–781.
Goyal, M., Singh, S., Sibinga, E. M., Gould, N. F., Rowland-Seymour, A., Sharma, R., Berger, Z., Sleicher, D., Maron, D. D., Shihab, H. M., Ranasinghe, P. D., Linn, S., Saha, S., Bass, E. B., & Haythornthwaite, J. A. (2014). Meditation programs for psychological stress and well-being: a systematic review and meta-analysis. JAMA Internal Medicine, 174(3), 357–368.
Guarino, A., Ashkenazi, S., Gendrel, D., Lo Vecchio, A., Shamir, R., & Szajewska, H. (2014). European Society for Pediatric Gastroenterology, Hepatology, and Nutrition/European Society for Pediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: update 2014. Journal of Pediatric Gastroenterology and Nutrition, 59(1), 132–152.
Gylling, H., & Miettinen, T. A. (1999). Cholesterol reduction by plant stanol esters. Current Opinion in Lipidology, 10(2), 113-116.
Hawkins, J., Baker, C., Cherry, L., & Dunne, E. (2019). Black elderberry (Sambucus nigra) supplementation effectively treats upper respiratory symptoms: A meta-analysis of randomized, controlled clinical trials. Complementary Therapies in Medicine, 42, 361–365.
Hewlings, S. J., & Kalman, D. S. (2017). Curcumin: A review of its effects on human health. Foods, 6(10), 92.
Lan, J., Zhao, Y., Dong, F., Cen, Z., Salazar, M. R., Song, J., … & Li, Y. (2015). Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. Journal of Ethnopharmacology, 161, 69–81.
Lee, A., & Done, M. L. (2015). The use of nonpharmacologic techniques for postoperative nausea and vomiting: a meta-analysis. Anesthesia and Analgesia, 84(4), 761- 770.
Lopresti, A. L., & Drummond, P. D. (2014). Saffron (Crocus sativus) for depression: a systematic review of clinical studies and examination of underlying antidepressant mechanisms of action. Human Psychopharmacology: Clinical and Experimental, 29(6), 517–527.
McFarland, L. V. (2010). Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World Journal of Gastroenterology, 16(18), 2202–2222.
McKay, D. L., Chen, C. Y. O., Saltzman, E., & Blumberg, J. B. (2010). Hibiscus sabdariffa L. tea (tisane) lowers blood pressure in prehypertensive and mildly hypertensive adults. The Journal of Nutrition, 140(2), 298–303.
National Eye Institute. (2013). Age-Related Eye Disease Study 2 (AREDS2) results. https://www.nei.nih.gov/research/clinical-trials/age-related-eye-disease-study-2-areds2
North American Menopause Society. (2023). The 2023 position statement on hormone therapy. https://www.menopause.org
Oduwole, O., Meremikwu, M. M., Oyo-Ita, A., & Udoh, E. E. (2018). Honey for acute cough in children. Cochrane Database of Systematic Reviews, 4, CD007094.
Rabago, D., & Zgierska, A. (2009). Saline nasal irrigation for upper respiratory conditions. American Family Physician, 80(10), 1117–1119.
Ravn-Haren, G., et al. (2022). Menopausal hormone therapy initiation timing and cardiovascular outcomes: A Danish cohort study. BMJ.
Science, M., Johnstone, J., Roth, D. E., Guyatt, G., & Loeb, M. (2012). Zinc for the treatment of the common cold: a systematic review and meta-analysis of randomized controlled trials. CMAJ: Canadian Medical Association Journal, 184(10), E551–E561.
Tursi, A., Brandimarte, G., Giorgetti, G. M., et al. (2010). Effect of VSL#3 on ulcerative colitis. Journal of Clinical Gastroenterology, 44(Suppl 1), S33-S35.

SEO Tags: integrative medicine, functional medicine, chiropractic care, non-pharmaceutical, Dr. Alex Jimenez, Dr. Maria Cardenas, El Paso Chiropractor, acute disease management, chronic disease, lifestyle medicine, nutritional therapy, herbal medicine, holistic health, P6 acupressure, sinusitis treatment, gastroenteritis relief, pain management, Hypertension, Type 2 Diabetes, Collaborative Care, Patient-Centered Care, menopause hormone therapy, MHT safety, testosterone replacement therapy, TRT monitoring, probiotics and prebiotics, gut microbiome, functional foods, liposomal curcumin, omega-3 fatty acids, DASH diet, continuous glucose monitoring, personalized supplementation, internal medicine oversight, El Paso integrative clinic, Injury Medical Clinic PA, Mission Plaza Injury Medical Clinic

June 17, 2026

Hormone Therapy: What You Need to Know About Men’s Health

Find out how hormone therapy for men’s health can play a crucial role in maintaining optimal health and longevity for men.

Abstract

I am Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. In this educational post, I take you through a clear, clinically grounded journey into two interconnected pillars of men’s health: erectile dysfunction (ED) and testosterone deficiency (low T). You will learn how erections work at the neurovascular level, why ED often reflects deeper cardiometabolic issues, and how we diagnose and treat ED with lifestyle foundations, oral medications, low-intensity shockwave therapy, injections, and surgical options. You will also learn how I evaluate testosterone deficiency using rigorous criteria and how I personalize treatment, from correcting root causes such as sleep apnea and obesity to offering judicious testosterone replacement therapy (TRT) or fertility-preserving alternatives.
At Injury Medical Clinic PA, also known as Mission Plaza Injury Medical Clinic in El Paso, Texas, our multidisciplinary team integrates chiropractic care, functional medicine, personal injury care, rehabilitation, and medical oversight. Our Medical Director and Collaborative Physician, Dr. Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine, NPI #1164426749, Texas MD License #J2933), brings over 40 years of internal medicine expertise to ensure our protocols are safe, evidence-based, and patient-centered. Together, we combine modern research with practical, whole-person care to restore sexual function, hormonal balance, and overall vitality.

Our Integrative Men’s Health Model in El Paso, Texas

As a clinician with dual training in chiropractic and advanced practice nursing, my work is centered on viewing health through multiple lenses. At Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic), I collaborate closely with Dr. Maria Guadalupe Cardenas, MD, our Medical Director and Collaborative Physician. Dr. Cardenas is Board Certified in Internal Medicine and has more than four decades of clinical experience. Her oversight strengthens our multidisciplinary approach and ensures that our diagnostic and treatment plans align with contemporary medical standards.
Here is how we blend disciplines to produce comprehensive and effective care:

Chiropractic care with a neuromusculoskeletal focus
- I emphasize optimizing spinal alignment and nervous system signaling, particularly in the lumbar and sacral regions that contribute to pelvic organ function. Targeted adjustments may reduce neurogenic impediments, support autonomic balance, and improve pelvic floor dynamics that influence sexual function.
Medical oversight by Internal Medicine
- Dr. Cardenas provides diagnostic leadership and pharmacologic management for comorbidities such as hypertension, diabetes, dyslipidemia, and sleep apnea—conditions that are often at the core of ED and low T. Her clinical judgment ensures treatment safety, efficacy, and adherence to guidelines.
Functional medicine and metabolics
- We investigate root causes through comprehensive testing (hormone panels, inflammatory markers, lipids, A1C, thyroid function) and implement structured plans for nutrition, sleep, stress management, and targeted supplementation to recalibrate physiology.
Rehabilitation and personal injury care
- We design programs to restore circulation, mobility, and strength. Improved vascular health and functional capacity are indispensable for erectile performance and hormonal resilience.

In my clinical observations across spine and integrative care practice, I have seen how coordinated improvements in neuromusculoskeletal function, metabolic health, and cardiovascular conditioning can elevate sexual function and endocrine balance. Our goal is to address both the symptom and its systemic roots.

Erectile Dysfunction Basics: What Every Man Should Know

The physiology of an erection

An erection is a precisely timed neurovascular event. When sexual stimulation triggers cortical and spinal pathways, cavernosal nerves release the neurotransmitter nitric oxide (NO). NO activates guanylate cyclase, increasing cyclic guanosine monophosphate (cGMP) inside smooth muscle cells of the penile arteries and the corpus cavernosum. Elevated cGMP drives smooth muscle relaxation, arterial dilation, and rapid blood influx. As the cavernosal bodies expand, venous outflow is mechanically restricted, trapping blood and producing rigidity. After ejaculation or the cessation of stimulation, phosphodiesterase type 5 (PDE5) degrades cGMP, and detumescence follows.
Why this matters:

Any pathology that diminishes endothelial NO production (e.g., diabetes, hypertension, smoking) or impairs neural input (e.g., neuropathy, spinal pathology) can disrupt erectile function.
This is why ED often prefaces or parallels broader cardiometabolic disease.

Why ED is a vascular health signal

ED shares risk factors with cardiovascular disease:

Age-related endothelial decline
Hypertension, diabetes, dyslipidemia, obesity
Smoking and alcohol overuse
Medications that blunt neural or vascular tone (e.g., some SSRIs, thiazides)
Neurological diseases and spinal injuries
Psychological stressors, anxiety, depression

From a systems perspective, the penis can serve as an early “barometer” of endothelial and autonomic function. When a patient reports new-onset ED, I look upstream to vascular and neurologic health with careful history, exam, and labs.

How I evaluate ED

I start with:

A detailed medical and sexual history, often including the Sexual Health Inventory for Men (SHIM) to categorize severity and monitor progress.
Focused physical examination (cardiovascular, neurologic, genitourinary, prostate).
Morning total and free testosterone, fasting lipids, A1C, thyroid panel, and PSA when indicated.

In my clinic, this structure promotes candid discussion and helps distinguish vasculogenic from neurogenic and psychogenic factors. It also guides whether integrative strategies, medications, or procedures are likely to succeed.

Treatment Options for Erectile Dysfunction: Evidence and Rationale

Lifestyle and functional foundations

Before medications, I emphasize core physiology:

Quit smoking: Nicotine is a potent vasoconstrictor that accelerates endothelial dysfunction.
Exercise consistently: Aerobic activity and resistance training increase endothelial NO synthase activity, improve insulin sensitivity, and enhance vascular compliance.
Lose excess weight: Reduced visceral fat improves inflammatory tone and hormone signaling.
Moderate alcohol: Excessive intake impairs neural conduction and can lower testosterone.
Optimize sleep and stress resilience: Better autonomic balance supports erectile function.

From a chiropractic and functional lens, I also target:

Lumbar-sacral alignment and pelvic mechanics: Adjustments, soft tissue work, and mobility training may improve neural conduction and pelvic floor synergy.
Core stability and hip mobility: These influence venous return, pelvic circulation, and endurance performance.
Breath mechanics and diaphragmatic function: They support autonomic tone and vascular reactivity.

These foundations often turn marginal medication responses into robust, sustainable outcomes.

Oral PDE5 inhibitors

How they work:
- Sildenafil and tadalafil inhibit PDE5, slowing cGMP breakdown and prolonging smooth muscle relaxation during sexual stimulation.
Practical points:
- Sexual arousal is still required to trigger NO release.
- Sildenafil is typically taken as needed about 60 minutes before activity; tadalafil can be used as needed or daily (e.g., 5 mg) to support spontaneity.
Safety:
- Common side effects include headache, flushing, nasal congestion, and dyspepsia.
- Absolute contraindication with nitrates due to hypotension risk.
Clinical pearl:
- If sildenafil produces inconsistent rigidity, switching to tadalafil (with a longer half-life and smoother kinetics) often improves confidence and function.

Low-intensity shockwave therapy (LiST)

Mechanism:
- Focused acoustic waves generate controlled microstress in penile tissue, thereby stimulating angiogenic pathways and neovascularization. Improved arterial inflow addresses vasculogenic ED at its source.
Protocol:
- Commonly six weekly sessions, with ongoing evaluation of hemodynamic response.
Evidence and role:
- Favorable data for mild-to-moderate vasculogenic ED continues to expand, though many insurers still classify it as investigational.
Why I integrate it:
- LiST aligns with our regenerative model—enhancing tissue-level blood flow rather than relying solely on pharmacologic support.

Intracavernosal injections (ICI)

What they are:
- Direct injection of vasoactive agents such as alprostadil or compounded Bimix/Trimix into the corpora cavernosa to induce a reliable erection.
Why they work:
- They bypass endothelial dysfunction by directly relaxing cavernosal smooth muscle.
Safety and technique:
- Proper training is essential to avoid vascular bundles and fibrosis.
- Priapism risk requires patient education and a clear action plan if an erection persists beyond four hours.
When I recommend them:
- For men who fail PDE5 inhibitors or who desire more consistent rigidity. Many patients appreciate the predictability once trained.

Vacuum erection devices (VED), urethral suppositories, and prostheses

VED:
- Mechanical negative pressure draws blood into the penis; a constriction ring maintains erection. Effective but sometimes cumbersome.
Urethral alprostadil (MUSE):
- Less invasive than ICI, but often less potent and more costly.
Penile prosthesis:
- Inflatable or malleable implants offer the highest satisfaction when other therapies fail. They provide on-demand rigidity and long-term reliability.

A practical case: ED in a man with cardiometabolic comorbidities

When a 66-year-old man presents with hypertension, diabetes, obesity, and dyslipidemia, with a moderate SHIM score and limited response to sildenafil, I typically:

Transition to on-demand tadalafil to leverage steadier kinetics.
Add low-intensity shockwave therapy to repair vascular supply.
Implement a structured plan for weight reduction, glucose optimization, sleep quality improvement, and smoking cessation, if applicable.
Use chiropractic adjustments and pelvic floor-informed rehab to enhance lumbosacral function and autonomic balance.
If needed, introduce intracavernosal injections as a highly effective second-line option.

The objective is not only to restore erections but also to reverse the physiologic terrain that produced ED.

Signs of Hormonal Imbalances In Men THIS IS WHY- Video

Testosterone Deficiency: Definitions, Drivers, and Diagnostics

What constitutes low testosterone

Clinically, testosterone deficiency (hypogonadism) requires:

Biochemical confirmation: Two separate morning total testosterone levels below approximately 300 ng/dL.
Compatible symptoms: Low libido, fatigue, decreased morning erections, reduced muscle mass, mood changes, and cognitive dulling.

Testosterone naturally declines about 1–2% per year with age. However, accelerated or symptomatic decline often reflects modifiable drivers such as obesity, insulin resistance, chronic inflammation, or untreated sleep apnea.

Primary vs. secondary hypogonadism

Primary hypogonadism (testicular origin):
- Testicular injury, infection, genetic conditions (e.g., Klinefelter), autoimmune damage, chemotherapy/radiation, or orchiectomy.
Secondary hypogonadism (hypothalamic-pituitary origin):
- Obesity (aromatase converts testosterone to estrogen), diabetes, chronic illness, medications, and obstructive sleep apnea (OSA) that suppress hypothalamic-pituitary-gonadal signaling.

In my practice, I prioritize correcting secondary factors first. For example, with OSA, I insist on consistent CPAP use for at least three months, then recheck morning testosterone. Many men improve without hormones when sleep, weight, and insulin sensitivity normalize.

Recognizing symptoms

Specific:
- Decreased libido, fewer morning erections, erectile dysfunction, reduced body hair, gynecomastia.
Nonspecific:
- Fatigue, low mood, irritability, brain fog, sarcopenia, increased visceral fat.

Because nonspecific symptoms overlap with other conditions, rigorous testing and reassessment are essential to avoid overdiagnosis or inappropriate TRT.

My diagnostic algorithm

Step 1: Morning total testosterone. If above 300 ng/dL and symptoms persist, I search for alternative explanations.
Step 2: If low, repeat morning total testosterone to confirm.
Step 3: Concurrent labs with confirmation draw:
- Luteinizing hormone (LH) to distinguish primary vs. secondary etiology.
- Hematocrit for baseline erythrocytosis risk.
- PSA for prostate health screening.
- Prolactin if secondary causes are suspected (pituitary concerns). Elevated prolactin may prompt endocrinology referral and pituitary MRI.

I use these data to map causal chains and select treatments that align with the patient’s physiology and goals.

Treating Low Testosterone: Lifestyle First, Medications When Needed

Foundational strategies

Stop smoking and moderate alcohol
Improve diet quality: Emphasize nutrient-dense, anti-inflammatory patterns that support insulin sensitivity and micronutrient sufficiency.
Exercise: Resistance training and cardio increase androgen receptor sensitivity and favorably shift body composition.
Correct sleep disorders (especially OSA): Restorative sleep rebalances the HPG axis.

From a chiropractic perspective, I complement these with:

Spinal adjustments to optimize autonomic regulation and reduce physiologic stress burden.
Movement prescriptions that reinforce posture, mobility, and neuromuscular efficiency—key to sustaining training adaptations and hormonal benefits.

Testosterone replacement therapy (TRT)

When low T is confirmed twice in the morning, symptoms are significant, and reversible drivers have been addressed, TRT becomes a reasonable option. It is a Schedule III therapy that requires medical oversight and consistent monitoring.

Intramuscular injections (testosterone cypionate or enanthate):
- Typical dosing: 75–100 mg weekly or 150–200 mg every two weeks.
- Pros: Cost-effective, potent.
- Cons: Peaks and troughs can lead to symptom variability; some men prefer weekly dosing to smooth out the dosing profile.
Topical gels (e.g., AndroGel, Fortesta):
- Pros: Stable daily levels.
- Cons: Risk of transference (black box warning); requires application discipline.
Pellets (Testopel):
- Pros: Set-and-forget, steady release for 3–6 months.
- Cons: Minor surgical insertion; less flexibility in dose adjustments.
Oral formulations (e.g., Jatenzo, Tlando) and nasal (Natesto):
- Orals bypass first-pass hepatic metabolism but can raise blood pressure and are often expensive.
- Nasal forms may cause local irritation and are less commonly used.

Monitoring and safety

Follow-up labs: Testosterone and hematocrit within the first 3 months, then every 6–12 months.
Target range: I generally aim for 450–650 ng/dL to balance symptom relief and safety.
Manage erythrocytosis: If hematocrit exceeds ~52–54%, we may reduce dose or arrange therapeutic phlebotomy.
Contraindications:
- Known or suspected prostate or breast cancer, severe untreated OSA, high hematocrit, severe LUTS, poorly controlled heart failure, recent MI or stroke, and active desire for fertility.

Preserving fertility: Off-label options.

Clomiphene citrate (Clomid)
- Mechanism: Selective estrogen receptor modulator that increases LH/FSH, stimulating endogenous testosterone and spermatogenesis.
- Typical dosing: 25–50 mg three times weekly.
- Advantages: Helps men who need higher testosterone without suppressing fertility.
- Caveats: Potential side effects include headaches, visual changes, and breast tenderness.

Supplements and the “T-booster” marketplace

Many commercial “boosters” are expensive and underwhelming. Evidence-based points:

Zinc is essential for Leydig cell function, but supplementation above sufficiency does not reliably increase testosterone in eugonadal men.
Fenugreek and certain botanicals show mixed, small-scale data; robust, consistent benefits are not well-established.
My advice: Invest in verified nutrient sufficiency (quality multivitamin, diet), then focus on sleep, training, body composition, and stress control. These reliably move the needle.

A Practical Case: Low Testosterone with Sleep Apnea and Metabolic Risk

Consider a 56-year-old man with hypertension, hyperlipidemia, obesity, and obstructive sleep apnea (OSA) who reports fatigue, low libido, mild ED, and declining exercise capacity. An afternoon testosterone measurement of 150 ng/dL was obtained before presentation.
My plan:

Step 1: Correct the testing method—obtain a fasting morning total testosterone level.
Step 2: Require nightly CPAP adherence for at least 3 months, alongside nutrition and training protocols to reduce visceral fat and improve insulin sensitivity.
Step 3: Provide PDE5 inhibitor support (e.g., sildenafil or tadalafil) to improve quality of life while systemic drivers are corrected.
Step 4: Reassess with a second morning testosterone. If both are below threshold and symptoms persist despite OSA control and lifestyle improvements, we discuss TRT versus fertility-sparing options like clomiphene.
Step 5: If TRT is chosen, initiate with a form that aligns with preferences and adherence, and implement our monitoring protocol for hematocrit, testosterone levels, and PSA.

This sequence respects physiology, minimizes unnecessary hormone exposure, and often yields broader cardiometabolic gains.

How Chiropractic Integrates With Medical and Functional Care

In our El Paso clinic, integration is not a slogan—it is our daily operating system:

I coordinate spinal adjustments and neuromuscular rehabilitation to support autonomic equilibrium and pelvic biomechanics that influence both erectile function and exercise capacity.
Dr. Cardenas anchors medical direction: optimizing blood pressure, lipids, glucose, and sleep disorders; selecting safe pharmacology; and monitoring labs for TRT and ED therapies.
Our functional medicine lens uncovers nutrient gaps, inflammatory drivers, and endocrine disruptors, then addresses them with nutrition, movement, and targeted supplementation.
For personal injury patients, we rebuild movement efficiency and cardiovascular conditioning, which frequently improves sexual function and vitality as “secondary wins.”

This synergy aligns with my clinical observations and practice philosophy: by removing structural impediments, normalizing metabolic signals, and stabilizing the autonomic nervous system, we create conditions in which sexual and hormonal health can recover more naturally—often with less medication or at lower doses.

Evidence, Standards, and Continuous Improvement

We track progress against validated measures (e.g., SHIM for ED), objective biometrics (lipids, A1C, blood pressure), and hormone panels. We incorporate guideline-driven care and peer-reviewed evidence:

European Association of Urology (EAU) Sexual and Reproductive Health guidelines underscore the importance of structured evaluation of ED and the expanding role of regenerative therapies.
American Urological Association (AUA) updates highlight best practices for ED management and careful indications and monitoring for TRT.
StatPearls and clinical epidemiology reports help frame prevalence and the importance of methodical diagnostic pathways.

By combining these standards with hands-on clinical reasoning, we design treatment plans that are both personalized and reproducible.

Conclusion: A Clear Path Forward for Men’s Health

Erectile dysfunction and low testosterone are common, intertwined conditions with real solutions. When addressed through a comprehensive lens—neuromusculoskeletal function, vascular health, sleep quality, metabolic control, and appropriate pharmacology—men can reclaim sexual performance, energy, muscle mass, and mental focus.
At Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic) in El Paso, Texas, our integrative model—chiropractic care, functional medicine, rehabilitation, and internal medicine oversight by Dr. Maria Guadalupe Cardenas, MD (NPI #1164426749, Texas MD License #J2933)—ensures safe, evidence-based pathways tailored to your physiology and goals. Whether you are starting with lifestyle changes, optimizing medication response, considering shockwave therapy, learning about intracavernosal injections, or evaluating TRT, we guide you step by step with clarity and data.
If you are experiencing ED or symptoms of low testosterone, schedule a thorough evaluation. With the right plan, you can restore function and build a foundation for long-term vitality.

References

European Association of Urology. (2024). EAU Guidelines on Sexual and Reproductive Health.
Montague, D. K., Jarow, J., Broderick, G. A., Dmochowski, R. R., Heaton, J. P., Lue, T. F., Nehra, A., & Sharlip, I. D. (2005). The management of erectile dysfunction: An AUA update. The Journal of Urology, 174(1), 230–239.
Sooriyamoorthy, T., & Leslie, S. W. (2023). Erectile dysfunction. In StatPearls. StatPearls Publishing.
Charles, J., Harrison, C., & Britt, H. (2011). Management of male-specific problems in Australian general practice. Medical Journal of Australia, 195(S10), S64–S68.
Layton, J. B., Li, D., Meier, C. R., Sharpless, J. L., Stürmer, T., Jick, S. S., & Brookhart, M. A. (2014). Testosterone lab testing and initiation in the United Kingdom and the United States, 2000 to 2011. Journal of Clinical Endocrinology & Metabolism, 99(3), 835–842.
Prasad, A. S., Mantzoros, C. S., Beck, F. W., Hess, J. W., & Brewer, G. J. (1996). Zinc status and serum testosterone levels of healthy adults. Nutrition, 12(5), 344–348.

Additional clinical observations:

Dr. Alexander Jimenez, DC, APRN, FNP-BC. ChiroMed.
Dr. Alexander Jimenez, DC, APRN, FNP-BC. LinkedIn profile.

SEO tags: Erectile dysfunction, ED treatment, Low testosterone, Testosterone deficiency, Hypogonadism, Testosterone replacement therapy, TRT monitoring, Clomiphene for fertility, Low-intensity shockwave therapy, PDE5 inhibitors, Intracavernosal injections, Penile prosthesis, Integrative chiropractic care, Functional medicine, Men’s health El Paso TX, Injury Medical Clinic, Mission Plaza Injury Medical Clinic, Dr. Alex Jimenez, Dr. Maria Guadalupe Cardenas, Vascular health and ED, Sleep apnea and testosterone

June 16, 2026

Hormone Optimization Strategies You Need for Thyroid Health

Achieve optimal thyroid health with effective hormone optimization strategies. Take control of your well-being now.

Introductory Abstract

As Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST, I often meet patients who tell me, “My thyroid labs are normal, but I still feel exhausted, cold, inflamed, foggy, constipated, anxious, or unable to lose weight.” This educational post explores why that can happen. I will explain the differences among TSH, free T4, and free T3; why T3 is the biologically active thyroid hormone; how stress and inflammation can reduce the conversion of T4 to T3; and why symptoms may persist even when a standard thyroid screening test appears normal.

I will also explain how our team at Injury Medical Clinic PA, also known as Mission Plaza Injury Medical Clinic, in El Paso, Texas, approaches thyroid-related symptoms through an integrative model. In our clinical setting, I provide chiropractic, functional medicine, rehabilitation, and personal injury care, while Dr. Maria Guadalupe Cardenas, MD, Board Certified in Internal Medicine, NPI #1164426749, Texas Medical License #J2933, serves as Medical Director and Collaborative Physician. With more than 40 years of experience as an internist, Dr. Cardenas provides medical oversight in a multidisciplinary care structure commonly used in integrative and injury care clinics.

Together, our goal is not to replace appropriate medical evaluation but to help patients understand the physiology behind their symptoms, identify contributing factors such as stress, metabolic dysfunction, nutrient depletion, inflammation, musculoskeletal pain, and autonomic nervous system imbalance, and develop coordinated care plans grounded in modern evidence-based research.

Why I Look Beyond Standard Thyroid Screening When Symptoms Persist

In my clinical experience, one of the most common concerns I hear from patients is that they have persistent symptoms despite being told their thyroid is “normal.” Many patients arrive with fatigue, poor sleep, weight resistance, dry skin, thinning hair, constipation, low mood, anxiety, cold hands, cold feet, and muscle aches. They may have already had a basic thyroid test, usually thyroid-stimulating hormone, or TSH, and were told everything looked fine.

As a clinician trained in chiropractic, family nurse practitioner care, functional medicine, rehabilitation, and integrative health, I have learned that symptoms must be viewed in context. A single screening marker may be useful, but it does not always tell the whole story.

The thyroid system is not simply a gland producing a hormone. It is a complex network involving:

The hypothalamus
The pituitary gland
The thyroid gland
The liver
The gut
The immune system
The adrenal stress response
Mitochondrial energy production
Cellular thyroid receptors
Inflammatory signaling pathways

When patients have lingering symptoms, I want to understand whether the issue is primary thyroid disease, poor thyroid hormone conversion, inflammation, autoimmune activity, medication effects, stress physiology, nutrient insufficiency, metabolic syndrome, or a combination of these factors.

This is why I believe thyroid education is essential. Patients deserve to understand what their labs mean, what they do not mean, and why their symptoms should not be dismissed simply because a single marker falls within a broad laboratory reference range.

Understanding TSH: What Thyroid-Stimulating Hormone Really Tells Us

TSH, or thyroid-stimulating hormone, is produced by the pituitary gland in the brain. Its primary job is to signal the thyroid gland to produce thyroid hormones. When circulating thyroid hormone levels are low, the pituitary typically releases more TSH to stimulate the thyroid. When thyroid hormone levels are high, the pituitary usually lowers TSH production.

This creates an inverse relationship:

Low thyroid hormone output may raise TSH
High thyroid hormone output may suppress TSH
Normal circulating T4 may keep TSH in the standard range

TSH is very useful for detecting many cases of primary hypothyroidism, especially when the thyroid gland itself is underproducing hormone. It is also useful in identifying patterns that may suggest hyperthyroidism, in which the thyroid gland is overactive or excessively stimulated.

However, TSH is a screening marker, not a complete evaluation of thyroid physiology. A normal TSH does not always indicate optimal thyroid hormone action at the cellular level. The American Thyroid Association and other endocrine organizations recognize TSH as a major tool in thyroid assessment. Still, clinical interpretation must account for the patient’s symptoms, medications, comorbidities, and additional thyroid markers when appropriate (Jonklaas et al., 2014).

This matters because the patient does not feel the effects of TSH. The patient experiences the downstream effects of thyroid hormone availability, conversion, receptor signaling, mitochondrial energy production, and metabolic regulation.

Free T4 and Free T3: Why Active Thyroid Hormone Matters

The thyroid gland primarily produces T4, also called thyroxine. T4 is often described as a prohormone because it has relatively limited direct metabolic activity compared with T3 (triiodothyronine).

The body must convert T4 into T3 through enzymes called deiodinases. These enzymes remove iodine atoms from thyroid hormones to activate or deactivate them. The conversion of T4 into T3 is especially important because T3 is the active thyroid hormone that binds to nuclear receptors inside cells and influences gene transcription.

T3 helps regulate:

Basal metabolic rate
Mitochondrial energy production
Body temperature
Lipid metabolism
Carbohydrate metabolism
Gut motility
Heart rate and vascular tone
Neurological function
Mood and cognition
Hair, skin, and nail health
Skeletal muscle metabolism

When free T3 is low or suboptimal, patients may experience symptoms consistent with reduced thyroid hormone activity even when TSH and T4 appear to be within acceptable ranges.

This is the clinical gap many patients fall into. They may have enough T4 to keep TSH within range, but they may not be converting T4 to T3 efficiently or may have impaired T3 signaling at the receptor level.

Why a Normal TSH May Not Explain Persistent Low-Thyroid Symptoms

A patient can have a normal TSH and still experience symptoms that resemble hypothyroidism if the issue is not thyroid gland production but rather thyroid hormone conversion, transport, or cellular response.

For example:

The thyroid may produce enough T4
TSH may remain within the laboratory reference range
But conversion of T4 to free T3 may be reduced
The patient may experience fatigue, cold intolerance, constipation, depression, hair thinning, and slowed metabolism.

This pattern is sometimes discussed in the medical literature under terms such as low T3 syndrome, non-thyroidal illness syndrome, or altered thyroid hormone metabolism during illness, stress, caloric restriction, inflammation, and systemic disease (Fliers et al., 2015; Warner & Mittag, 2012).

In conventional endocrinology, these patterns are often interpreted cautiously because not every low-T3 pattern requires thyroid medication. I agree with that caution. In my practice, the goal is not to medicate every lab variation. The goal is to understand why the body is downregulating active thyroid hormone and whether that change reflects stress, inflammation, undernutrition, illness, medication effects, or metabolic dysfunction.

That is where integrative functional medicine becomes valuable. We ask a broader question: What is the body adapting to?

Common Symptoms of Low Free T3 and Reduced Thyroid Hormone Activity

When thyroid hormone action is reduced, symptoms can be broad because thyroid hormones affect nearly every tissue. Many patients describe a gradual slowing of their system.

Common symptoms may include:

Cold hands and cold feet
Low body temperature
Dry skin
Dry or thinning hair
Thinning eyebrows
Brittle nails
Constipation
Bloating
Irritable bowel symptoms
Fatigue
Brain fog
Low motivation
Depressive symptoms
Anxiety
Difficulty losing weight
Weight regain after dieting
Muscle stiffness
Joint discomfort
Menstrual changes
Reduced exercise tolerance

These symptoms are not specific to thyroid dysfunction alone. They can overlap with anemia, insulin resistance, menopause, low testosterone, nutrient deficiencies, chronic pain, autoimmune disease, depression, sleep apnea, medication side effects, and chronic stress. This is why a comprehensive clinical evaluation is essential.

As I often explain to patients, symptoms are clues. They are not diagnoses in themselves, but they tell us where to investigate.

THYROID DYSFUNCTION MUST WATCH (Assessment and treatment)- Video

Laboratory Reference Ranges Versus Optimal Clinical Interpretation

One of the most important concepts in functional medicine is understanding the difference between a laboratory reference range and an optimal physiological range.

A laboratory reference range is usually based on statistical patterns in a tested population. It tells us where most tested people fall. It does not necessarily tell us where an individual patient functions best.

For example, if a patient’s free T3 is at the low end of the reference range, the report may not flag it as abnormal. However, if that patient has fatigue, cold intolerance, constipation, hair loss, and metabolic slowdown, I do not ignore the pattern simply because the lab software says it is “normal.”

In clinical practice, I consider:

The patient’s symptoms
The full thyroid panel
Medication history
Dieting history
Stress burden
Inflammation markers
Metabolic markers
Autoimmune risk
Gut health
Nutrient status
Personal and family history
Physical exam findings

The goal is not to chase numbers. The goal is to understand physiology and restore function safely.

How Stress Reduces T4-to-T3 Conversion

Stress is one of the most powerful regulators of thyroid physiology. When the body is under chronic stress, it prioritizes survival over optimal metabolism.

The stress response involves the hypothalamic-pituitary-adrenal (HPA) axis. During prolonged stress, cortisol patterns may become dysregulated, inflammation may rise, sleep may worsen, and thyroid hormone conversion may shift.

Chronic stress can influence thyroid function by:

Reducing conversion of T4 to T3
Increasing production of reverse T3, an inactive thyroid hormone metabolite
Altering pituitary signaling
Increasing inflammatory cytokines
Disrupting gut barrier function
Increasing insulin resistance
Reducing mitochondrial efficiency

From a physiological standpoint, this makes sense. If the brain perceives stress, threat, starvation, pain, or illness, it may reduce the availability of active thyroid hormone to conserve energy. This can feel terrible to the patient, but biologically it may represent an adaptive response.

This is why stress management is not a luxury. It is a thyroid-supportive strategy.

Useful interventions may include:

Breathing retraining
Box breathing
Meditation
Sleep optimization
Gentle exercise
Time-restricted digital exposure
Pain reduction
Rehabilitation
Nutrient repletion
Counseling when appropriate
Autonomic nervous system regulation

In my clinical observations, patients with chronic pain, whiplash injuries, spinal dysfunction, poor sleep, and high sympathetic tone often present with metabolic symptoms that overlap with thyroid dysfunction. Addressing the nervous system and musculoskeletal system can be a meaningful part of the broader care plan.

Caloric Restriction, GLP-1 Medications, and Low T3 Patterns

Another important clinical issue is rapid weight loss or prolonged caloric restriction. Many patients now use GLP-1 receptor agonist medications, such as semaglutide or tirzepatide, under medical supervision for obesity, diabetes, and insulin resistance. These medications can be highly effective for appetite regulation and metabolic improvement, but any rapid reduction in food intake can influence thyroid hormone metabolism.

When the body senses low energy availability, it may reduce the conversion of T4 to T3. This lowers active thyroid hormone signaling and slows metabolic rate. From an evolutionary perspective, this helps conserve energy during famine. In modern clinical practice, it may appear as:

Cold intolerance
Hair shedding
Fatigue
Reduced resting metabolic rate
Constipation
Weight-loss plateau
Difficulty maintaining weight loss after stopping medication

This does not mean GLP-1 medications are “bad.” It means patients using them should be monitored carefully. Adequate protein intake, resistance training, micronutrient sufficiency, hydration, bowel regularity, and medical oversight are essential.

In our integrative model, we pay attention to:

Lean muscle preservation
Protein intake
Electrolytes
Micronutrients
Thyroid markers
Blood glucose
Insulin resistance
Liver function
Gut motility
Functional capacity
Strength and balance

Weight loss is not just about pounds lost. It is about improving metabolic resilience while protecting muscle, thyroid function, and long-term health.

Inflammation, Autoimmunity, and Thyroid Function

Inflammation can interfere with thyroid physiology at multiple levels. Pro-inflammatory cytokines can alter hypothalamic and pituitary signaling, reduce peripheral conversion of T4 to T3, affect receptor sensitivity, and contribute to fatigue and mood symptoms.

Autoimmune thyroid disease is also common. Hashimoto’s thyroiditis is one of the leading causes of hypothyroidism in iodine-sufficient regions. It involves immune-mediated thyroid tissue injury and may be associated with antibodies such as:

Thyroid peroxidase antibodies
Thyroglobulin antibodies

When clinically appropriate, antibody testing may help identify autoimmune patterns. If autoimmune thyroid disease is present, treatment planning may include medical management, anti-inflammatory nutrition, gut health support, vitamin D optimization, selenium sufficiency, stress reduction, and monitoring for associated autoimmune conditions.

Research has shown that thyroid autoimmunity and thyroid dysfunction can be associated with systemic immune activity, and management should be individualized rather than reduced to a single lab value (Chaker et al., 2017).

Why Gut Health Matters for Thyroid Hormone Metabolism

The gut and thyroid communicate through immune, metabolic, and endocrine pathways. Gut dysfunction may contribute to inflammation, nutrient malabsorption, constipation, altered detoxification, and immune activation.

The gut affects thyroid function through:

Nutrient absorption
Microbiome metabolism
Immune regulation
Bile flow and hormone clearance
Intestinal barrier integrity
Inflammatory signaling

Key nutrients for thyroid physiology include:

Iodine
Selenium
Zinc
Iron
Magnesium
Vitamin D
Vitamin A
B vitamins
Protein and amino acids

Selenium, for example, is required for deiodinase enzymes that help convert T4 to T3. Iron is needed for thyroid peroxidase function. Zinc participates in thyroid hormone metabolism and immune regulation.

This is why I often assess digestive symptoms when patients present with thyroid-like complaints. Constipation may be a symptom of low thyroid activity, but gut dysfunction can also worsen thyroid-related physiology. It is a bidirectional relationship.

Integrative Chiropractic Care and Thyroid-Related Symptoms

Chiropractic care does not replace thyroid medication, endocrinology evaluation, or internal medicine oversight. However, integrative chiropractic care can support patients with thyroid-related symptoms by addressing musculoskeletal, neurological, rehabilitative, and lifestyle factors that influence whole-body function.

In my role as a chiropractor and nurse practitioner, I look at how the spine, nervous system, muscles, fascia, movement patterns, and pain pathways interact with metabolic health.

Chronic pain and spinal dysfunction may contribute to:

Sympathetic nervous system overactivity
Poor sleep
Reduced physical activity
Inflammation
Stress hormone dysregulation
Muscle deconditioning
Weight gain
Fatigue
Mood changes

When a patient is in pain, the body often remains in a protective state. This can increase stress load and reduce the patient’s capacity to exercise, sleep deeply, and maintain healthy metabolic rhythms.

Integrative chiropractic care may include:

Spinal assessment and targeted adjustments
Soft tissue therapy
Corrective exercise
Postural rehabilitation
Functional movement evaluation
Neuromuscular re-education
Injury rehabilitation
Ergonomic coaching
Anti-inflammatory lifestyle planning
Coordination with medical providers

The purpose is to reduce pain, improve mobility, restore function, and help the nervous system move away from chronic threat signaling. When patients move better and hurt less, they often sleep better, breathe better, train better, and regulate stress more effectively. These improvements can indirectly support metabolic and endocrine resilience.

The Role of Dr. Maria Guadalupe Cardenas, MD, in Our Multidisciplinary Care Model

At Injury Medical Clinic PA, also known as Mission Plaza Injury Medical Clinic, in El Paso, Texas, our care model includes medical oversight and interdisciplinary coordination.

Dr. Maria Guadalupe Cardenas, MD, Board Certified in Internal Medicine, NPI #1164426749, Texas Medical License #J2933, has more than 40 years of experience as an internist. She serves as the Medical Director and Collaborative Physician for our practice.

This type of multidisciplinary structure is common in integrative, injury, rehabilitation, and functional medicine settings. It allows a clinic to combine the strengths of different professional disciplines while maintaining appropriate medical oversight.

In our setting:

I provide chiropractic care, functional medicine assessment, rehabilitation planning, personal injury care, and advanced clinical evaluation within my professional scope.
Dr. Cardenas provides internal medicine oversight, medical direction, and collaborative support.
The team works together to identify when patients need medical testing, medication review, specialist referral, imaging, laboratory evaluation, or urgent medical attention.
Patients benefit from an integrated care pathway that considers structure, function, inflammation, metabolism, pain, and recovery.

This approach is especially important for patients with complex symptoms. A patient may present after an auto accident with neck pain, headaches, poor sleep, fatigue, weight gain, anxiety, and digestive dysfunction. If we only look at the spine, we miss the metabolic picture. If we only look at labs, we miss the injury and nervous system picture. Integrative care allows us to connect the dots.

Functional Medicine Evaluation for Thyroid-Related Concerns

When evaluating thyroid-related symptoms, I often consider a broader laboratory and clinical picture. Depending on the patient’s history and medical necessity, a clinician may consider:

TSH
Free T4
Free T3
Reverse T3
Thyroid peroxidase antibodies
Thyroglobulin antibodies
Complete blood count
Comprehensive metabolic panel
Fasting insulin
Hemoglobin A1c
Lipid panel
Vitamin D
Ferritin and iron studies
B12 and folate
Inflammatory markers
Sex hormones when appropriate
Cortisol rhythm assessment when clinically indicated

The purpose is not to order excessive testing but to answer clinical questions. If a patient has thyroid-like symptoms, we need to know whether the problem is thyroid gland output, hormone conversion, inflammation, autoimmunity, anemia, insulin resistance, nutrient deficiency, menopause, chronic stress, pain, medication effects, or sleep disruption.

Functional medicine works best when it is disciplined, evidence-informed, and clinically practical.

Treatment Reasoning: Why Each Strategy May Be Used

Nutrition and Protein Intake

Adequate nutrition supports thyroid hormone production, conversion, detoxification, immune balance, and mitochondrial function. Protein provides amino acids needed for tissue repair, enzyme function, neurotransmitter production, and muscle maintenance.

When patients diet aggressively, active thyroid signaling may decline. Therefore, I emphasize sustainable nutrition rather than extreme restriction.

Resistance Training and Rehabilitation

Muscle is a metabolic organ. It improves glucose disposal, supports insulin sensitivity, protects joints, and helps maintain resting metabolic rate. For patients recovering from injury or fatigue, rehabilitation must be progressive and individualized.

Stress Regulation

Stress can alter thyroid conversion, sleep, cortisol rhythms, blood sugar, gut function, and inflammation. Breathing strategies, meditation, chiropractic care, sleep routines, and pain reduction all help regulate the nervous system.

Gut Health Support

Because the gut influences immune tone, nutrient absorption, inflammation, and bowel motility, it must be considered in patients with thyroid symptoms. Constipation, bloating, reflux, and IBS-like symptoms can provide important clues.

Medical Oversight and Medication Review

Some patients require thyroid medication. Others do not. Some patients need evaluation for autoimmune thyroid disease, nodules, hyperthyroidism, or medication interactions. This is where medical collaboration with Dr. Cardenas and appropriate referrals become essential.

Chiropractic and Neuromusculoskeletal Care

Pain and restricted movement can perpetuate sympathetic dominance and reduce physical activity. Chiropractic and rehabilitation interventions help improve function, reduce pain burden, and support whole-person recovery.

Medication Myths: Does Starting Thyroid Medication Always Mean Taking It Forever?

One common fear is that starting thyroid medication automatically means lifelong dependence. The answer depends on why the medication is being used.

If a patient has permanent primary hypothyroidism, thyroid removal, thyroid destruction, or significant autoimmune gland failure, long-term medication may be necessary.

However, if thyroid hormone changes are related to transient stress, caloric restriction, illness, medication effects, or reversible metabolic dysfunction, the situation may be different. Medication decisions should always be individualized, supervised, and based on appropriate diagnosis and monitoring.

It is also important to understand that thyroid physiology operates through feedback loops. The pituitary senses circulating hormone levels and adjusts TSH signaling accordingly. This system is dynamic. Patients should never start, stop, or change thyroid medication without medical guidance.

Clinical Observations From My Practice in El Paso

In my clinical work, including the integrative care I provide through my professional platforms at ChiroMed and my clinical profile, I frequently observe that complex patients rarely have a single isolated problem. Many have overlapping patterns involving:

Auto injury trauma
Neck and back pain
Headaches
Poor sleep
Stress overload
Inflammatory nutrition patterns
Insulin resistance
Gut dysfunction
Hormonal transitions
Fatigue
Reduced exercise capacity

When these factors accumulate, the body may downshift energy production. Patients may interpret this as “my thyroid is broken,” but the deeper truth may be that the body is adapting to pain, stress, inflammation, under-recovery, or metabolic dysfunction.

My job is to help patients understand the pattern, coordinate care, and build a plan that restores function step by step.

A Patient-Centered Thyroid and Integrative Care Plan

A comprehensive care plan may include:

Full history and symptom review
Medication and supplement review
Thyroid panel when appropriate
Inflammation and metabolic screening
Nutrient status evaluation
Postural and spinal assessment
Functional movement testing
Pain and injury evaluation
Nutrition planning
Stress and sleep interventions
Rehabilitation and strengthening
Medical oversight
Referral to endocrinology or other specialists when needed

This approach helps ensure that patients are not reduced to a lab value. They are evaluated as whole people with interconnected systems.

Key Takeaways About Thyroid Labs, Symptoms, and Integrative Care

The most important points I want patients to remember are:

TSH is useful, but it is not the entire thyroid story
Free T4 and free T3 may provide additional clinical context
T3 is the active thyroid hormone that drives many metabolic effects
Stress, inflammation, aging, illness, and caloric restriction may reduce T4-to-T3 conversion
Normal labs do not always mean optimal function
Symptoms must be interpreted in context
Chiropractic care can support thyroid-related recovery by reducing pain, improving movement, and calming nervous system stress.
Medical oversight is essential when thyroid disease, medication, or systemic illness is involved.
Multidisciplinary care allows us to evaluate the patient more completely

At Injury Medical Clinic PA in El Paso, our mission is to integrate the best of chiropractic, functional medicine, internal medicine oversight, rehabilitation, and personal injury care to help patients recover function, understand their physiology, and move toward better health.

References

Chaker, L., Bianco, A. C., Jonklaas, J., & Peeters, R. P. (2017). Hypothyroidism. The Lancet, 390(10101), 1550-1562.
Fliers, E., Bianco, A. C., Langouche, L., & Boelen, A. (2015). Thyroid function in critically ill patients. The Lancet Diabetes & Endocrinology, 3(10), 816-825.
Jonklaas, J., Bianco, A. C., Bauer, A. J., Burman, K. D., Cappola, A. R., Celi, F. S., Cooper, D. S., Kim, B. W., Peeters, R. P., Rosenthal, M. S., & Sawka, A. M. (2014). Guidelines for the treatment of hypothyroidism: Prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement. Thyroid, 24(12), 1670-1751.
McAninch, E. A., & Bianco, A. C. (2016). The history and future of treatment of hypothyroidism. Annals of Internal Medicine, 164(1), 50-56.
Mullur, R., Liu, Y. Y., & Brent, G. A. (2014). Thyroid hormone regulation of metabolism. Physiological Reviews, 94(2), 355-382.
Warner, A., & Mittag, J. (2012). Thyroid hormone and the central control of homeostasis. Journal of Endocrinology, 212(3), 307-317.
Wiersinga, W. M. (2014). Paradigm shifts in thyroid hormone replacement therapies for hypothyroidism. Nature Reviews Endocrinology, 10(3), 164-174.

SEO Tags

thyroid symptoms normal labs, low T3 syndrome, free T3, TSH, free T4, thyroid conversion, hypothyroidism symptoms, integrative chiropractic care, functional medicine thyroid, El Paso chiropractor, Dr Alex Jimenez, Dr Alexander Jimenez DC APRN FNP-BC, Dr Maria Guadalupe Cardenas MD, Injury Medical Clinic PA, Mission Plaza Injury Medical Clinic, internal medicine oversight, thyroid and stress, thyroid and inflammation, GLP-1 thyroid metabolism, chiropractic functional medicine, personal injury rehabilitation, thyroid fatigue, cold hands cold feet thyroid, Hashimoto thyroiditis, metabolic health, thyroid hormone conversion, deiodinase enzyme, evidence-based integrative care

Category: Bioidentical Hormone Replacement Therapy in El Paso, TX

Clinical Application: Weight Management for Success

Abstract: A Modern, Integrative Approach to Obesity Management

Our Collaborative and Integrative Care Model in El Paso

Deconstructing Obesity: A Chronic and Complex Disease

The Social and Environmental Drivers of Obesity

The Overwhelming Complexity of Appetite Regulation

Binge Eating Disorder and the Physiology of Loss of Control Eating

Confronting Weight Bias: The Last Socially Acceptable Discrimination

Shifting the Conversation: How to Engage Patients Effectively

A Framework for Treatment: Lifestyle, Medication, and Surgery

Why “First, Do No Harm” Matters in Obesity Treatment

Modern Pharmacotherapy for Weight Management

Emerging Obesity Medications and Future Directions

Discovering the Benefits of Chiropractic Care- Video

The Role of Integrative Chiropractic Care in Weight Management

Final Clinical Takeaway

References

GLP-1 Receptor Agonist Effects On Cardiometabolic Health

Abstract

Our Collaborative Approach at Injury Medical Clinic PA

The Unseen Connection: How Diabetes Fuels Heart Failure

Understanding the Two Faces of Heart Failure

Heart Failure with Preserved Ejection Fraction (HFpEF)

Heart Failure with Reduced Ejection Fraction (HFrEF)

Optimizing Your Wellness- Video

The Four Pillars of Modern Diabetes and Cardiovascular Care

The Revolutionary Role of SGLT2 Inhibitors

Landmark Trials: The Evidence Speaks for Itself

How SGLT2 Inhibitors Protect the Heart and Kidneys

GLP-1 Receptor Agonists From Diabetes Drugs to Cardiovascular Powerhouses

How GLP-1 Receptor Agonists Work

The FDA-Mandated Outcomes Trials: A Turning Point

The ADA Algorithm Drug Selection Framework

A Clinical Case Example Transitioning Patients to Modern Therapy

The Integrative Chiropractic and Functional Medicine Perspective

How Our Integrative Care Fits In

References

SGLT2 Inhibitors in Diabetes & Cardio-Renal Benefits

Abstract

My Path Toward Cardio-Renal Integration in Diabetes Care

Our Integrative Practice Model: A Symphony of Care

A Patient’s Journey: From Uncontrolled Diabetes to Renewed Health

Treatment Plan Part 1: Building a Foundation Through Education and Trust

Comprehensive Diabetes Self-Management Education (DSME)

Overcoming Barriers to Technology

Cardio-Renal Pathophysiology Made Simple

Cardiometabolic Risk *Causes & Effects*- Video

SGLT2 Inhibitors: How They Work and Why We Use Them

Treatment Plan Part 2: Two Weeks Later – Progress and Precision

Clinical Indications and Patient Selection

Safety and Monitoring Protocols

Treatment Plan Part 3: Three Months – Remarkable Improvement

Integrative Chiropractic Care and Rehabilitation

Treatment Plan Part 4: Seven Months – Approaching Full Remission

Why This Matters: From Risk Reduction to Life Quality

Key Takeaways

References

Additional Clinical Observations

Cardiometabolic Research Advances Using GLP-1 Receptor Therapy

Abstract

Our Collaborative and Integrative Practice at Injury Medical Clinic PA

The Critical Link Between Diabetes and Cardiovascular Disease

Rethinking Treatment Algorithms: A Risk-Based Approach

The History and Evolution of Diabetes Medication Trials

A Deeper Dive into SGLT2 Inhibitors

Landmark Cardiovascular Outcomes Trials for SGLT2 Inhibitors

The Multifaceted Mechanisms of SGLT2 Inhibitors

SGLT2 Inhibitors in Heart Failure and Kidney Disease

Heart Failure Trials

Kidney Disease Trials

Understanding the Incretin Effect: TheBody’ss Natural Glucose Response System

The Blunted Incretin Effect in Type 2 Diabetes

The Silent Threat: Hyperhomocysteinemia and its Impact on Your Health- Video

How GLP-1 Receptor Agonists Revolutionize Treatment

The Challenge of Over-Basalization: A Case Study

Beyond Blood Sugar: The Cardiovascular and Renal Benefits of GLP-1s

Navigating Side Effects and Safety Considerations of GLP-1 Agonists

An Integrative Chiropractic Perspective on Metabolic Health

References

Cardiometabolic Risk Causes & Effects- Video

Root Causes of GUT DYSFUNCTION- Video